Stable lipid or lipidoid nanoparticle suspensions

Abstract

Provided are stabilized lipid nanoparticle (LNP) / lipidoid nanoparticle (LiNP) formulations and LNP / LiNP suspensions, their uses, and uses in methods of treatment based on the finding that adding a surfactant to a formulation or suspension avoids aggregation, allowing for surprisingly long shelf life and long-term stability against shaking. The reduction in aggregation according to the present invention results in reduced side effects of the formulations and suspensions of the present invention, particularly reduced side effects caused by vaccine and anticancer formulations comprising LNPs and / or LiNPs.

Description

[Technical Field]

[0001] The present invention relates to the stabilization of suspension formulations containing lipid or lipidoid nanoparticles for the delivery of nucleic acids. [Background technology]

[0002] Lipid or lipidoid nanoparticles (LNPs or LiNPs) are often used to deliver active pharmaceutical ingredients to patients. For example, lipid or lipidoid formulations of nucleic acids are very useful and effective for introducing nucleic acids into cells. These advantageous properties of lipid or lipidoid formulations of nucleic acids have been used for decades in biological and medical research and in therapeutic approaches to i) overexpress genes or complement genetic defects in target cells, ii) downregulate or upregulate endogenous gene expression in cells, or iii) repair genetic defects (mutations). Nanoparticle-based mRNA formulations are also now established as vaccines against COVID-19.

[0003] However, it has been found that the physical stress conditions that suspension formulations containing lipid or lipidoid nanoparticles may be subjected to during handling or transportation can affect the formulation's effectiveness in delivering nucleic acids to patients. In particular, exposure of the formulation to vibrational stress or shaking of the formulation can have a destabilizing effect or reduce its efficacy (Kudsiova L, Lansley A, Scutt G, et al. Stability testing of the Pfizer-BioNTech BNT162b2 COVID-19 vaccine: a translational study in UK vaccination centers. BMJ Open Science 2021;5:e100203. doi:10.1136 / bmjos-2021-100203; S. Grau et al., Clinical Microbiology and Infection 27 (2021) 1698.e1e1698.e4).

[0004] Therefore, a reliable strategy to stabilize suspension formulations containing lipid or lipidoid nanoparticles for nucleic acid delivery would be desirable. Summary of the Invention

[0005] In the context of the present invention, the presence of a surfactant has been found to stabilize suspensions of lipid or lipidoid nanoparticles in an aqueous vehicle solution against particle aggregation under conditions of physical stress.

[0006] To that extent, the following aspects provided by the present invention are presented in a non-exclusive manner.

[0007] In one aspect, the present invention provides a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle solution, wherein the aqueous vehicle solution comprises a surfactant, and the lipid or lipidoid nanoparticles comprise the following components (a) and (b): (a) a therapeutic agent, preferably a nucleic acid; and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; Also provided is a suspension comprising: a suspension comprising: a) a suspension having a viscosity of 1000 psi;

[0008] According to another aspect, the present invention provides the use of a surfactant to stabilize a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle against particle aggregation under conditions of physical stress, the lipid or lipidoid nanoparticles comprising the following components (a) and (b): (a) a therapeutic agent, preferably a nucleic acid; and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; Provide for use, including

[0009] In a related aspect, the present invention provides a method for stabilizing a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle against particle aggregation under conditions of physical stress, the method comprising the steps of: (a) a therapeutic agent, preferably a nucleic acid; and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; wherein the surfactant is incorporated into a suspension of lipid or lipidoid nanoparticles.

[0010] Furthermore, the present invention provides a suspension according to the present invention, including a suspension obtained by a method according to the present invention, for use as a medicament. In a related context, a formulation according to the present invention, including a suspension obtained by a method according to the present invention, is suitable for reducing the side effects of treatment with lipid or lipidoid nanoparticles.

[0011] Without wishing to be bound by theory, the present invention provides stabilized LNP / LiNP formulations and LNP / LiNP suspensions, their uses, and uses in methods of treatment based on the discovery that adding a surfactant to a formulation or suspension avoids aggregation, allowing, for example, a surprisingly long shelf life and long-term stability against shaking. Said reduction in aggregation according to the present invention results in reduced side effects of the formulations and suspensions of the invention, such as reduced side effects caused by vaccine or anti-cancer formulations comprising LNPs or LiNPs.

[0012] A summary of various aspects of the invention is presented in the first set of items below.

[0013] 1. A suspension of lipid or lipidoid nanoparticles in an aqueous vehicle solution, wherein the aqueous vehicle solution comprises a surfactant, and the lipid or lipidoid nanoparticles comprise the following components (a) and (b): (a) a therapeutic agent, and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; A suspension comprising:

[0014] 2. The suspension according to item 1, wherein the therapeutic agent is a nucleic acid.

[0015] 3. The suspension according to item 2, wherein the nucleic acid is selected from RNA and plasmid DNA.

[0016] 4. The suspension according to item 2 or 3, wherein the nucleic acid is selected from mRNA, siRNA, miRNA, antisense RNA, tRNA, and non-coding RNA.

[0017] 5. The suspension according to item 4, wherein the nucleic acid is mRNA.

[0018] 6. The suspension according to any of items 2 to 5, wherein the concentration of the nucleic acid in the suspension is in the range of 0.01 to 10 mg / mL, more preferably 0.02 to 10 mg / mL, even more preferably 0.05 to 5 mg / mL, and most preferably 0.05 to 2.5 mg / mL, relative to the total volume of the suspension.

[0019] 7. The suspension according to any of items 1 to 6, wherein the weight-to-volume ratio (grams / liter) of nanoparticles in the aqueous vehicle solution is in the range of 0.1 g / L to 300 g / L, more preferably 0.2 g / L to 300 g / L, even more preferably 0.5 g / L to 250 g / L and most preferably 0.5 g / L to 125 g / L.

[0020] 8. A suspension according to any of items 1 to 7, wherein the suspended nanoparticles have a Z-average diameter in the range of 10 to 500 nm, more preferably in the range of 10 to 250 nm, and even more preferably in the range of 20 to 200 nm, as determined by dynamic light scattering.

[0021] 9. A suspension according to any of items 1 to 8, wherein the suspended nanoparticles have a polydispersity index, as determined by dynamic light scattering, in the range of 0.02 to 0.4, more preferably in the range of 0.03 to 0.2.

[0022] 10. Nanoparticles comprising the following components (c1) to (c6): (c1) Non-ionizable lipids with sterol structure (c2) Phosphoglyceride lipids (c3) PEG-conjugated lipid (c4) Polysarcosine-conjugated lipid (c5) PAS-modified lipid, and (c6) Cationic polymer 10. The suspension according to any of items 1 to 9, further comprising one or more of:

[0023] 11. Nanoparticles are 30-65 mol % of at least one of a permanent cationic lipid, an ionizable lipid and an ionizable lipidoid (b), preferably an ionizable lipid or an ionizable lipidoid (b), and the following components: a lipid (c1) having 10 to 50 mol% of a sterol structure; 4 to 50 mol% phosphoglyceride lipids (c2), 0.5 to 10 mol% of one of a PEG-conjugated lipid (c3), a polysarcosine-conjugated lipid (c4), and a PAS-modified lipid (c5), or any combination thereof; 11. A suspension according to any of items 1 to 10, comprising 0.5 to 10 mol % of one or more of the cationic polymers (c6), such that the sum of (b) and (c1) to (c6) amounts to 100 mol %.

[0024] 12. Nanoparticles comprising the following components (c1) to (c3): (c1) Non-ionizable lipids with sterol structure (c2) phosphoglyceride lipids, and (c3) PEG-conjugated lipid 12. The suspension according to any of items 1 to 11, further comprising:

[0025] 13. Nanoparticles are 30 to 65 mol % of at least one of a permanent cationic lipid, an ionizable lipid and an ionizable lipidoid (b), preferably an ionizable lipid or an ionizable lipidoid (b); a lipid (c1) having 10 to 50 mol% of a sterol structure; 4 to 50 mol% of phosphoglyceride lipids (c2), and Item 13. The suspension according to item 12, comprising 0.5 to 10 mol% of a PEG-conjugated lipid (c3), such that the sum of (b) and (c1) to (c3) is 100 mol%.

[0026] 14. A suspension according to any of items 2 to 13, wherein the nanoparticles further comprise a polyanionic component different from the nucleic acid.

[0027] 15. A suspension according to any of items 2 to 14, wherein the composition of the nanoparticles is such that the weight ratio of the weight of nucleic acid to the sum of the weights of components other than nucleic acid in the nanoparticles is in the range of 50:1 to 1:1, more preferably 40:1 to 2:1 and most preferably 30:1 to 3:1.

[0028] 16. The nanoparticles are prepared by dissolving an ionizable lipidoid (b) of the following formula (b-1):

[0029] [ka] (In the formula, a is 1 and b is an integer from 2 to 4, or a is an integer from 2 to 4 and b is 1; p is 1 or 2; m is 1 or 2, n is 0 or 1, and m+n is ≧2; R 1A ~R 6A are, independently of each other, hydrogen; -CH2-CH(OH)-R 7A , -CH(R 7A )-CH2-OH, -CH2-CH2-(C=O)-OR 7A , -CH2-CH2-(C=O)-NH-R 7A ;-CH2-R 7A -C(NH)-NH; a poly(ethylene glycol) chain; and a receptor ligand, R 7A is selected from C3-C18 alkyl and C3-C18 alkenyl having one C-C double bond; However, R 1A ~R 6A At least two residues of -CH2-CH(OH)-R 7A , -CH(R 7A )-CH2-OH, -CH2-CH2-(C=O)-OR 7A , -CH2-CH2-(C=O)-NH-R 7A and -CH2-R 7A Selected from R 7Ais selected from C3-C18 alkyl or C3-C18 alkenyl having one C-C double bond) or a protonated form thereof, in which one or more of the nitrogen atoms contained in the compound of formula (b-1) are protonated to give a compound having a positive charge. A suspension according to any of items 1 to 15, including:

[0030] 17. The nanoparticles are prepared by dissolving an ionizable lipidoid (b-1) of the following formula (b-1b):

[0031] [ka] (In the formula, R 1A ~R 6A is as defined in item 16) or a protonated form thereof, wherein one or more of the nitrogen atoms contained in the compound of formula (b-1b) are protonated to result in a compound having a positive charge. A suspension according to any of items 1 to 16, including:

[0032] 18.R 1A ~R 6A is hydrogen and -CH2-CH(OH)-R 7A are independently selected from R 7A is selected from C8-C18 alkyl, and C8-C18 alkenyl having one C-C double bond, with the proviso that R 1A ~R 6A At least two residues, preferably at least three residues and more preferably at least four residues of -CH-CH(OH)-R 7A and R 7A 18. The suspension according to item 16 or 17, with the proviso that is selected from C8-C18 alkyl and C8-C18 alkenyl having one CC double bond.

[0033] 19. A nanoparticle is a compound of formula

[0034] [ka] 19. A suspension according to any of items 1 to 18, comprising an ionizable lipidoid dL_05(R) having the formula:

[0035] 20. The nanoparticles comprise an ionizable lipid (b) of the following formula (a-III):

[0036] [ka] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof (In the formula, L 1 or L 2 One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond, G 1 and G 2 are independently C1 to C 12 Alkylene or C1-C 12 is alkenylene, G 3 is C1~C 24 Alkylene, C1-C 24alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene, each of alkylene, alkenylene, cycloalkylene, and cycloalkenylene optionally substituted; R a is H or C1~C 12 alkyl, wherein the alkyl is optionally substituted; R 1 and R 2 are independently C6 to C 24 Alkyl or C6-C 24 alkenyl, each of the alkyl and alkenyl being optionally substituted; R 3 H, OR 5 , CN, -C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 and R 4 is C1~C 12 alkyl, wherein the alkyl is optionally substituted; R 5 is H or C1-C6 alkyl, wherein alkyl is optionally substituted; 16. The suspension according to any of items 1 to 15, including wherein x is 0, 1 or 2.

[0037] 21. A suspension according to any of items 1 to 15, in which the nanoparticles comprise, as the ionizable lipid (b), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, or a protonated form thereof, in which a nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0038] 22. A suspension according to any of items 1 to 15, wherein the nanoparticles comprise, as the ionizable lipid (b), ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) or a protonated form thereof, in which a nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0039] 23. A suspension according to any of items 1 to 15 or 22, wherein the nanoparticles comprise, as the ionizable lipid (b), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102), or a protonated form thereof, in which a nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0040] 24. The lipid (c1) having a non-ionizable sterol structure is a non-ionizable lipid of formula (c1-1):

[0041] [ka] (In the formula, R 1L is a C3 to C12 alkyl group).

[0042] 25. A suspension according to any one of items 10 to 24, wherein the lipid having a non-ionizable sterol structure (c1) contains cholesterol.

[0043] 26. The phosphoglyceride lipid (c2) is a phosphoglyceride lipid of the formula (c2-1):

[0044] [ka] (In the formula, R 1F and R 2F are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group), or a pharmaceutically acceptable salt thereof, or a phosphoglyceride lipid of formula (c2-2)

[0045] [ka] (In the formula, R 1G and R 2G are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group), or a pharmaceutically acceptable salt thereof Suspension of any of items 10 to 25, including:

[0046] 27. A suspension according to any of items 10 to 26, wherein the phosphoglyceride lipid (c2) comprises 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or a pharmaceutically acceptable salt thereof, or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or a pharmaceutically acceptable salt thereof.

[0047] 28. The PEG-conjugated lipid (c3) is a PEG-conjugated lipid of formula (c3-1):

[0048] [ka] (In the formula, R 1H and R 2H are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group, and p is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60; or a PEG-conjugated lipid of formula (c3-2):

[0049] [ka] (In the formula, R 1J and R 2J are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group, and q is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60; or a pharmaceutically acceptable salt thereof, or a PEG-conjugated lipid of formula (c3-3):

[0050] [ka] (In the formula, R 1K and R 2K are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group, and q is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60. A suspension according to any of items 10 to 27, including:

[0051] 29. A suspension according to items 10 to 28, wherein the PEG-conjugated lipid (c3) comprises 1,2-dimyristoyl-sn-glycerol methoxy(polyethylene glycol)-2000 (DMG-PEG2k) or 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159).

[0052] 30. The nanoparticles comprise, as the ionizable lipid (b), ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) or a protonated form thereof, in which the nitrogen atom of the compound is protonated to give a compound having a positive charge, and the following components (d1) to (d8): (d1) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) (d2) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) (d3) cholesterol (d4) Potassium chloride (d5) Potassium dihydrogen phosphate (d6) Sodium chloride (d7) disodium phosphate dihydrate (d8) Sucrose 23. The suspension according to item 22, further comprising one or more of:

[0053] 31. The nanoparticles comprise, as the ionizable lipid (b), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102) or a protonated form thereof, in which the nitrogen atom of the compound is protonated to give a compound having a positive charge, and the nanoparticles comprise the following components (e1) to (e7): (e1) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), (e2) cholesterol, (e3) 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000 DMG), (e4) Trometamol hydrochloride (e5) Sodium acetate trihydrate (e6) acetic acid (e7) Sucrose 24. The suspension according to item 23, further comprising one or more of:

[0054] 32. A suspension according to any of items 1 to 31, wherein the N / P ratio in the nanoparticles is in the range of 0.5 to 20, more preferably in the range of 0.5 to 10.

[0055] 33. A suspension according to any of items 1 to 32, in which the surfactant is essentially not bound to the nanoparticles.

[0056] 34. A suspension according to any of items 1 to 33, wherein the surfactant is a non-ionic surfactant.

[0057] 35. A suspension according to item 34, wherein the nonionic surfactant is at least one selected from the group consisting of fatty alcohol ethoxylates, fatty acid ethoxylates, block copolymers of ethylene oxide and propylene oxide, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil, and ethoxylated vitamin E.

[0058] 36. A suspension according to item 35, wherein the block copolymer of ethylene oxide and propylene oxide is a poloxamer.

[0059] 37. The poloxamer comprises one poly(propylene oxide) block B of formula (p-1):

[0060] [ka] (wherein s is an integer of 15 to 60), and Two poly(ethylene oxide) blocks A of formula (p-2):

[0061] [ka] (wherein, r is independently an integer of 8 to 150, preferably 10 to 150, for each block.) 37. A suspension according to item 36, containing

[0062] 38. A suspension according to item 35, wherein the nonionic surfactant is at least one selected from the group consisting of fatty alcohol ethoxylates, fatty acid ethoxylates, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil, and ethoxylated vitamin E.

[0063] 39. The suspension according to any of items 35 to 37, wherein the nonionic surfactant is at least one selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 80, polyoxyethylene lauryl ether, polyoxyethylene-35 castor oil, D-α-tocopherol polyethylene glycol 1000 succinate, and tyloxapol.

[0064] 40. The suspension of item 39, wherein the nonionic surfactant is at least one selected from the group consisting of polysorbate 20, polysorbate 80, polyoxyethylene lauryl ether, polyoxyethylene-35 castor oil, D-α-tocopherol polyethylene glycol 1000 succinate, and tyloxapol.

[0065] 41. A suspension according to any of items 1 to 40, in which the surfactant does not contain poloxamer 188.

[0066] 42. A suspension according to any of items 1 to 41, in which the surfactant does not contain poloxamer 407.

[0067] 43. A suspension according to any of items 1 to 42, comprising a surfactant at a concentration of 0.01 to 10% (w / v), preferably 0.1 to 10% (w / v), more preferably 0.25 to 5% (w / v), even more preferably 0.33 to 2.5% (w / v), even more preferably 0.45 to 10% (w / v) and most preferably 0.5 to 1.5% (w / v), relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0068] 44. A suspension according to item 43, comprising a surfactant at a concentration of 0.5 to 1.5% (w / v) relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0069] 45. A suspension according to any of items 1 to 44, wherein the nanoparticles are not freeze-dried.

[0070] 46. ​​A method for preparing a suspension according to any one of items 1 to 45, comprising: producing a lipid or lipidoid nanoparticle preparation by mixing at least one selected from a permanent cationic lipid, an ionizable lipid, and an ionizable lipidoid dissolved in an organic phase with a therapeutic agent dissolved in an aqueous solution; and combining the nanoparticles with a surfactant to obtain a suspension of nanoparticles in the aqueous vehicle solution; A method comprising:

[0071] 47.Follow these steps: i) producing a preparation of lipid or lipidoid nanoparticles by mixing at least one selected from a permanent cationic lipid, an ionizable lipid, and an ionizable lipidoid dissolved in an organic phase with a therapeutic agent dissolved in an aqueous solution; ii) diluting the lipid or lipidoid nanoparticle preparation by diluting with a first solution; iii) concentrating the diluted preparation of lipid or lipidoid nanoparticles by buffer exchange using ultra / diafiltration in a TFF, wherein a second solution is used for ultra / diafiltration; iv) Obtaining a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle containing a surfactant. and / or wherein the first solution comprises between 0.01% w / v and 10% w / v surfactant, preferably between 0.1% w / v and 10% w / v surfactant, more preferably between 0.25% w / v and 5% w / v surfactant, even more preferably between 0.33% w / v and 2.5% w / v surfactant, even more preferably between 0.45% w / v and 1.5% w / v surfactant, and most preferably between 0.5% w / v and 1.5% w / v surfactant; and / or the second solution comprises between 0.01% w / v and 10% w / v surfactant, preferably between 0.1% w / v and 10% w / v surfactant, more preferably between 0.25% w / v and 5% w / v surfactant, even more preferably between 0.33% w / v and 2.5% w / v surfactant, even more preferably between 0.45% w / v and 1.5% w / v surfactant, and most preferably between 0.5% w / v and 1.5% w / v surfactant; 47. The method according to item 46, wherein the final concentration of surfactant from the combined first and second solutions is between 0.01% w / v and 10% w / v surfactant, preferably between 0.1% w / v and 10% w / v surfactant, more preferably between 0.25% w / v and 5% w / v surfactant, even more preferably between 0.33% w / v and 2.5% w / v surfactant, even more preferably between 0.45% w / v and 1.5% w / v surfactant, and most preferably between 0.5% w / v and 1.5% w / v surfactant, relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0072] 48. The method according to item 47, wherein incorporation of surfactant into the suspension does not occur before or during step i).

[0073] 49. The method according to item 47 or 48, wherein a surfactant is added to both the first and second solutions.

[0074] 50. The method according to any of items 47 to 49, wherein 30 to 70 wt% of surfactant, preferably 40 to 60 wt% and more preferably 45 to 55 wt% of surfactant, based on the total weight of surfactant in the suspension obtained in step iv) is added to the first solution, and 70 to 30 wt% of surfactant, preferably 60 to 40 wt% and more preferably 55 to 45 wt% of surfactant, based on the total weight of surfactant in the suspension obtained in step iv) is added to the second solution, so that the sum of the surfactants added to the first and second solutions amounts to 100 wt%.

[0075] 51. The method according to any of items 47 to 50, wherein approximately half of the surfactant is added with the first solution and approximately half of the surfactant is added with the second solution.

[0076] 52. A suspension of lipid nanoparticles or lipidoid nanoparticles (LNP or LiNP suspension) obtained by a method according to any of items 46 to 51.

[0077] 53. A formulation of lipid nanoparticles or lipidoid nanoparticles, comprising a suspension of lipid nanoparticles or lipidoid nanoparticles according to any of items 1 to 45 or 52.

[0078] 58. A suspension or formulation of lipid nanoparticles or lipidoid nanoparticles according to any of items 1 to 45, 52 or 53 for use in the treatment or prevention of a disease.

[0079] 59. A suspension or formulation of lipid nanoparticles or lipidoid nanoparticles according to any of items 1 to 45, 52 or 53 for use as a medicament.

[0080] 60. A suspension or formulation of lipid or lipidoid nanoparticles according to any of items 1 to 45, 52 or 53 for use in vaccination or immunization.

[0081] 61. A method for inducing an immune response against a target pathogen in a subject in need thereof, the method comprising administering to the subject a formulation comprising a suspension of lipid nanoparticles or lipidoid nanoparticles as defined in any of items 1 to 45 or 52.

[0082] 62. A method for reducing the occurrence or severity of one or more side effects associated with an LNP / LiNP-based vaccine in a subject, the method comprising administering to the subject a vaccine formulation or anticancer formulation comprising a suspension of lipid nanoparticles or lipidoid nanoparticles as defined in any of items 1 to 45 or 52.

[0083] 63. The method of item 62, wherein the reduction in the occurrence or severity of one or more side effects is caused by a reduction in LNP / LiNP aggregation.

[0084] 64. The method of item 63, wherein the reduction in aggregation is measured by determining the hydrodynamic diameter of the nanoparticles, for example, by dynamic light scattering or photon correlation spectroscopy.

[0085] Further aspects of the invention are summarized in the second set of items below. 1b. Use of a surfactant to stabilize a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle against particle aggregation under physical stress conditions, wherein the lipid or lipidoid nanoparticles comprise the following components (a) and (b): (a) a therapeutic agent, and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; Including, use.

[0086] 2b. A method for stabilizing a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle against particle aggregation under conditions of physical stress, the lipid or lipidoid nanoparticles comprising the following components (a) and (b): (a) a therapeutic agent, and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; and incorporating a surfactant into a suspension of lipid or lipidoid nanoparticles.

[0087] 3b. Use or method according to item 1b or 2b, wherein the therapeutic agent is a nucleic acid.

[0088] 4b. The use or method according to item 3b, wherein the nucleic acid is selected from RNA and plasmid DNA.

[0089] 5b. The use or method according to item 3b, wherein the nucleic acid is selected from mRNA, siRNA, miRNA, antisense RNA, tRNA, and non-coding RNA, more preferably mRNA.

[0090] 6b. The use or method according to any of items 3b to 5b, wherein the concentration of nucleic acid in the suspension is in the range of 0.01 to 10 mg / mL, more preferably 0.02 to 10 mg / mL, even more preferably 0.05 to 5 mg / mL and most preferably 0.05 to 2.5 mg / mL, relative to the total volume of the suspension.

[0091] 7b. The use or method according to any of items 1b to 6b, wherein the weight to volume ratio (grams / liter) of the nanoparticles in the aqueous vehicle solution is in the range of 0.1 g / L to 300 g / L, more preferably 0.2 g / L to 300 g / L, even more preferably 0.5 g / L to 250 g / L and most preferably 0.5 g / L to 125 g / L.

[0092] 8b. Use or method according to any of items 1b to 7b, wherein the suspended nanoparticles have a Z-average diameter in the range of 10 to 500 nm, more preferably 10 to 250 nm, even more preferably 20 to 200 nm, as determined by dynamic light scattering.

[0093] 9b. Use or method according to any of items 1b to 8b, wherein the suspended nanoparticles have a polydispersity index in the range of 0.02 to 0.4, more preferably in the range of 0.03 to 0.2, as determined by dynamic light scattering.

[0094] 10b. The nanoparticles are one or more of the following components (c1) to (c6): (c1) a lipid having a non-ionizable sterol structure; (c2) phosphoglyceride lipids, (c3) PEG-conjugated lipids, (c4) Polysarcosine-conjugated lipid (c5) PAS-modified lipid, and (c6) Cationic polymer The use or method according to any of items 1b to 9b, further comprising:

[0095] 11b. Nanoparticles are: 30-65 mol % of at least one of a permanent cationic lipid, an ionizable lipid and an ionizable lipidoid (b), preferably an ionizable lipid or an ionizable lipidoid (b), and the following components: a lipid (c1) having 10 to 50 mol% of a sterol structure; 4 to 50 mol% phosphoglyceride lipids (c2), 0.5 to 10 mol% of one of a PEG-conjugated lipid (c3), a polysarcosine-conjugated lipid (c4), and a PAS-modified lipid (c5), or any combination thereof; The use or method according to any of items 1b to 10b, comprising 0.5 to 10 mol % of one or more of the cationic polymers (c6), such that the sum of (b) and (c1) to (c6) amounts to 100 mol %.

[0096] 12b. Nanoparticles comprising the following components (c1) to (c3): (c1) a lipid having a non-ionizable sterol structure; (c2) phosphoglyceride lipids, and (c3) PEG-conjugated lipid The use or method according to any of items 1b to 11b, further comprising:

[0097] 13b. Nanoparticles are: 30 to 65 mol % of at least one of a permanent cationic lipid, an ionizable lipid and an ionizable lipidoid (b), preferably an ionizable lipid or an ionizable lipidoid (b); a lipid (c1) having 10 to 50 mol% of a sterol structure; 4 to 50 mol% of phosphoglyceride lipids (c2), and The use or method according to item 12b, comprising 0.5 to 10 mol % of a PEG-conjugated lipid (c3), such that the sum of (b) and (c1) to (c3) is 100 mol %.

[0098] 14b. Use or method according to any of items 3b to 13b, wherein the nanoparticles further comprise a polyanionic component, different from the nucleic acid.

[0099] 15b. The use or method according to any of items 3b to 14b, wherein the composition of the nanoparticles has a weight ratio of the weight of nucleic acid to the sum of the weights of components other than nucleic acid in the nanoparticles in the range of 50:1 to 1:1, more preferably 40:1 to 2:1 and most preferably 30:1 to 3:1.

[0100] 16b. The nanoparticles are prepared by dissolving an ionizable lipidoid (b) of the following formula (b-1):

[0101] [ka] (In the formula, a is 1 and b is an integer from 2 to 4, or a is an integer from 2 to 4 and b is 1; p is 1 or 2; m is 1 or 2, n is 0 or 1, and m+n is ≧2; R 1A ~R 6A are, independently of each other, hydrogen; -CH2-CH(OH)-R 7A , -CH(R 7A )-CH2-OH, -CH2-CH2-(C=O)-OR 7A , -CH2-CH2-(C=O)-NH-R 7A ;-CH2-R 7A -C(NH)-NH; a poly(ethylene glycol) chain; and a receptor ligand, R 7A is selected from C3-C18 alkyl and C3-C18 alkenyl having one C-C double bond; However, R 1A ~R 6AAt least two residues of -CH2-CH(OH)-R 7A , -CH(R 7A )-CH2-OH, -CH2-CH2-(C=O)-OR 7A , -CH2-CH2-(C=O)-NH-R 7A and -CH2-R 7A Selected from R 7A is selected from C3-C18 alkyl or C3-C18 alkenyl having one C-C double bond) or a protonated form thereof, in which one or more of the nitrogen atoms contained in the compound of formula (b-1) are protonated to give a compound having a positive charge. 1. A use or method according to any of items 1b to 15b, including:

[0102] 17b. Nanoparticles comprising an ionizable lipidoid (b-1) of the following formula (b-1b):

[0103] [ka] (In the formula, R 1A ~R 6A is as defined in item 16b) or a protonated form thereof, wherein one or more of the nitrogen atoms contained in the compound of formula (b-1b) are protonated to result in a compound having a positive charge. 16. A use or method according to any of items 1b to 16b, including:

[0104] 18b.R 1A ~R 6A is hydrogen and -CH2-CH(OH)-R 7A are independently selected from R 7A is selected from C8-C18 alkyl, and C8-C18 alkenyl having one C-C double bond, with the proviso that R 1A ~R 6A At least two residues, preferably at least three residues and more preferably at least four residues of -CH-CH(OH)-R 7A and R7A Use or process according to item 16b or 17b, with the proviso that is selected from C8-C18 alkyl, and C8-C18 alkenyl having one CC double bond.

[0105] 19b. A nanoparticle having the formula

[0106] [ka] 18. The use or method according to any of items 1b to 18b, comprising an ionizable lipidoid dL_05(R) having the formula:

[0107] 20b. The nanoparticles are prepared by dissolving an ionizable lipid (b) of the following formula (a-III):

[0108] [ka] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof (In the formula, L 1 or L 2 One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR aC(=O)O- or a direct bond, G 1 and G 2 are independently C1 to C 12 Alkylene or C1-C 12 is alkenylene, G 3 is C1~C 24 Alkylene, C1-C 24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene, each of alkylene, alkenylene, cycloalkylene, and cycloalkenylene optionally substituted; R a is H or C1~C 12 alkyl, wherein the alkyl is optionally substituted; R 1 and R 2 are independently C6 to C 24 Alkyl or C6-C 24 alkenyl, each of the alkyl and alkenyl being optionally substituted; R 3 H, OR 5 , CN, -C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 and R 4 is C1~C 12 alkyl, wherein the alkyl is optionally substituted; R 5 is H or C1-C6 alkyl, wherein alkyl is optionally substituted; x is 0, 1 or 2).

[0109] 21b. Use or method according to any of items 1b to 15b, wherein the nanoparticles comprise, as ionizable lipid (b), (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, or a protonated form thereof, in which a nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0110] 22b. Use or method according to any of items 1b to 15b, wherein the nanoparticles comprise, as ionizable lipid (b), ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), or a protonated form thereof, in which a nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0111] 23b. The use or method according to any of items 1b to 15b or 22b, wherein the nanoparticles comprise, as the ionizable lipid (b), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102), or a protonated form thereof, wherein a nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0112] 24b. The lipid (c1) having a non-ionizable sterol structure is a non-ionizable lipid of formula (c1-1):

[0113] [ka] (In the formula, R 1L is a C3 to C12 alkyl group.

[0114] 25b. The use or method according to any of items 10b to 24b, wherein the lipid having a non-ionizable sterol structure (c1) comprises cholesterol.

[0115] 26b. The phosphoglyceride lipid (c2) is a phosphoglyceride lipid of the formula (c2-1)

[0116] [ka] (In the formula, R 1F and R 2F are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group. or a pharmaceutically acceptable salt thereof, or a phosphoglyceride lipid of formula (c2-2)

[0117] [ka] (In the formula, R 1G and R 2G are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group. or a pharmaceutically acceptable salt thereof.

[0118] 27b. The use or method according to any of items 10b to 26b, wherein the phosphoglyceride lipid (c2) comprises 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or a pharmaceutically acceptable salt thereof, or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or a pharmaceutically acceptable salt thereof.

[0119] 28b. The PEG-conjugated lipid (c3) is a PEG-conjugated lipid of formula (c3-1):

[0120] [ka] (In the formula, R 1H and R 2Hare independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group, and p is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60. or a PEG-conjugated lipid of formula (c3-2):

[0121] [ka] (In the formula, R 1J and R 2J are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group, and q is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60. or a pharmaceutically acceptable salt thereof, or a PEG-conjugated lipid of formula (c3-3):

[0122] [ka] (In the formula, R 1K and R 2K are independently a C8 to C18 alkyl group or a C8 to C18 alkenyl group, preferably a C12 to C18 alkyl group or a C12 to C18 alkenyl group, and q is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60. A use or method according to any of items 10b to 27b, including

[0123] 29b. Use or method according to items 10b to 28b, wherein the PEG-conjugated lipid (c3) comprises 1,2-dimyristoyl-sn-glycerol methoxy(polyethylene glycol)-2000 (DMG-PEG2k) or 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159).

[0124] 30b. The nanoparticles comprise, as the ionizable lipid (b), ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) or a protonated form thereof, in which the nitrogen atom of the compound is protonated to give a compound having a positive charge, and the following components (d1) to (d8): (d1) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) (d2) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) (d3) cholesterol (d4) Potassium chloride (d5) Potassium dihydrogen phosphate (d6) Sodium chloride (d7) disodium phosphate dihydrate (d8) Sucrose The use or method according to item 22b, further comprising one or more of:

[0125] 31b. The nanoparticles comprise, as the ionizable lipid (b), heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102) or a protonated form thereof, in which the nitrogen atom of the compound is protonated to give a compound having a positive charge, and the nanoparticles comprise the following components (e1) to (e7): (e1) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), (e2) cholesterol, (e3) 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000 DMG), (e4) Trometamol hydrochloride (e5) Sodium acetate trihydrate (e6) acetic acid (e7) Sucrose The use or method according to item 23b, further comprising one or more of:

[0126] 32b. Use or method according to any of items 1b to 31b, wherein the N / P ratio in the nanoparticles is in the range of 0.5 to 20, more preferably in the range of 0.5 to 10.

[0127] 33b. The use or method according to any of items 1b to 32b, wherein the physical stress state is selected from a physical stress state caused by shaking, stirring, vibrating, mixing, inverting, tapping or dripping the nanoparticle suspension, or any combination thereof, or by pumping the nanoparticle suspension into a syringe or by withdrawing it.

[0128] 34b. The use or method according to any of items 1b to 33b, wherein the surfactant is incorporated into the aqueous vehicle solution as an excipient.

[0129] 35b. Use or method according to any of items 1b to 34b, wherein the surfactant is not essentially bound to the nanoparticles.

[0130] 36b. The use or method according to any of items 1b to 35b, wherein the surfactant is a non-ionic surfactant.

[0131] 37b. The use or method according to item 36b, wherein the nonionic surfactant is at least one selected from the group consisting of fatty alcohol ethoxylates, fatty acid ethoxylates, block copolymers of ethylene oxide and propylene oxide, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil, and ethoxylated vitamin E.

[0132] 38b. Use or method according to item 37b, wherein the block copolymer of ethylene oxide and propylene oxide is a poloxamer.

[0133] 39b. The poloxamer comprises one poly(propylene oxide) block B of formula (p-1):

[0134] [ka] (wherein s is an integer of 15 to 60), and Two poly(ethylene oxide) blocks A of formula (p-2):

[0135] [ka] (wherein, r is independently an integer of 8 to 150, preferably 10 to 150, for each block.) 38. The use or method according to claim 38b, comprising

[0136] 40b. The use or method according to item 36b, wherein the nonionic surfactant is at least one selected from the group consisting of fatty alcohol ethoxylates, fatty acid ethoxylates, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil and ethoxylated vitamin E.

[0137] 41b. The use or method according to item 36b or 37b, wherein the non-ionic surfactant is at least one selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 80, polyoxyethylene lauryl ether, polyoxyethylene-35 castor oil, D-α-tocopherol polyethylene glycol 1000 succinate, and tyloxapol.

[0138] 42b. The use or method according to item 36b or 37b, wherein the non-ionic surfactant is at least one selected from the group consisting of polyoxyethylene lauryl ether, polyoxyethylene-35 castor oil, D-α-tocopherol polyethylene glycol 1000 succinate, and tyloxapol.

[0139] 43b. The use or method according to any of items 1b to 41b, wherein the surfactant does not comprise poloxamer 188.

[0140] 44b. The use or method according to any of items 1 to 43b, wherein the surfactant does not comprise poloxamer 407.

[0141] 45b. Use according to any of items 1b to 44b, wherein the suspension of lipid or lipidoid nanoparticles in the aqueous vehicle solution comprises surfactant at a concentration of 0.01 to 10% (w / v), preferably 0.1 to 10% (w / v), more preferably 0.25 to 5% (w / v), even more preferably 0.33 to 2.5% (w / v), even more preferably 0.45 to 1.5% (w / v) and most preferably 0.5 to 1.5% (w / v), relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0142] 46b. Use according to item 45b, wherein the suspension of nanoparticles comprises the surfactant at a concentration of 0.5 to 1.5% (w / v) relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0143] 47b. Use according to any of items 1b to 46b, wherein the nanoparticles are not freeze-dried.

[0144] 48b. Use according to any of items 1b to 46b, wherein the surfactant is not present in the vehicle solution during the freeze-drying process.

[0145] 49b. Use according to any of items 1b to 46b, wherein a surfactant is added before the freeze-drying process.

[0146] 50b. The method according to any of items 2b to 44b, wherein a surfactant is incorporated into the suspension of lipid or lipidoid nanoparticles to achieve a concentration of surfactant of 0.01 to 10% (w / v), preferably 0.1 to 10% (w / v), more preferably 0.25 to 5% (w / v), even more preferably 0.33 to 2.5% (w / v), even more preferably 0.45 to 1.5% (w / v) and most preferably 0.5 to 1.5% (w / v) relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0147] 51b. The method according to item 50b, wherein the surfactant is incorporated into the suspension of nanoparticles to achieve a concentration of 0.5 to 1.5% (w / v) of surfactant relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0148] 52b. The method according to any of items 2b to 44b, 50b or 51b, which does not include a freeze-drying step.

[0149] 53b. The method according to any of items 2b to 44b, 50b or 51b, wherein the surfactant is not present in the vehicle solution during the freeze-drying step.

[0150] 54b. The method according to any of items 2b to 44b, 50b or 51b, wherein a surfactant is added before the freeze-drying step.

[0151] 55b.Follow these steps: i) producing a preparation of lipid or lipidoid nanoparticles by mixing at least one selected from a permanent cationic lipid, an ionizable lipid, and an ionizable lipidoid dissolved in an organic phase with a therapeutic agent dissolved in an aqueous solution; ii) diluting the lipid or lipidoid nanoparticle preparation by diluting with the first solution; iii) concentrating the diluted preparation of lipid or lipidoid nanoparticles by buffer exchange using ultra / diafiltration in a TFF, wherein a second solution is used for ultra / diafiltration; iv) obtaining a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle solution, the first solution comprising 0.01% w / v to 10% w / v surfactant, preferably 0.1% w / v to 10% surfactant, more preferably 0.25% w / v to 5% w / v surfactant, even more preferably 0.33% w / v to 2.5% w / v surfactant, even more preferably 0.45% w / v to 1.5% w / v surfactant, and most preferably 0.5% w / v to 1.5% w / v surfactant; and / or the second solution comprises 0.01% w / v and 10% w / v surfactant, preferably 0.1% w / v to 10% surfactant, more preferably 0.25% w / v to 5% w / v surfactant, even more preferably 0.33% w / v to 2.5% w / v surfactant, even more preferably 0.45% w / v to 1.5% w / v surfactant, and most preferably 0.5% w / v to 1.5% w / v surfactant; The method according to any of items 2b to 44b, 50b or 51b, wherein the final concentration of surfactant from the combined first and second solutions is 0.01% w / v and 10% w / v surfactant, preferably 0.1% w / v to 10% surfactant, more preferably 0.25% w / v to 5% w / v surfactant, even more preferably 0.33% w / v to 2.5% w / v surfactant, even more preferably 0.45% w / v to 1.5% w / v surfactant, and most preferably 0.5% w / v to 1.5% w / v surfactant, relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0152] 56b. The method according to item 55b, wherein incorporation of surfactant into the suspension does not occur before or during step i).

[0153] 57b. The method according to item 55b or 56b, wherein a surfactant is added to both the first and second solutions.

[0154] 58b. The method according to any of items 55b to 57b, wherein 30 to 70 wt% of surfactant, preferably 40 to 60 wt% and more preferably 45 to 55 wt% of surfactant, based on the total weight of surfactant in the suspension obtained in step iv) is added to the first solution, and 70 to 30 wt% of surfactant, preferably 60 to 40 wt% and more preferably 55 to 45 wt% of surfactant, based on the total weight of surfactant in the suspension obtained in step iv) is added to the second solution, so that the sum of the surfactants added to the first and second solutions amounts to 100 wt%.

[0155] 59b. The method according to any of items 55b-58b, wherein approximately half of the surfactant is added with the first solution and approximately half of the surfactant is added with the second solution.

[0156] 60b. A suspension of lipid nanoparticles or lipidoid nanoparticles (LNP or LiNP suspension) obtained by a method according to any of items 55b to 59b.

[0157] 61b. A suspension of lipid nanoparticles or lipidoid nanoparticles according to item 60b for use in the treatment or prevention of diseases.

[0158] 62b. A suspension of lipid nanoparticles or lipidoid nanoparticles according to item 60b for use as a medicament.

[0159] 63b. A suspension of lipid or lipidoid nanoparticles according to item 60b for use in vaccination or immunization.

[0160] 64b. A method for avoiding side effects in treatment with lipid or lipidoid nanoparticles having at least one therapeutic agent, comprising: i) determining whether a pharmaceutical composition comprising lipid or lipidoid nanoparticles aggregates when subjected to mechanical or thermal stress by determining the aggregation level of said pharmaceutical composition before and after subjecting said pharmaceutical composition to said mechanical or thermal stress; ii) if the lipid nanoparticles or lipidoid nanoparticles show aggregation after the test of step (i), then adding surfactant to the lipid nanoparticle or lipidoid nanoparticle formulation to obtain an LNP or LiNP suspension with a final surfactant concentration of 0.01% w / v to 10% w / v, preferably 0.1% w / v to 10% w / v (between 0.1% w / v and 10% w / v), more preferably 0.25% w / v to 5% w / v, even more preferably 0.33% w / v to 2.5% w / v, even more preferably 0.45% w / v to 1.5% w / v, and most preferably 0.5% w / v to 1.5% w / v; iii) Reconstitution by mixing to produce a stable suspension of lipid or lipidoid nanoparticles. A method comprising:

[0161] 65b. A method for reducing one or more side effects associated with a vaccine or anticancer formulation comprising lipid or lipidoid nanoparticles carrying nucleic acids, the method comprising modifying the vaccine or anticancer formulation by adding a surfactant to the vaccine or anticancer formulation comprising a suspension of lipid or lipidoid nanoparticles.

[0162] 66b. The method of item 65b, wherein the surfactant is 0.01% w / v to 10% w / v, preferably 0.1% w / v to 10% w / v, more preferably 0.25% w / w to 5%, even more preferably 0.33% to 2.5%, even more preferably 0.45% to 1.5%, and most preferably 0.5% to 1.5%.

[0163] 67b. The method of item 66b, wherein the surfactant is at least one nonionic surfactant selected from the group consisting of fatty alcohol ethoxylates, fatty acid ethoxylates, block copolymers of ethylene oxide and propylene oxide, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil, and ethoxylated vitamin E, and preferably at least one selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 80, polyoxyethylene lauryl ether, polyoxyethylene-35 castor oil, D-α-tocopherol polyethylene glycol 1000 succinate, and tyloxapol.

[0164] 68b. The method of item 67b, wherein the surfactant is a block copolymer of ethylene oxide and propylene oxide, preferably a poloxamer selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 338, and poloxamer 407.

[0165] 69b. The method of item 67b, wherein the poloxamer is not poloxamer 188 or poloxamer 407.

[0166] 70b. ​​A method for inducing an immune response against a target pathogen in a subject in need thereof, comprising administering to the subject a formulation comprising a suspension of lipid nanoparticles or lipidoid nanoparticles as defined in any of items 1b to 49b or 60b.

[0167] 71b. A method for reducing the occurrence or severity of one or more side effects associated with an LNP / LiNP-based vaccine in a subject, comprising administering to the subject a vaccine formulation or anticancer formulation comprising a suspension of lipid nanoparticles or lipidoid nanoparticles as defined in any of paragraphs 1b-49b or 60b.

[0168] 72b. The method of item 71b, wherein the reduction in the occurrence or severity of one or more side effects is caused by a reduction in LNP / LiNP aggregation.

[0169] 73b. The method of item 72b, wherein the reduction in aggregation is measured by determining the hydrodynamic diameter of the nanoparticles, for example, by dynamic light scattering or photon correlation spectroscopy.

[0170] It will be understood that the summaries of the above items form part of the general disclosure of the present invention, and thus information presented in the detailed description below, e.g., information regarding further preferred embodiments or optional features, also applies to the above items, and vice versa. DETAILED DESCRIPTION OF THE INVENTION

[0171] Unless indicated to the contrary in any particular context, the following descriptions, for example, regarding therapeutic agents, lipid or lipidoid nanoparticles, or surfactants, apply to all aspects of the invention.

[0172] For ease of discussion, lipid nanoparticles ("LNP") or lipidoid nanoparticles ("LiNP") can be collectively referred to herein as "nanoparticles."Similarly, a suspension of lipid nanoparticles or lipidoid nanoparticles in an aqueous vehicle, wherein the lipid nanoparticles or lipidoid nanoparticles comprise (a) nucleic acid and (b) at least one of permanent cationic lipids, ionizable lipids and ionizable lipidoids, is briefly referred to herein as a "nanoparticle suspension."It should be understood that the term "or" used when referring to lipid nanoparticles or lipidoid nanoparticles does not have an exclusive meaning unless otherwise indicated.Thus, a suspension of lipid nanoparticles or lipidoid nanoparticles may contain lipid nanoparticles but not lipidoid nanoparticles, may contain lipid nanoparticles but not lipid nanoparticles, or may contain lipid nanoparticles and lipidoid nanoparticles.The same is expressed, for example, by the abbreviation LNP / LiNP.

[0173] The nanoparticles of the suspension and their components are described below. Unless otherwise specified, the term "nanoparticles" as used herein encompasses lipid nanoparticles (also referred to as LNPs) and lipidoid nanoparticles (also referred to as LiNPs). According to various embodiments of the present invention, the nanoparticles of the nanoparticle suspension comprise (a) a therapeutic agent and (b) at least one selected from a permanent cationic lipid, an ionizable lipid, and an ionizable lipidoid. Therefore, in the context of the present invention, when a suspension contains only LNPs but not LiNPs, components (a) and (b) are contained in the LNPs. When a suspension contains only LiNPs but not LNPs, components (a) and (b) are contained in the LiNPs. Also, in the context of the present invention, when a suspension contains both LNPs and LiNPs, both LNPs and LiNPs typically contain components (a) and (b).

[0174] As component (a), the nanoparticles comprise a therapeutic agent. Preferably, the therapeutic agent is a nucleic acid, which therefore generally provides the pharmaceutically active component of the nanoparticle.

[0175] The nature of nucleic acid is not particularly limited.In principle, any type of nucleic acid can be used in the context of the present invention.Nucleic acid is known to those skilled in the art and refers to a biopolymer or small biomolecule that is composed of nucleotides, which are monomers made up of three components: a five-carbon sugar, a phosphate group and a nitrogenous base.

[0176] The term nucleic acid is a collective term for DNA (deoxyribonucleic acid) and RNA (ribonucleic acid), members of the above family of biopolymers. When the sugar is the compound ribose, the polymer is RNA; when the sugar is derived from ribose as deoxyribose, the polymer is DNA. The term "nucleic acid" encompasses oligonucleotides or polynucleotides. Because nucleic acids are biopolymers made up of nucleotides, the term "nucleic acid" is also often referred to as a "sequence of nucleotides," and therefore, as will be understood by those skilled in the art, the terms "nucleic acid" and "nucleic acid sequence" are often used interchangeably.

[0177] In a preferred embodiment, the nanoparticles comprise ribonucleic acid (RNA) as the nucleic acid, more preferably single-stranded RNA, and most preferably mRNA.

[0178] The term "nucleic acid" encompasses all forms of naturally occurring nucleic acids, as well as chemically and / or enzymatically synthesized nucleic acids, and also encompasses nucleic acid analogs and nucleic acid derivatives. This term particularly encompasses single-stranded or double-stranded nucleic acids with modified backbone, sugar-modified, or base-modified, such as locked nucleic acids (LNA), peptide nucleic acids (PNA), oligonucleoside thiophosphates and phosphotriesters, morpholino oligonucleotides, cationic oligonucleotides (U.S. Pat. No. 6,017,700, WO 2007 / 069092), substituted ribonucleotides, or phosphorothioates. Furthermore, the term "nucleic acid" also refers to any molecule containing nucleotides or nucleotide analogs. There are no limitations on the sequence or size of the nucleic acid contained in the nanoparticles of the present invention. Nucleic acids are primarily defined by the biological action they will achieve in the biological target to which the nanoparticles of the present invention are delivered. For example, as outlined in further detail below, for applications in gene or nucleic acid therapy, the nucleic acid or nucleic acid sequence may be defined by the gene or gene fragment to be expressed, or by the intended replacement or repair of a defective gene or any gene target sequence, or by the target sequence of the gene to be inhibited, knocked down, down-regulated or up-regulated.

[0179] The nanoparticles in the suspension can contain nucleic acids, which are DNA molecules. A preferred embodiment of such DNA molecules is a DNA molecule that can be transcribed into an mRNA molecule. Transcription is the first step in gene expression, in which a specific segment of a DNA molecule is copied into an mRNA molecule by the enzyme RNA polymerase. During transcription, the DNA sequence is read by the RNA polymerase, which generates a complementary antiparallel RNA strand, called the primary transcript.

[0180] DNA molecules can be introduced into vectors, preferably expression vectors, by standard molecular biology techniques (see, for example, Sambrook et al., Molecular Cloning, A Laboratory Manual, 2nd Ed., 1989). The term "vector," such as "expression vector" or "cloning vector," in the sense of the present invention is understood as a circular, double-stranded unit of DNA that can preferably replicate within a cell independently of chromosomal DNA and is used as a vehicle for introducing genetic material into a cell, where it can be (replicated and / or) expressed (i.e., transcribed into RNA and translated into an amino acid sequence). A vector containing foreign DNA is called recombinant DNA. A vector itself is generally a DNA sequence that usually consists of an insert sequence (e.g., a nucleic acid molecule / DNA molecule of the present invention) and a larger sequence that serves as the "backbone" of the vector. Plasmids in the sense of the present invention are most often found in bacteria and are used in recombinant DNA research to transfer genes between cells, and therefore constitute a subset of the "vectors" used in the sense of the present invention.

[0181] It will be apparent to those skilled in the art that additional regulatory sequences may be added to the DNA molecule of the present invention. For example, transcription enhancers and / or sequences that allow expression to be induced may be used. Suitable inducible systems include, for example, the tetracycline-regulated gene expression system described by Gossen and Bujard, Proc. Natl. Acad. Sci. USA 89 (1992), 5547-5551) and Gossen, Trends Biotech. 12 (1994), 58-62, or the dexamethasone-inducible gene expression system described by Crook, EMBO J. 8 (1989), 513-519. The present invention may also use a vector, preferably an expression vector containing the DNA molecule. The vector may be, for example, a plasmid, cosmid, virus, bacteriophage, or another vector commonly used in genetic engineering, and may contain additional genes, such as marker genes, that allow the vector to be selected in a suitable host cell under suitable conditions.

[0182] When a nucleic acid used in the context of the present invention is a DNA molecule, the nucleic acid may be a plasmid DNA (pDNA) molecule.

[0183] As specified above, the nanoparticles preferably contain ribonucleic acid (RNA) as nucleic acid, more preferably single-stranded RNA, most preferably mRNA.

[0184] Regarding RNA, in principle, any type of RNA can be used in the context of the present invention.In a preferred embodiment, RNA is single-stranded RNA.The term "single-stranded RNA" refers to a single continuous chain of ribonucleotides, in contrast to RNA molecules, where two or more individual chains form a double-stranded molecule by hybridization of the individual chains.The term "single-stranded RNA" does not exclude that single-stranded molecule forms a double-stranded structure itself, such as secondary structure (for example, loop and stem-loop) or tertiary structure.Examples are not only tRNA and mRNA, but also any other type of single-stranded RNA, such as antisense-RNA, siRNA, miRNA, etc.

[0185] The term "RNA" encompasses RNA that encodes amino acid sequences and RNA that does not encode amino acid sequences. It has been suggested that over 80% of the genome contains functional DNA elements that do not encode proteins. These non-coding sequences include regulatory DNA elements (binding sites for transcription factors, regulators, and co-regulators, etc.) and sequences that encode transcripts that are never translated into proteins. Such transcripts that are encoded by the genome and transcribed into RNA but not translated into proteins are called non-coding RNAs (ncRNAs). Thus, in one embodiment, the RNA is a non-coding RNA. Preferably, the non-coding RNA is a single-stranded molecule. Studies have demonstrated that ncRNAs are important players in gene regulation, maintaining genome integrity, cell differentiation and development, and that they are misregulated in various human diseases. There are various types of ncRNAs: short (20-50 nt), medium (50-200 nt), and long (>200 nt) ncRNAs. Short ncRNAs include microRNAs (miRNAs), small interfering RNAs (siRNAs), piwi-interacting RNAs (piRNAs), and transcription initiation RNAs (tiRNAs). Examples of medium-stranded ncRNAs include small nuclear RNAs (snRNAs), small nucleolar RNAs (snoRNAs), transfer RNAs (tRNAs), transcription start site-associated RNAs (TSSaRNAs), small promoter-associated RNAs (PASRs), and promoter upstream transcripts (PROMPTs). Long noncoding RNAs (lncRNAs) include long intergenic noncoding RNAs (lincRNAs), antisense lncRNAs, intronic lncRNAs, and transcribed ultraconserved region RNAs (T-UCRs) (Bhan A, Mandal SS, ChemMedChem. 2014 Mar 26. doi: 10.1002 / cmdc.201300534). Of the above noncoding RNAs, only siRNAs are double-stranded. Therefore, in a preferred embodiment, the non-coding RNA is single-stranded and therefore preferably is not an siRNA. In another embodiment, the RNA is a coding RNA, i.e., an RNA that codes for an amino acid sequence.Such RNA molecules are also called mRNA (messenger RNA) and are single-stranded RNA molecules. RNA may be produced by synthetic chemical and enzymatic methods known to those skilled in the art, or by using recombinant technology, or may be isolated from natural sources, or a combination thereof.

[0186] Messenger RNA (mRNA) is a copolymer constructed primarily from nucleosides, adenosine, cytidine, uridine, and guanosine, and nucleoside phosphate building blocks, which act as intermediates to carry genetic information from DNA in the cell nucleus to the cytoplasm, where it is translated into proteins. Therefore, it is suitable as a surrogate for gene expression.

[0187] In the context of the present invention, mRNA should be understood to mean any polyribonucleotide molecule, which, once in the cell, is suitable for the expression of a protein or a fragment thereof or can be translated into a protein or a fragment thereof. The term "protein" here encompasses any kind of amino acid sequence, i.e., a chain of two or more amino acids linked to each other via peptide bonds, and also includes peptides and fusion proteins.

[0188] mRNA includes ribonucleotide sequences that encode proteins or fragments thereof whose function in or near a cell is necessary or beneficial, such as proteins whose missing or defective form triggers a disease or disorder and whose supply can alleviate or prevent the disease or disorder, or proteins that can promote processes beneficial to the body in or near a cell. mRNA may contain the sequence of a complete protein or its functional variant. Furthermore, ribonucleotide sequences can encode proteins that act as factors, i.e., inducers, regulators, stimulators, or enzymes, or functional fragments thereof, where such proteins are proteins whose function is required to treat disorders, particularly metabolic disorders, or to initiate in vivo processes such as the formation of new blood vessels, tissues, etc. Examples of proteins that can be encoded by mRNA include antibodies, cytokines, or chemokines. Here, functional variants are understood to mean fragments capable of assuming the function of a protein whose function in a cell is necessary or whose missing or defective form is pathogenic. In addition, mRNA may also have additional functional regions and / or 3' or 5' non-coding regions, particularly 3' and / or 5' UTR. The 3' and / or 5' non-coding regions may be regions naturally adjacent to the protein-encoding sequence or artificial sequence, such as sequences that contribute to RNA stabilization. Those skilled in the art can determine suitable sequences for this in each case by routine experimentation.

[0189] In preferred embodiments, the mRNA comprises a 5' cap consisting of m7GpppG linked to the mRNA via a 5'-to-5' triphosphate linkage (five prime cap; cap 0), an additional methyl group on the penultimate nucleotide from the 5' end of the mRNA (cap-1, anti-reverse cap analog (ARCA)), and / or an internal ribosome entry site (IRES) and / or a polyA tail at the 3' end, specifically to improve translation. The mRNA can have additional regions that facilitate translation, such as, for example, a cap 2 structure or a histone stem-loop structure.

[0190] The RNA that may be present in the nanoparticles may contain unmodified and modified nucleotides. As used herein, the term "unmodified nucleotides" refers to A, C, G, and U nucleotides. As used herein, the term "modified nucleotides" refers to either naturally occurring or non-naturally occurring isomers of A, C, G, and U nucleotides, as well as naturally occurring or non-naturally occurring analogs, alternative nucleotides, or modified nucleotides, or their isomers, for example, with chemically modified or substituted residues. Modified nucleotides can have base modifications and / or sugar modifications. Modified nucleotides can also have phosphate group modifications, for example, with respect to the 5' prime cap of an mRNA molecule. Modified nucleotides also include nucleotides synthesized post-transcriptionally by covalent modification of the nucleotide. Furthermore, any suitable mixture of unmodified and modified nucleotides is contemplated. A non-limiting number of examples of modified nucleotides can be found in the literature (e.g., U.S. Patent Application Publication No. 2013 / 0123481; Cantara et al., Nucleic Acids Res, 2011, 39(Issue suppl_1):D195-D201; Helm and Alfonzo, Chem Biol, 2014, 21(2):174-185; or Carell et al., Angew Chem Int Ed Engl, 2012, 51(29):7110-31), and some preferred modified nucleotides are illustratively specified below based on their individual nucleoside residues: 1-methyladenosine, 2-methylthio-N6-hydroxynorvalylcarbamoyl adenosine, 2-methyladenosine, 2'-O-ribosylphosphate adenosine, N6-methyl-N6-threonylcarbamoyl adenosine, N6-acetyladenosine, N6-glycinylcarbamoyl adenosine, N6-isopentenyl adenosine, N6-methyl adenosine, N6-threonylcarbamoyl adenosine, N6,N6-dimethyl adenosine, N6-(cis-hydroxyisopentenyl) adenosine, N6-hydroxynorvalylcarbamoyl adenosine, 1,2'-O-dimethyl adenosine, N6,2'-O-Dimethyladenosine, 2'-O-Methyladenosine, N6,N6,2'-O-Trimethyladenosine, 2-Methylthio-N6-(cis-hydroxyisopentenyl)adenosine, 2-Methylthio-N6-methyladenosine, 2-Methylthio-N6-isopentenyladenosine, 2-Methylthio-N6-threonylcarbamoyladenosine, N6-2-Methylthio-N6-threonylcarbamoyladenosine, 2-Methylthio-N6-(cis-hydroxyisopentenyl)adenosine, 7-Methyladenosine, 2-Methylthio-adenosine, 2-Methoxy-adenosine, 2'-Amino-2'-deoxyadenosine, 2'-Azido-2'-deoxyadenosine, 2'-Fluoro-2'-deoxyadenosine adenosine, 2-aminopurine, 2,6-diaminopurine, 7-deaza-adenosine, 7-deaza-8-aza-adenosine, 7-deaza-2-aminopurine, 7-deaza-8-aza-2-aminopurine, 7-deaza-2,6-diaminopurine, 7-deaza-8-aza-2,6-diaminopurine; 2-thiocytidine, 3-methylcytidine, N4-acetylcytidine, 5-formylcytidine, N4-methylcytidine, 5-methylcytidine, 5-hydroxymethylcytidine, 5-hydroxycytidine, lysidine, N4-acetyl-2'-O-methylcytidine, 5-formyl-2'-O-methylcytidine, 5,2'-O-dimethylcytidine, 2-O-methylcytidine, N4,2'-O-dimethylcytidine, N4,N4,2'-O-trimethylcytidine, isocytidine, pseudocytidine, pseudoisocytidine, 2-thio-cytidine, 2'-methyl-2'-deoxycytidine, 2'-amino-2'-deoxycytidine, 2'-fluoro-2'-deoxycytidine, 5-iodocytidine, 5-bromocytidine, 2'-azido-2'-deoxycytidine, 2'-amino-2'-deoxycytidine, 2'-fluoro(flu or)-2'-deoxycytidine, 5-aza-cytidine, 3-methyl-cytidine, 1-methyl-pseudoisocytidine, pyrrolo-cytidine, pyrrolo-pseudoisocytidine, 2-thio-5-methyl-cytidine, 4-thio-pseudoisocytidine, 4-thio-1-methyl-pseudoisocytidine, 4-thio-1-methyl-1-deaza-pseudoisocytidine, 1-methyl-1-deaza-pseudoisocytidine Cytidine, 2-methoxy-cytidine, 2-methoxy-5-methyl-cytidine, 4-methoxy-pseudoisocytidine, 4-methoxy-1-methyl-pseudoisocytidine, Zebularine, 5-aza-zebularine, 5-methyl-zebularine, 5-aza-2-thio-zebularine, 2-thio-zebularine; 1-methylguanosine, N2,7-dimethylguanosine, N2-methylguanosine, 2'-O-ribosyl Guanosine phosphate, 7-methylguanosine, hydroxywybutosine, 7-aminomethyl-7-deazaguanosine, 7-cyano-7-deazaguanosine, N2,N2-dimethylguanosine, N2,7,2'-O-trimethylguanosine, N2,2'-O-dimethylguanosine, 1,2'-O-dimethylguanosine, 2'-O-methylguanosine, N2,N2,2'-O-trimethylguanosine, N2,N2J-trimethylguanosine, isoguanosine, 4-demethylwyosine, epoxyqueosine, undermodified hydroxywyosine, undermethylated hydroxywyosine, isowyosine, peroxyqueosine, galactosyl-queosine, mannosyl-queosine, queosine, archaeosine, wyosine, methylwyosine, wyosine, 7-aminocarboxypropyldemethylwyosine, 7-aminocarboxypropylwyosine, 7-amino Carboxypropyl iosine methyl ester, 7-deaza-guanosine, 7-deaza-8-aza-guanosine, 6-thio-guanosine, 6-thio-7-deaza-guanosine, 6-thio-7-deaza-8-aza-guanosine, 7-methyl-guanosine, 6-thio-7-methyl-guanosine, 7-methylinosine, 6-methoxy-guanosine, 1-methylguanosine, 8-oxo-guanosine, 7-methyl-8-oxo-guanosine, 1-methyl-6-thio-guanosine, N2-methyl-6-thio-guanosine N2,N2-dimethyl-6-thio-guanosine, N1-methylguanosine, 2'-amino-3'-deoxyguanosine, 2'-azido-2'-deoxyguanosine, 2'-fluoro-2'-deoxyguanosine, 2-thiouridine, 3-(3-amino-3-carboxypropyl)uridine, 3-methyluridine, 4-thiouridine, 5-methyl-2-thiouridine, 5-methylaminomethyluridine, 5-carboxymethyluridine, 5-carboxymethylaminomethyluridine, 5-hydroxyuridine uridine, 5-methyluridine, 5-taurinomethyluridine, 5-carbamoylmethyluridine, 5-(carboxyhydroxymethyl)uridine methyl ester, dihydrouridine, 5-methyldihydrouridine, 5-methylaminomethyl-2-thiouridine, 5-(carboxyhydroxymethyl)uridine, 5-(carboxyhydroxymethyl)-2'-O-methyluridine methyl ester, 5-(isopentenylaminomethyl)uridine, 5-(isopentenylaminomethyl)-2-thiouridine, 3,2'-O-Dimethyluridine, 5-Carboxymethylaminomethyl-2'-O-methyluridine, 5-Carbamoylhydroxymethyluridine, 5-Carbamoylmethyl-2'-O-methyluridine, 5-Carbamoylmethyl-2-thiouridine, 5-Methoxycarbonylmethyl-2'-O-methyluridine, 5-(Isopentenylaminomethyl)-2'-O-methyluridine, 5,2'-O-Dimethyluridine, 2'-O-Methyluridine, 2'-O-Methyl-2-thiouridine (thiorudine), 2-Thio-2'-O-Methyluridine, Uridine 5-Oxyacetic Acid, 5-Methoxycarbonylmethyluridine, Uridine 5-Oxyacetic Acid Methyl Ester, 5-Methoxyuridine, 5-Aminomethyl-2-thiouridine, 5-Carboxy Methylaminomethyl-2-thiouridine, 5-methylaminomethyl-2-selenouridine, 5-methoxycarbonylmethyl-2-thiouridine, 5-taurinomethyl-2-thiouridine, pseudouridine, 1-methyl-3-(3-amino-3-carboxypropyl)pseudouridine, 1-methylpseudouridine, 3-methylpseudouridine, 2'-O-methylpseudouridine, 5-formyluridine, 5-aminomethyl-2-geranyluridine, 5-taurinomethyluridine, 5-iodouridine, 5-bromouridine, 2'-methyl-2'-deoxyuridine, 2'-amino-2'-deoxyuridine, 2'-azido-2'-deoxyuridine, 2'-fluoro-2'-deoxyuridine, inosine, 1-methylinosine, 1,2'-O-Dimethylinosine, 2'-O-Methylinosine, 5-Aza-uridine, 2-Thio-5-Aza-uridine, 4-Thio-Pseudouridine, 2-Thio-Pseudouridine, 5-Carboxymethyl-uridine, 1-Carboxymethyl-Pseudouridine, 5-Propynyl-uridine, 1-Propynyl-Pseudouridine, 1-Taurinomethyl-Pseudouridine, 5-Taurinomethyl-2-Thio-uridine, 1-Taurinomethyl-4-Thio-uridine, 5-Methyl-uridine, 1-Methyl-Pseudouridine, 4-Thio -1-methyl-pseudouridine, 2-thio-1-methyl-pseudouridine, 1-methyl-1-deaza-pseudouridine, 2-thio-1-methyl-1-deaza-pseudouridine, dihydropseudouridine, 2-thio-dihydrouridine, 2-thio-dihydropseudouridine, 2-methoxyuridine, 2-methoxy-4-thio-uridine, 4-methoxy-pseudouridine, 4-methoxy-2-thio-pseudouridine, 1,2'-O-dimethyladenosine, 1,2'-O-dimethylguanosine, 1,2'-O-dimethyl Chilinosine, 2,8-dimethyladenosine, 2-methylthiomethylenethio-N6-isopentenyl-adenosine, 2-geranylthiouridine, 2-lysidine, 2-methylthiocyclic N6-threonylcarbamoyl adenosine, 2-methylthio-N6-(cis-hydroxyisopentenyl)adenosine, 2-methylthio-N6-hydroxynorvalylcarbamoyl adenosine, 2-methylthio-N6-threonylcarbamoyl adenosine, 2-selenouridine, 2-thio-2'-O-methyluridine, 2'-O-methyladenosine Inosine, 2'-O-methylcytidine, 2'-O-methylguanosine, 2'-O-methylinosine, 2'-O-methylpseudouridine, 2'-O-methyluridine, 2'-O-methyluridine 5-oxyacetic acid methyl ester, 2'-O-ribosyladenosine phosphate, 2'-O-ribosylguanosine phosphate, 3,2'-O-dimethyluridine, 3-(3-amino-3-carboxypropyl)-5,6-dihydrouridine, 3-(3-amino-3-carboxypropyl)pseudouridine, 5,2'-O-dimethylcytidine, 5,2'-O-dimethyluridine, 5-(carboxyhydroxymethyl)-2'-O-methyluridine methyl ester, 5-(isopentenylaminomethyl)-2'-O-methyluridine, 5-aminomethyl-2-geranylthiouridine, 5-aminomethyl-2-selenouridine, 5-aminomethyluridine, 5-carbamoylmethyl-2'-O-methyluridine, 5-carboxyhydroxymethyluridine, 5-carboxymethyl-2-thiouridine, 5-carboxymethylaminomethyl-2-geranylthiouridine, 5-carboxymethylaminomethyl-2-selenouridine, 5-carboxymethylaminomethyl-2'-O-methyluridine, 5-cyanomethyluridine, 5-formyl-2'-O-methylcytidine, 5-methoxycarbonylmethyl-2'-O-methyluridine, 5-methylaminomethyl-2, -Geranylthiouridine, 7-aminocarboxypropyl-demethyl-wyosine, 7-methylguanosine, 8-methyladenosine, N2,2'-O-dimethylguanosine, N2,7,2'-O-trimethylguanosine, N2,7-dimethylguanosine, N2,N2,2'-O-trimethylguanosine, N2,N2,7-trimethylguanosine, N2,N2,7-trimethylguanosine, N4,2'-O-dimethylcytidine, N4,N4,2'-O-trimethylcytidine, N4,N4-dimethylcytidine, N4-acetyl-2'-O-methylcytidine, N6,2'-O-dimethyladenosine, N6,N6,2' -O-trimethyladenosine, N6-formyladenosine, N6-hydroxymethyladenosine, agamatidine, 2-methylthiocyclic N6-threonylcarbamoyladenosine, glutamyl-queosine, guanosine attached to any nucleotide, guanylylated 5' terminus, hydroxy-N6-threonylcarbamoyladenosine; most preferably pseudo-uridine, N1-methyl-pseudo-uridine, 2'-fluoro-2'-deoxycytidine, 5-iodocytidine, 5-methylcytidine, 2-thiouridine, 5-iodouridine and / or 5-methyl-uridine.

[0191] Furthermore, the term "modified nucleotide" includes nucleotide that contains isotopes such as deuterium.The term "isotope" refers to an element that has the same number of protons but different number of neutrons, resulting in different mass numbers.Therefore, for example, hydrogen isotopes are not limited to deuterium, but also include tritium.In addition, polyribonucleotide can also contain isotopes of other elements, including, for example, carbon, oxygen, nitrogen and phosphorus.Modified nucleotide can be deuterated or contain other isotopes of hydrogen, or isotopes of oxygen, carbon, nitrogen or phosphorus.

[0192] Among U, C, A and G nucleotides, none of them can be modified, or one, two, three or all of them can be modified.Therefore, in some embodiments, at least one nucleotide of one nucleotide type, for example, at least one U nucleotide, can be modified nucleotide.In some embodiments, at least one nucleotide of two nucleotide types in total, for example, at least one U nucleotide and at least one C nucleotide, can be modified nucleotide.In some embodiments, at least one nucleotide of three nucleotide types in total, for example, at least one G nucleotide, at least one U nucleotide and at least one C nucleotide, can be modified nucleotide.In some embodiments, at least one nucleotide of all four nucleotide types can be modified nucleotide. In all these embodiments, one or more nucleotides per nucleotide type may be modified, and the percentage of modified nucleotides per nucleotide type is 0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 100%.

[0193] In some embodiments, the total percentage of modified nucleotides in an mRNA molecule is 0%, 2.5%, 5%, 7.5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90% or 100%.

[0194] In a preferred embodiment, the mRNA is an mRNA containing a combination of modified and unmodified nucleotides. Preferably, it is an mRNA containing a combination of modified and unmodified nucleotides as described in International Publication No. 2011 / 012316. The mRNA described therein has been reported to exhibit improved stability and reduced immunogenicity. In a preferred embodiment, in such modified mRNA, 5 to 50% of the cytidine nucleotides and 5 to 50% of the uridine nucleotides are modified. In another preferred embodiment, 5 to 50% of the uridine nucleotides are substituted with N1-methyl-pseudo-uridine. Adenosine- and guanosine-containing nucleotides may be unmodified. The adenosine and guanosine nucleotides may be unmodified or partially modified, and they are preferably present in unmodified form.

[0195] In certain embodiments of any of the above, the percentage of an analog of a given nucleotide refers to the rate introduced (e.g., the rate of the analog in an initial reaction, such as an initial in vitro transcription reaction). In certain embodiments of any of the above, the percentage of an analog of a given nucleotide refers to the rate produced (e.g., the rate in a synthesized or transcribed compound). Both options are equally contemplated.

[0196] RNA, preferably mRNA molecules, can be produced recombinantly in vivo by methods known to those skilled in the art.

[0197] Alternatively, modified RNA, preferably mRNA, molecules may be produced in vitro, for example, using an in vitro transcription system known to those skilled in the art. An in vitro transcription system capable of producing RNA, preferably mRNA, requires an input mixture of modified and unmodified nucleoside triphosphates to produce modified RNA. In certain embodiments, 5-50% of the cytidines in such an input mixture are cytidine analogs, and 5-50% of the uridines in such an input mixture are uridine analogs. In certain embodiments, 5-40% of the cytidines in such an input mixture are cytidine analogs, and 5-40% of the uridines in such an input mixture are uridine analogs. In certain embodiments, 5-30% of the cytidines in such a mixture are cytidine analogs, and 5-30% of the uridines in such an input mixture are uridine analogs. In certain embodiments, 5-30% of the cytidines in such a mixture are cytidine analogs and 10-30% of the uridines are uridine analogs in such a mixture. In certain embodiments, 5-20% of the cytidines in such an input mixture are cytidine analogs and 5-20% of the uridines in such an input mixture are uridine analogs. In certain embodiments, 5-10% of the cytidines in such an input mixture are cytidine analogs and 5-10% of the uridines in such an input mixture are uridine analogs. In certain embodiments, 25% of the cytidines in such an input mixture are cytidine analogs and 25% of the uridines in such an input mixture are uridine analogs. In certain embodiments, the input mixture does not contain an adenosine and / or guanosine analog. In other embodiments, the input mixture optionally contains one or more analogs of adenosine and / or guanosine (or contains neither, or both).

[0198] In certain embodiments, the proportion of cytidine analogs, cytidine, in the input mixture is not the same as the proportion of uridine analogs, uridine, in the input mixture. In certain embodiments, the proportion of cytidine analogs in the input mixture is lower than the proportion of uridine analogs in the input mixture. As noted above, this means that adenosine and guanosine analogs may or may not be present in the input mixture, but in certain embodiments, adenosine analogs and guanosine analogs are absent in the input mixture.

[0199] In certain embodiments, an input mixture of nucleotides for an in vitro transcription system producing RNA, preferably mRNA, of the invention comprises a cytidine analog and a uridine analog, wherein 5-20% of the cytidines in the input mixture are cytidine analogs and 25-45% of the uridines in the input mixture are uridine analogs. In other words, the input mixture comprises modified and unmodified cytidines, as well as modified and unmodified uridines, wherein 5-20% of the cytidines in the input mixture comprise cytidine analogs, while 25-45% of the uridines in the input mixture comprise uridine analogs. In other embodiments, the input mixture comprises 5-10% cytidine analogs, such as 7-9%, e.g., 7%, 7.5%, or 8%, and 32-38%, e.g., 33%, 34%, 35%, or 36%, of uridine analogs, and 30-40% uridine analogs.

[0200] In certain embodiments, any of the uridine analogs and cytidine analogs described herein may be used, optionally excluding pseudouridine. In certain embodiments, the cytidine analog comprises or consists of 5-iodocytidine (e.g., it is the type of single C analog used), and the uridine analog comprises or consists of 5-iodouridine (e.g., it is the type of single U analog used).

[0201] Exemplary analogs are described above. In the case of a modified polyribonucleotide encoding a desired polypeptide, it should be understood that the level of analog and modification is considered throughout the entire polyribonucleotide encoding the desired polypeptide, including the 5' and 3' untranslated regions, unless otherwise specified (e.g., the level of modification is based on the input ratio of the analog in an in vitro transcription reaction such that the analog can be incorporated into the transcribed position).

[0202] Furthermore, modified RNA, preferably mRNA molecules may be chemically synthesized, for example by conventional chemical synthesis in an automated nucleotide sequence synthesizer using a solid phase support and standard techniques, or by chemical synthesis of the respective DNA sequence and subsequent transcription of the DNA sequence in vitro or in vivo.

[0203] In another preferred embodiment, the mRNA may be combined with a target binding site, target sequence, and / or microRNA binding site to allow the desired mRNA activity only in relevant cells. In a further preferred embodiment, the RNA may be combined with a microRNA or shRNA in the untranslated region.

[0204] Generally, therapeutic effect can be realized by the interaction of ribonucleic acid with cellular molecules and organelles.Such interaction can be achieved by itself, for example, in the case of certain CpG oligonucleotides and sequences that are designed to specifically interact with toll-like receptors and other extracellular or intracellular receptors, and can activate the innate immune system.Furthermore, the uptake or introduction of nucleic acid (preferably ribonucleic acid, more preferably mRNA) into cells can be intended to cause the expression of nucleotide sequences such as genes contained in nucleic acid (preferably ribonucleic acid, more preferably mRNA), and can be intended to downregulate, silence or knock down endogenous gene expression as a result of the presence of introduced exogenous nucleic acid in cells, or can be intended to modify endogenous nucleic acid sequences, such as repair, removal, insertion or replacement of selected bases or the entire stretch of endogenous nucleic acid sequence, or can be intended to interfere with virtually any cellular process as a result of the presence and interaction of introduced exogenous ribonucleic acid (preferably mRNA) in cells. Overexpression of introduced exogenous nucleic acids (preferably ribonucleic acids, more preferably mRNA) is intended to offset or complement endogenous gene expression, particularly when the endogenous gene is defective or silent, and does not result in insufficient, defective, or dysfunctional products of gene expression, as in the case of numerous metabolic and genetic diseases such as cystic fibrosis, hemophilia, or muscular dystrophy, to name a few. Overexpression of introduced exogenous nucleic acids (preferably ribonucleic acids, more preferably mRNA) may also be intended to cause the expression product to interact with or interfere with any endogenous cellular process, such as the regulation of gene expression, signal transduction, and other cellular processes. Overexpression of introduced exogenous nucleic acids (preferably ribonucleic acids, more preferably mRNA) may also be intended to provoke an immune response in the context of an organism in which transfected or transduced cells are present or in which these cells are made present. An example is the genetic modification of antigen-presenting cells, such as dendritic cells, to present antigens for vaccination purposes.Another example is the overexpression of cytokines in tumors to induce tumor-specific immune responses. Furthermore, overexpression of introduced exogenous ribonucleic acid (preferably mRNA) may also be intended to produce in vivo or ex vivo transiently genetically modified T cells, NK cells and other lymphocytes for cell therapy, or precursor or stem cells or other cells for regenerative medicine.

[0205] The downregulation, silencing or knockdown of endogenous gene expression for therapeutic purposes can be achieved by, for example, RNA interference (RNAi) with ribozymes, antisense oligonucleotides, tRNA, long double-stranded RNA, in which case, such downregulation can be sequence-specific or non-specific, and can also cause cell death, as when long double-stranded RNA is introduced into cells.The downregulation, silencing or knockdown of endogenous gene expression or existing gene expression can be useful for treating acquired diseases, hereditary diseases or spontaneously occurring diseases, including viral infection and cancer.It can also be envisioned that the introduction of nucleic acid into cells can be practiced as a preventive measure, for example, to prevent viral infection or neoplasia.The downregulation, silencing or knockdown of endogenous gene expression can be exerted at the transcriptional and translational levels. Multiple mechanisms are known to those skilled in the art, including, for example, epigenetic modification, changes in chromatin structure, selective binding of transcription factors by introduced nucleic acid, hybridization of introduced nucleic acid with complementary sequences in genomic DNA, mRNA or other RNA species by base pairing, including non-conventional base pairing mechanisms such as triple helix formation.Similarly, gene repair, base or sequence change can be achieved at the genome level and mRNA level, including exon skipping.Base or sequence change can be achieved, for example, by RNA-induced site-specific DNA cleavage, by trans-splicing, trans-splicing ribozyme, chimeraplast, spliceosome-mediated RNA trans-splicing by a cut-and-paste mechanism, by using group II or retargeting intron, by using virus-mediated insertion mutagenesis, or by using targeted genome insertion using the integrase system of prokaryotic, eukaryotic or viral organisms. Nucleic acids are carriers of the architectural plans of living systems and, because they are directly and indirectly involved in numerous cellular processes, theoretically any cellular process can be affected by the introduction of nucleic acids into cells from outside.In particular, such introduction can be performed directly in vivo, in cell or organ cultures, and ex vivo, followed by transplantation of the thus modified organ or cells into a recipient. Particles for use in the context of the present invention with nucleic acids as therapeutically active agents can be useful for all of the above purposes.

[0206] As mentioned above, the RNA, preferably the mRNA, may comprise a ribonucleotide sequence that encodes a protein or fragment thereof, the function of which is necessary or beneficial in or near a cell, such as a protein or fragment thereof, the supply of which can alleviate or prevent the disease or disorder, or a protein that can promote a process in or near a cell that is beneficial to the body.

[0207] Indeed, in recent years, RNA (especially mRNA) has become increasingly relevant as a novel drug entity. In contrast to DNA-based gene therapy agents, mRNA does not require transport into the nucleus but is directly translated into proteins in the cytoplasm (J Control Release, 2011, 150:238-247, and Eur J Pharm Biopharm, 2009, 71:484-489).

[0208] Furthermore, numerous genetic disorders caused by single gene mutations are known and are candidates for therapeutic approaches using RNA, preferably mRNA. Disorders caused by single gene mutations, such as cystic fibrosis, hemophilia, and many others, can be dominant or recessive in terms of the likelihood that a particular trait will appear in offspring. A dominant allele manifests a phenotype in an individual who has only one copy of the allele, while a recessive allele requires that the individual have two copies, one from each parent, to be manifested. In contrast, polygenic disorders are caused by two or more genes, and the symptoms of each disease are often mild and related to environmental factors. Examples of polygenic disorders include hypertension, elevated cholesterol levels, cancer, neurodegenerative disorders, and psychiatric disorders. Similarly, in these cases, therapeutic RNA, preferably mRNA, targeting one or more of these genes can be beneficial to such subjects. Furthermore, genetic disorders are not necessarily inherited from parental genes, and may also be caused by new mutations. Similarly, in these cases, therapeutic RNA, preferably mRNA, with the correct gene sequence may be beneficial to the subject.

[0209] An online catalog of 22,993 current entries of human genes and genetic disorders, along with descriptions of their individual genes and their phenotypes, is available at the ONIM (Online Mendelian Inheritance in Man) webpage (http: / / onim.org). Respective sequences are available from the Uniprot database (http: / / www.uniprot.org). As a non-limiting example, Table A below lists several congenital diseases and disorders and the corresponding genes. Due to the sophisticated interaction of cellular signaling pathways, mutations in certain genes can cause multiple pathogenic symptoms, and only characteristic of these symptoms are listed in Table A.

[0210] In some embodiments of the invention, the therapeutic protein encoded by the RNA, preferably an mMRA, and which may be present in the suspension formulations and aerosols of the invention is selected from the cellular proteins listed in Table A. Thus, the RNA, preferably an mRNA molecule, can encode a therapeutic cellular protein, where the encoded therapeutic protein is one listed in Table A or a homolog thereof.

[0211] In another embodiment of the invention, the therapeutic protein encoded by the RNA, preferably mRNA, is selected from the secreted proteins listed in Table A. Thus, the RNA, preferably mRNA, can encode a therapeutic fusion protein, wherein the encoded therapeutic protein or a homolog thereof is one listed in Table A, and the second protein is a signal peptide that allows secretion of the therapeutic protein. A signal peptide is a short, typically 5-30 amino acid long, sequence present at the N-terminus of the therapeutic protein that directs the fusion protein into the cellular secretory pathway via certain organelles (i.e., the endoplasmic reticulum, the Golgi apparatus, or endosomes). Thus, such fusion proteins are either secreted from the cell or from a cellular organelle, or inserted into the cell membrane (e.g., multispanning membrane proteins) in an intracellular compartment or at the cell surface.

[0212] Thus, in a preferred embodiment of the present invention, the RNA, preferably mRNA, can encode one or more of the following proteins, including but not limited to, genes that cause, predispose to, or protect against disease: Non-limiting examples of such diseases or disorders that may be treated (or prevented) are those in which the polypeptide, protein, or peptide is selected from the group consisting of those outlined in Table A below.

[0213] In some embodiments, the encoding sequence of the RNA, preferably mRNA, can be transcribed and translated into a partial or full-length protein that has cellular activity at levels equal to or higher than the level of the native protein. In some embodiments, the RNA, preferably mRNA, encodes a therapeutically or pharmaceutically active polypeptide, protein, or peptide that has a therapeutic or preventive effect, wherein the polypeptide, protein, or peptide is selected from the group consisting of those outlined in Table A below. The RNA, preferably mRNA, and more particularly its encoding sequence, can be used to express a partial or full-length protein that has cellular activity at levels equal to or lower than the level of the native protein. This can enable the treatment of diseases for which administration of RNA molecules is indicated.

[0214] [Table 1-1]

[0215] [Table 1-2]

[0216] [Table 1-3]

[0217] [Table 1-4]

[0218] [Table 1-5]

[0219] [Table 1-6]

[0220] [Table 1-7]

[0221] [Table 1-8]

[0222] Table A above shows examples of genes whose defects result in diseases that can be treated with RNA, preferably mRNA, that can be present in the suspension formulations and aerosols of the present invention, where the RNA, preferably mRNA, comprises a ribonucleotide sequence encoding an intact form of the protein or a functional fragment thereof of the defective gene disclosed above. In particularly preferred embodiments, the RNA is a ribonucleotide sequence encoding an intact form of the protein or a functional fragment thereof, for example, a disease affecting the lungs, such as SPB (surfactant protein B) deficiency, ABCA3 deficiency, cystic fibrosis and α1-antitrypsin deficiency, or a disease affecting plasma proteins (e.g., congenital hemochromatosis (hepcidin deficiency), thrombotic thrombocytopenic purpura (TPP, ADAMTS13 deficiency), and a disease affecting coagulation (e.g., hemophilia a and b) and complement (e.g., protein C deficiency), immune deficiency (RA), such as SCID. Genetic diseases may be addressed that cause adenosine deaminase deficiency, such as caused by mutations in various genes, such as G1, RAG2, JAK3, IL7R, CD45, CD3δ, CD3ε, or adenosine deaminase deficiency, e.g. (ADA-SCID), septic granulomatosis (caused, for example, by mutations in the gp-91-phox, p47-phox, p67-phox, or p33-phox genes), and storage diseases such as Gaucher disease, Fabry disease, Krabbe disease, MPS I, MPS II (Hunter syndrome), MPS VI, glycogen storage disease type II, or mucopolysaccharidoses.

[0223] Other disorders for which the RNA, preferably mRNA, of the invention may be useful include SMN1-associated spinal muscular atrophy (SMA); amyotrophic lateral sclerosis (ALS); GALT-associated galactosemia; cystic fibrosis (CF); SLC3A1-associated disorders, including cystinuria; COL4A5-associated disorders, including Alport syndrome; galactocerebrosidase deficiency; X-linked adrenoleukodystrophy and adrenomyeloneuropathy; Friedreich's ataxia; Pelizaeus-Merzbacher disease; TSC1- and TSC2-associated tuberous sclerosis; Sanfilippo B syndrome (MPS). IIIB); CTNS-associated cystinosis; FMR1-associated disorders including fragile X syndrome, fragile X-associated tremor / ataxia syndrome, and fragile X-associated premature ovarian failure syndrome; Prader-Willi syndrome; hereditary hemorrhagic telangiectasia (AT); Niemann-Pick disease type C1; neuronal ceroid lipofuscinosis-associated disorders including juvenile neuronal ceroid lipofuscinosis (JNCL), juvenile Batten disease, Santavuori-Haltia disease, Jansky-Bielschowsky disease, and PTT-1 and TPP1 deficiency; EIF2B1-, EIF2B2-, EIF2B3-, EIF2B4-, and EIF2B5-associated childhood ataxia with central nervous system white matter hypoplasia / vanishing; CACNA1A- and CACNB4-associated repeats Paroxysmal ataxia type 2; MECP2-related disorders including classic Rett syndrome, MECP2-related severe neonatal encephalopathy and PPM-X syndrome; CDKL5-related atypical Rett syndrome; Kennedy disease (SBMA); Notch-3-associated autosomal dominant cerebral arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL); SCN1A- and SCN1B-associated seizure disorders; Alpers-Huttenlocher syndrome, polymerase G-related disorders including POLG-associated sensory ataxic neuropathy, dysarthria, and ophthalmoplegia, and autosomal dominant and recessive progressive external ophthalmoplegia with mitochondrial DNA deletions; X-linked adrenal hypoplasia; X-linked agammaglobulinemia; Fabry disease; and Wilson disease.

[0224] In all of these diseases, proteins, such as enzymes, are deficient, and can be treated with RNA, preferably mRNA, encoding any of the above proteins, whereby the protein is encoded by a defective gene or its available functional fragment.Transcript replacement therapy / protein replacement therapy does not affect the underlying genetic defect, but improves the concentration of the protein that the subject is deficient in.As an example, in Pompe disease, transcript replacement therapy / enzyme replacement therapy replaces the deficiency of the lysosomal enzyme acid α-glucosidase (GAA).

[0225] Thus, non-limiting examples of proteins that can be encoded by mRNA include erythropoietin (EPO), growth hormone (somatotropin, hGH), cystic fibrosis transmembrane conductance regulator (CFTR), growth factors (such as GM-SCF and G-CSF), MPS, protein C, hepcidin, ABCA3, and surfactant protein B. Further examples of diseases that can be treated by the RNA of the present invention include hemophilia A / B, Fabry disease, CGD, ADAMTS13, Hurler disease, X-chromosome-mediated A-gammaglobulinemia, adenosine deaminase-associated immunodeficiency, and respiratory distress syndrome in newborns linked to SP-B. Particularly preferably, the RNA, preferably mRNA, of the present invention contains a coding sequence for surfactant protein B (SP-B) or erythropoietin. Further examples of proteins that can be encoded by the RNA, preferably mRNA, of the present invention are growth factors such as human growth hormone hGH, BMP-2, or angiogenic factors.

[0226] Although the above embodiments are described in the context of RNA, preferably mRNA, molecules that may be present in the nanoparticles used in the present invention, the above invention is not limited to the use of RNA, preferably mRNA, and other nucleic acid molecules, such as DNA molecules, may be used.

[0227] Said DNA molecule is capable of encoding said RNA, preferably said mRNA, and therefore contains the genetic information for the corresponding transcribed RNA molecule.

[0228] Thus, with regard to preferred embodiments, the same applies mutatis mutandis to the DNA molecules of the invention as described above and below in the context of RNA molecules, preferably mRNA molecules, which may be present in the nanoparticles used in the present invention.

[0229] Alternatively, RNA, preferably mRNA, may contain a ribonucleotide sequence encoding a full-length antibody or a smaller antibody (e.g., both heavy and light chains), which can be used in therapeutic situations, for example, to immunize a subject. Corresponding antibodies and their therapeutic uses are known in the art. Antibodies can be encoded by a single mRNA strand or by more than one mRNA strand.

[0230] In another embodiment, the RNA, preferably mRNA, can encode a functional monoclonal or polyclonal antibody that may be useful for targeting and / or inactivating a biological target (e.g., a stimulatory cytokine such as tumor necrosis factor). Similarly, the RNA, preferably mRNA sequence can encode a functional anti-nephrotic factor antibody useful, for example, in the treatment of membranoproliferative glomerulonephritis type II or acute hemolytic uremic syndrome, or alternatively, an anti-vascular endothelial growth factor (VEGF) antibody useful in the treatment of VEGF-mediated diseases such as cancer.

[0231] In another embodiment, the RNA, preferably mRNA, may encode a functional monoclonal or polyclonal antibody that may be useful for neutralizing or otherwise inhibiting a virus or viral replication.

[0232] Alternatively, the RNA, preferably mRNA, may comprise a ribonucleotide sequence that encodes an antigen, which may preferably be used in a prophylactic or therapeutic context.

[0233] In another embodiment, the mRNA can encode a protein or proteins that can induce immune modulation such as cytokines, including chemokines, interferons (such as interferon lambda), interleukins, lymphokines, and tumor necrosis factors.

[0234] In another embodiment, RNA, preferably mRNA, may contain a ribonucleotide sequence encoding a polypeptide or protein that can be used in genome editing technology. Genome editing is a type of genetic engineering in which DNA is inserted, deleted, or replaced in the genome of an organism using nucleases. These nucleases generate site-specific breaks at desired positions in the genome. The induced breaks are repaired by non-homologous end joining or homologous recombination, resulting in targeted mutations in the genome, thereby "editing" the genome. The breaks can be either single-strand breaks or double-strand breaks (DSBs), but double-strand breaks (DSBs) are preferred. Numerous genome editing systems that utilize various polypeptides or proteins are known in the art, such as CRISPR-Cas systems, meganucleases, zinc finger nucleases (ZFNs), and transcription activator-like effector-based nucleases (TALENs). Genome engineering methods are reviewed in Trends in Biotechnology, 2013, 31 (7), 397-405.

[0235] Therefore, in a preferred embodiment, RNA, preferably mRNA, can contain the ribonucleotide sequence encoding the polypeptide or protein of Cas (CRISPR-associated protein) protein family, preferably Cas9 (CRISPR-associated protein 9).The protein of Cas protein family, preferably Cas9, can be used in CRISPR / Cas9-based method and / or CRISPR / Cas9 genome editing technology.The CRISPR-Cas system for genome editing, control and targeting is reviewed in Nat. Biotechnol., 2014, 32(4):347-355.

[0236] In another preferred embodiment, the RNA, preferably mRNA, can contain a ribonucleotide sequence encoding a meganuclease. Meganucleases, in contrast to "conventional" endodeoxyribonucleases, are endodeoxyribonucleases that recognize large recognition sites (e.g., double-stranded DNA sequences consisting of 12 to 40 base pairs). As a result, each site occurs only a few times, preferably only once, in any given genome. Meganucleases are therefore considered to be the most specific naturally occurring restriction enzymes and are therefore suitable tools in genome editing technologies.

[0237] In another preferred embodiment, RNA, preferably mRNA, contains a ribonucleotide sequence encoding zinc finger nuclease (ZFN). ZFN is an artificial restriction enzyme that is generated by fusing a zinc finger DNA binding domain with a DNA cleavage domain. The zinc finger domain can be engineered to target a specific desired DNA sequence, allowing zinc finger nuclease to target a unique sequence in a complex genome. By utilizing endogenous DNA repair mechanisms, ZFN can be used to precisely modify the genome of higher organisms, and therefore ZFN is a suitable tool for genome editing technology.

[0238] In another preferred embodiment, RNA, preferably mRNA, can contain a ribonucleotide sequence encoding a transcription activator-like effector nuclease (TALEN). TALEN is a restriction enzyme that can be engineered to cleave specific sequences in DNA. TALEN is a fusion protein in which the TAL effector DNA binding domain is fused to the DNA cleavage domain of a nuclease. Transcription activator-like effector (TALE) can be engineered to bind to virtually any desired DNA sequence. Therefore, when combined with a nuclease, it can cleave DNA at a specific desired position.

[0239] Although the above embodiments are described in the context of RNA, preferably mRNA molecules, the above invention is not limited to the use of RNA, preferably mRNA, but can use any nucleic acid molecule, such as a DNA molecule.

[0240] Said DNA molecule is capable of encoding said RNA, preferably said mRNA, and therefore contains the genetic information for the corresponding transcribed RNA molecule.

[0241] Thus, with regard to preferred embodiments, the same applies mutatis mutandis to DNA molecules as described above and below in the context of RNA molecules, preferably mRNA molecules, which may be present in the nanoparticles used in the present invention.

[0242] As an alternative to the above, RNA contains the ribonucleotide sequence that is not expressed as protein or polypeptide.Therefore, the term RNA should not be understood to mean only any polynucleotide molecule that can be translated into polypeptide / protein or their fragments when introduced into cell.Rather, it is also intended that RNA contains the ribonucleotide sequence that is not translated into protein.In this context, it is intended that RNA contains the ribonucleotide sequence that preferably provides the genetic information for antisense RNA, siRNA or miRNA sequence, or other desired non-coding ribonucleotide sequence.

[0243] Therefore, RNA can also be antisense RNA, siRNA or miRNA sequence.Antisense RNA, siRNA or miRNA sequence can be used to silence the action of certain RNA molecules at a certain stage.This can be particularly desirable and useful in the treatment of certain medical conditions and certain diseases, and particularly in the RNA-based therapeutic methods described above and below in this specification.

[0244] Silencing the action of RNA molecules can be achieved by utilizing the RNAi (RNA interference) mechanism, using nucleic acid strands complementary to a specific RNA sequence. The term "RNA interference" or "inhibiting RNA" (RNAi / iRNA) describes the use of double-stranded RNA to target specific mRNAs for degradation, thereby silencing their translation. Preferred inhibiting RNA molecules can be selected from the group consisting of double-stranded RNA (dsRNA), siRNA, shRNA, and stRNA. dsRNA matching the gene sequence can be synthesized in vitro and introduced into cells. dsRNA can also be introduced into cells in the form of a vector that expresses the target gene sequence in sense and antisense orientations, for example, in the form of a hairpin mRNA. The sense and antisense sequences can be expressed from separate vectors, whereby the individual antisense and sense molecules form double-stranded RNA upon their expression. It is known in the art that in some cases, the expression of sequence in sense orientation, or even the expression of promoter sequence, is sufficient to produce dsRNA and then siRNA due to the internal amplification mechanism in cells.Therefore, all of the means and methods that can reduce the activity of the polypeptide or protein coded by coding region will be used by the present invention.For example, these siRNAs can be produced / introduced using sense constructs, antisense constructs, hairpin constructs, sense and antisense molecules, and their combinations.dsRNA is sent into the natural process, including the highly conserved nuclease Dicer, which cleaves dsRNA precursor molecules into short interfering RNA (siRNA).The method of producing and preparing siRNA and inhibiting the expression of target gene is described in, among others, WO 02 / 055693, Wei (2000) Dev. Biol. 15:239-255; La Count (2000) Biochem. Paras. 111:67-76; Baker (2000) Curr. Biol. 10:1071-1074; Svoboda (2000) Development 127:4147-4156 or Marie (2000) Curr. Biol. 10:289-292.These siRNA then assemble the sequence-specific part of the RNA-induced silencing complex (RISC), which is a multicomplex nuclease that destroys the messenger RNA that is homologous to the silencing trigger. Elbashir (2001) EMBO J. 20:6877-6888 showed that 21-nucleotide RNA duplexes may be used in cell culture to interfere with gene expression in mammalian cells.

[0245] The method of predicting and constructing siRNA is known in the art and is described in Elbashir (2002) Methods 26:199-213, and on the internet website of the commercial supplier of siRNA, for example, Qiagen GmbH (https: / / www1.qiagen.com / GeneGlobe / Default.aspx); Dharmacon (www.dharmacon.com); Xeragon Inc. (http: / / www.dharmacon.com / Default.aspx) and Ambion (www.ambion.com), or Tom Tuschl's research group website (http: / / www.rockefeller.edu / labheads / tuschl / sirna.html).In addition, the program that predicts siRNA from given mRNA sequence is available online (for example, http: / / www.ambion.com / techlib / misc / siRNA_finder.html or http: / / katahdin.cshl.org:9331 / RNAi / html / rnai.html). The uridine residues in the 2-nt 3' overhangs can be replaced by 2' deoxythymidine without loss of activity, significantly reducing the cost of RNA synthesis and enhancing the tolerance of siRNA duplexes when applied to mammalian cells (Elbashir (2001) in the appended text). siRNAs can also be enzymatically synthesized (sythesized) using T7 or other RNA polymerases (Donze (2002) Nucleic Acids Res 30:e46). Short RNA duplexes that mediate effective RNA interference (esiRNA) can also be generated by hydrolysis using Escherichia coli RNase III (Yang (2002) PNAS 99:9942-9947). Furthermore, expression vectors have been developed to express double-stranded siRNAs linked by small hairpin RNA loops in eukaryotic cells (e.g., Brummelkamp (2002) Science 296:550-553).All of these constructs can be developed with the aid of the programs named above. Additionally, commercially available sequence prediction tools, either integrated into sequence analysis programs or sold separately, can be used to predict siRNA sequences, for example, the siRNA design tool provided by www.oligoEngine.com (Seattle, WA).

[0246] MicroRNA (miRNA) is similar to the above-mentioned short interfering RNA (siRNA). MicroRNA (miRNA) is a short non-coding RNA molecule (containing approximately 22 nucleotides) found in plants, animals, and some viruses that functions in RNA silencing and post-transcriptional regulation of gene expression. miRNA functions by base pairing with complementary sequences within mRNA molecules. As a result, these mRNA molecules are silenced by one or more of the following processes: (1) cleavage of the mRNA strand into two small pieces, (2) destabilization of the mRNA by shortening its poly(A) tail, and (3) inefficient translation of the mRNA into protein by ribosomes. As mentioned above, miRNA is similar to the siRNA of the RNA interference (RNAi) pathway, except that miRNA is derived from a region of an RNA transcript that folds back on itself to form a short hairpin, while short interfering RNA (siRNA) is derived from a longer region of double-stranded RNA.

[0247] The DNA molecules used in the suspension formulations and aerosols of the present invention can also code for the above-mentioned RNA, for example the above-mentioned siRNA or miRNA, and thus contain the genetic information for the RNA molecules transcribed accordingly.Therefore, in preferred embodiments, the same applies mutatis mutandis to the DNA molecules described above in the context of the RNA molecules, preferably mRNA molecules, that can be present in the nanoparticles used in the present invention.

[0248] It will be appreciated that nanoparticles in the context of the present invention may comprise a single type of nucleic acid, preferably RNA such as mRNA, but may alternatively comprise more than one type of nucleic acid, preferably RNA, contained therein, for example in the form of particles comprising more than one type of nucleic acid, preferably RNA, in the form of a single particle or in the form of a blend of particles with different types of nucleic acid, preferably RNA, such as mRNA.

[0249] Together with the therapeutic agent (a), the nanoparticles further comprise component (b), a permanent cationic lipid, an ionizable lipid, or an ionizable lipidoid, i.e., component (b) is at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids. This includes the possibility that the nanoparticles may comprise a combination of different permanent cationic lipids, a combination of different ionizable lipids, a combination of different ionizable lipidoids, or a combination of one or more permanent cationic lipids, one or more ionizable lipids, and / or one or more ionizable lipidoids. Ionizable lipids and ionizable lipidoids are preferred as component (b), i.e., the nanoparticles preferably comprise at least one selected from ionizable lipids and ionizable lipidoids as component (b). The nanoparticles used in the context of the present invention comprise a nucleic acid (a) and a permanent cationic lipid, an ionizable lipid or an ionizable lipidoid (b), usually in the form of a mixture of components (a) and (b).

[0250] The term "permanently cationic lipid" is used in the field of lipid nanoparticles to refer to lipids that contain a permanent positive charge, for example in the form of a quaternary nitrogen atom.

[0251] The term " ionizable lipid " and " ionizable lipidoid " are used in the field of lipid nanoparticles and lipidoid nanoparticles, and refer to the lipid or lipidoid that is protonated and has a positive charge, or can be protonated and has a positive charge.Therefore, ionizable lipid and lipidoid are also referred to as " protonizable lipid " and " protonizable lipidoid ", respectively, or " ionizable cationic lipid " and " ionizable cationic lipidoid ", respectively, or also referred to as " titratable lipid " or " titratable lipidoid ".As will be understood by skilled readers, when referring to " ionizable lipid " or " ionizable lipidoid ", it includes the ionizable lipid or lipidoid in its protonated form or non-protonated form. As will be further understood, the protonated or unprotonated state of a lipid or lipidoid is generally determined by the pH value of the medium surrounding the lipid or lipidoid, for example, the pH value of the aqueous vehicle in which the nanoparticles are suspended. Thus, the terms "ionizable lipid" and "ionizable lipidoid" also include lipids or lipidoids that are positively charged at neutral pH.

[0252] In the context of the present invention, the counterion (anion) of the positive charge of the positively charged permanent cationic lipid, ionizable lipid or ionizable lipidoid is usually provided by the anionic moiety contained in nucleic acid.If the positively charged group is present in excess compared to the anionic moiety in nucleic acid, the positive charge can be balanced by other pharmaceutically acceptable anions such as chloride, bromide or iodide, sulfate, nitrate, phosphate, hydrogen phosphate, dihydrogen phosphate, carbonate or bicarbonate, or by polyanionic components other than nucleic acid, which can be present as optional components in nanoparticles.

[0253] Permanently cationic lipids, ionizable lipids, and ionizable lipidoids are well known as components of lipid or lipidoid nanoparticles. In the context of the present invention, no particular limitations are imposed on the type of permanently cationic lipid, ionizable lipid, or ionizable lipidoid contained in the nanoparticles.

[0254] Generally, ionizable lipids or lipidoids contain primary, secondary, or tertiary amino groups, respectively, that can act as proton acceptors, and thus may be protonated or unprotonated. Ionizable lipidoids generally contain a plurality of such amino groups, such as two or more, preferably three or more.

[0255] Preferably, the ionizable lipids that may be comprised by the nanoparticles are lipids that include a protonatable head group that contains one or more, preferably one, primary, secondary, or tertiary amino groups as the protonatable or protonated group, and one or more, preferably one or two, hydrophobic moieties linked to the head group.

[0256] Examples of these preferred ionizable lipids are: i) a lipid comprising a protonatable head group containing one or more, preferably one, primary, secondary or tertiary amino groups as the protonatable or protonated group, and one hydrophobic moiety linked to the head group. ii) lipids containing a secondary or tertiary amino group as a protonatable or protonated head group and two hydrophobic moieties linked to the head group; is.

[0257] The hydrophobic moieties contained in these preferred lipids preferably contain one or more of the following: a linear aliphatic residue, e.g., a linear residue containing 8 to 18 carbon atoms; a branched aliphatic residue, e.g., a branched residue containing 8 to 18 carbon atoms; or an alicyclic ring structure, which may be a fused ring structure, e.g., an alicyclic ring structure containing 10 to 18 carbon atoms. Additionally, the hydrophobic moiety may contain one or more linking groups that facilitate linking the moiety to a head group or that allow two or more of the aliphatic residues described above to be joined together. Furthermore, the hydrophobic moiety may contain one or more substituents, provided that the hydrophobic character of the moiety is maintained.

[0258] Preferably, the ionizable lipidoid to be included in the nanoparticles is an oligoamine, more preferably an oligoalkylamine, which contains at least two, preferably at least three, amino groups selected from protonatable or protonated secondary and tertiary amino groups, each of which may have a hydrophobic moiety attached thereto. In addition to the amino group bearing the hydrophobic residue, the lipidoid may contain additional protonatable or protonated amino groups selected from primary, secondary, and tertiary amino groups. Preferably, the total number of amino groups is 2 to 10, more preferably 3 to 6. Preferably, the total number of hydrophobic moieties attached to the amino groups is 2 to 6, more preferably 3 to 6. Preferably, the ratio of the number of hydrophobic moieties attached to the amino groups to the total number of amino groups in the oligoalkylamine is 0.5 to 2, more preferably 0.75 to 1.5.

[0259] The hydrophobic moiety contained in such preferred lipidoids preferably contains one or more of a linear aliphatic residue, e.g., a linear residue containing 8 to 18 carbon atoms, and a branched aliphatic residue, e.g., a branched residue containing 8 to 18 carbon atoms. Furthermore, the hydrophobic moiety may contain one or more linking groups that facilitate linking the moiety to an amino group or that allow two or more of the aliphatic residues described above to be joined together. Furthermore, the hydrophobic moiety may contain one or more substituents, provided that the hydrophobic character of the moiety is maintained.

[0260] Suitable exemplary ionizable lipids or ionizable lipidoids that may be included as component (b) in the nanoparticles used in the context of the present invention are described, for example, in WO 2006 / 138380, EP 2476756, U.S. 2016 / 0114042, U.S. Pat. No. 8,058,069, U.S. Pat. No. 8,492,359, U.S. Pat. No. 8,822,668, and the like. Nos. 8,969,535, 9,006,417, 9,018,187, 9,345,780, 9,352,042, 9,364,435, 9,394,234, 9,492,386, 9,504,651, and 9,518,272, and German Patent Publication No. 1983 No. 4683, International Publication No. 2010 / 053572, U.S. Patent No. 9,227,917, U.S. Patent No. 9,556,110, U.S. Patent No. 8,969,353, U.S. Patent No. 10,189,802, International Publication No. 2012 / 000104, International Publication No. 2010 / 053572, International Publication No. 2014 / 028487, International Publication No. 2015 / 095351 brochure, U.S. Patent Application Publication No. 2013 / 0156849 (e.g., claims 13, 33, 34), U.S. Patent No. 9,254,311 (e.g., claim 14), U.S. Patent No. 10,501,512 (e.g., claims 1, 6, 9), U.S. Patent Application Publication No. 2014 / 0010861 (e.g., claims 44 and 78-82), U.S. Patent Application Publication No. 2013 / 0115272 (e.g., claim 12), or Akinc, A., et al., Nature Biotechnology, 26(5), 2008, 561-569; Sabnis, S. et al., Molecular Therapy, 26(6), 2018, Vol. 26 No. 6 June 2018, 1509-1519; Kowalski, P.S., et al., Molecular Therapy, 27(4), 2019, 710-728; Kulkarni, JA et al, Nucleic Acid Therapeutics, 28(3), 2018, 146-157; and Li, B. et al., Nano Letters, 15, 2015, 8099-8107.

[0261] Preferably, the permanent cationic lipids that may be included in the nanoparticles are lipids that contain a quaternary nitrogen atom and a head group containing one or more, preferably one or two, hydrophobic moieties linked to the head group. Preferably, the quaternary nitrogen atom has the formula -N(Me)3 + where Me is a methyl group.

[0262] The hydrophobic moiety contained in these preferred lipids preferably contains one or more of a linear aliphatic residue, e.g., a linear residue containing 8 to 18 carbon atoms, or a branched aliphatic residue, e.g., a branched residue containing 8 to 18 carbon atoms. Furthermore, the hydrophobic moiety may contain one or more linking groups that facilitate linking the moiety to a head group or that allow two or more of the aliphatic residues described above to be joined together. Furthermore, the hydrophobic moiety may contain one or more substituents, provided that the hydrophobic character of the moiety is maintained. Examples of permanent cationic lipids include DOTMA (dioleoyl-3-trimethylammonium propane) and DOTAP (dioleoyl-3-trimethylammonium propane).

[0263] In one preferred embodiment, component (b) of the nanoparticles is an ionizable lipid or lipidoid of formula aI:

[0264] [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, or more preferably consisting of L 1 or L 2 One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond, R a is H or C1~C 12 is alkyl, R 1a and R 1b is, in each occurrence, independently (a) H or C1-C 12 alkyl, or (b) R 1a is H or C1~C 12 alkyl, and R 1b together with the carbon atom attached to it, the adjacent R 1b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 2a and R 2b is, in each occurrence, independently (a) H or C1-C 12 alkyl, or (b) R 2a is H or C1~C 12 alkyl, and R 2b together with the carbon atom attached to it, the adjacent R2b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 3a and R 3b is, in each occurrence, independently (a) H or C1-C 12 alkyl, or (b) R 3a is H or C1~C 12 alkyl, and R 3b together with the carbon atom attached to it, the adjacent R 3b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 4a and R 4b is, in each occurrence, independently (a) H or C1-C 12 alkyl, or (b) R 4a is H or C1~C 12 alkyl, and R 4b together with the carbon atom attached to it, the adjacent R 4b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 5 and R 6 are each independently methyl or cycloalkyl; R 7 is, in each occurrence, independently H or C1-C 12 is alkyl, R 8 and R 9 are each independently unsubstituted C1 to C 12 alkyl, or R 8 and R 9 together with the nitrogen atom to which they are bonded, form a 5-, 6-, or 7-membered heterocyclic ring containing one nitrogen atom; a and d are each independently an integer of 0 to 24; b and c are each independently an integer of 1 to 24; e is 1 or 2; where x is 0, 1, or 2).

[0265] In some embodiments, the ionizable lipid has the structure of formula a-II:

[0266] [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof (In the formula, L 1 or L 2 One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond, G 1 is C1-C2 alkylene, -(C=O)-, -O(C=O)-, -SC(=O)-, -NR a C(=O)- or a direct bond, G 2 -C(=O)-, -(C=O)O-, -C(=O)S-, -C(=O)NR a - or a direct bond, G 3 is a C1-C6 alkylene, R a is H or C1~C 12is alkyl, R 1a and R 1b is, in each occurrence, independently: (a) H or C1-C 12 alkyl, or (b) R 1a is H or C1~C 12 alkyl, and R 1b together with the carbon atom attached to it, the adjacent R 1b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 2a and R 2b is, in each occurrence, independently: (a) H or C1-C 12 alkyl, or (b) R 2a is H or C1~C 12 alkyl, and R 2b together with the carbon atom attached to it, the adjacent R 2b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 3a and R 3b is, in each occurrence, independently (a): H or C1-C 12 alkyl, or (b) R 3a is H or C1~C 12 alkyl, and R 3b together with the carbon atom attached to it, the adjacent R 3b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 4a and R 4b is, in each occurrence, independently: (a) H or C1-C 12 alkyl, or (b) R 4a is H or C1~C 12 alkyl, and R 4b together with the carbon atom attached to it, the adjacent R 4b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 5 and R 6 are each independently H or methyl; R 7 is C4~C 20 is alkyl, R 8 and R 9 are independently C1 to C 12 alkyl, or R 8 and R 9 together with the nitrogen atom to which they are attached form a 5-, 6- or 7-membered heterocyclic ring; a, b, c, and d are each independently an integer of 1 to 24; where x is 0, 1, or 2).

[0267] In some embodiments, the ionizable lipid has the structure of formula a-III:

[0268] [ka] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof (In the formula, L 1 or L 2 One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NRa -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond, G 1 and G 2 are each independently unsubstituted C1 to C 12 Alkylene or C1-C 12 is alkenylene, G 3 is C1~C 24 Alkylene, C1-C 24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene; R a is H or C1~C 12 is alkyl, R 1 and R 2 are independently C6 to C 24 Alkyl or C6-C 24 is alkenyl, R 3 H, OR 5 , CN, -C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 and R 4 is C1~C 12 is alkyl, R 5 is H or C1-C6 alkyl, where x is 0, 1, or 2).

[0269] In some embodiments, the ionizable lipid has the following formula IV:

[0270] [ka] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof (In the formula, G 1 or G 2In each occurrence, one of the following is selected from -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, and -S(O) y -, -SS-, -C(=O)S-, SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(=O)O-, and G 1 or G 2 The other is, in each occurrence, -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) y -, -SS-, -C(=O)S-, -SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(=O)O- or a direct bond; L, in each occurrence, ~ O(C=O)-, ~ represents a covalent bond to X, X is CR a and Z is an alkyl, cycloalkyl, or, when n is 1, a monovalent moiety containing at least one polar functional group; or Z is an alkylene, cycloalkylene, or, when n is greater than 1, a polyvalent moiety containing at least one polar functional group; R a are independently H, C1 through C in each occurrence. 12 Alkyl, C1-C 12 Hydroxyl alkyl, C1-C 12 Aminoalkyl, C1-C 12 Alkylaminylalkyl, C1-C 12 Alkoxyalkyl, C1-C 12 Alkoxycarbonyl, C1-C 12 Alkylcarbonyloxy, C1-C12 Alkylcarbonyloxyalkyl or C1-C 12 alkylcarbonyl, R, in each occurrence, is independently: (a) H or C1-C 12 alkyl, or (b) R, together with the carbon atom to which it is bonded, forms a carbon-carbon double bond with an adjacent R and its bonded carbon atom; R 1 and R 2 In each occurrence, the following structure:

[0271] [ka] and R 1 , R 2 , a 1 and a 2 is, in each occurrence, independently an integer from 3 to 12; b 1 and b 2 is independently 0 or 1 in each occurrence, c 1 and c 2 is, in each occurrence, independently an integer from 5 to 10; and d 1 and d 2 is, in each occurrence, independently an integer from 5 to 10; y is, in each occurrence, independently an integer from 0 to 2; and n is an integer from 1 to 6; Each of alkyl, alkylene, hydroxylalkyl, aminoalkyl, alkylaminylalkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, and alkylcarbonyl is optionally substituted with one or more substituents.

[0272] In some embodiments, the ionizable lipid has the following formula (aV):

[0273] [ka] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof (In the formula, G 1 or G 2 In each occurrence, one of the following is selected from -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, and -S(O) y -, -SS-, -C(=O)S-, SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(=O)O-, and G 1 or G 2 The other is, in each occurrence, -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) y -, -SS-, -C(=O)S-, -SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(=O)O- or a direct bond; L, in each occurrence, ~ O(C=O)-, ~ represents a covalent bond to X, X is CR a and Z is an alkyl, cycloalkyl, or, when n is 1, a monovalent moiety containing at least one polar functional group; or Z is an alkylene, cycloalkylene, or, when n is greater than 1, a polyvalent moiety containing at least one polar functional group; R a are independently H, C1 through C in each occurrence. 12 Alkyl, C1-C 12 Hydroxyl alkyl, C1-C 12Aminoalkyl, C1-C 12 Alkylaminylalkyl, C1-C 12 Alkoxyalkyl, C1-C 12 Alkoxycarbonyl, C1-C 12 Alkylcarbonyloxy, C1-C 12 Alkylcarbonyloxyalkyl or C1-C 12 alkylcarbonyl, R, in each occurrence, is independently: (a) H or C1-C 12 alkyl, or (b) R, together with the carbon atom to which it is bonded, forms a carbon-carbon double bond with an adjacent R and its bonded carbon atom; R 1 and R 2 In each occurrence, the following structure:

[0274] [ka] Each has R' in each occurrence is independently H or C1-C 12 alkyl, and a 1 and a 2 is, in each occurrence, independently an integer from 3 to 12; b 1 and b 2 is independently 0 or 1 in each occurrence, c 1 and c 2 is, in each occurrence, independently an integer from 2 to 12; and d 1 and d 2 is, in each occurrence, independently an integer from 2 to 12; y is, in each occurrence, independently an integer from 0 to 2; and n is an integer from 1 to 6; a 1 , a 2 , c 1 , c 2 , d 1 and d 2 is a 1 +c 1 +d1 The sum of the numbers must be an integer between 18 and 30. 2 +c 2 +d 2 are selected to be an integer from 18 to 30, and each of the alkyl, alkylene, hydroxylalkyl, aminoalkyl, alkylaminylalkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, and alkylcarbonyl is optionally substituted with one or more substituents.

[0275] In some embodiments, the ionizable lipid is selected from the lipids in Table 1, Table 2, Table 3, or Table 4.

[0276] [Table 2-1]

[0277] [Table 2-2]

[0278] [Table 2-3]

[0279] [Table 2-4]

[0280] [Table 2-5]

[0281] [Table 2-6]

[0282] [Table 2-7]

[0283]

Table 3-1

[0284]

Table 3-2

[0285]

Table 3-3

[0286]

Table 3-4

[0287]

Table 3-5

[0288]

Table 3-6

[0289]

Table 3-7

[0290]

Table 3-8

[0291]

Table 4-1

[0292]

Table 4-2

[0293] [Table 4-3]

[0294] [Table 4-4]

[0295] [Table 4-5]

[0296] [Table 4-6]

[0297] [Table 4-7]

[0298] [Table 4-8]

[0299] [Table 5]

[0300] In some embodiments, the ionizable lipid has the following structure:

[0301] [ka] It has one of the following.

[0302] In some embodiments, the ionizable lipid has the following structure:

[0303] [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof, wherein R and R are each independently for each occurrence an optionally substituted C 10 ~C 30 Alkyl, optionally substituted C 10 ~C 30 Alkenyl, optionally substituted C 10 ~C 30 Alkynyl or optionally substituted C 10 ~C 30 It is acyl, R3 is H, optionally substituted C 10 ~C 10 Alkyl, optionally substituted C-C 10 Alkenyl, optionally substituted C-C 10 alkynyl, alkylhetrocycle, alkylphosphate, alkylphosphorothioate, alkylphosphorodithioate, alkylphosphonate, alkylamine, hydroxyalkyl, ω-aminoalkyl, ω-(substituted)aminoalkyl, ω-phosphoalkyl, ω-thiophosphoalkyl, optionally substituted polyethylene glycol (PEG, mw 100-40K), optionally substituted mPEG (mw 120-40K), heteroaryl or heterocycle, or linker-ligand; E is O, S, N(Q), C(O), N(Q)C(O), C(O)N(Q),(Q)N(CO)O, O(CO)N(Q), S(O), NS(O)2N(Q), S(O)2, N(Q)S(O)2, SS, O=N, aryl, heteroaryl, cyclic or heterocycle; Q is H, alkyl, ω-aminoalkyl, ω-(substituted)aminoalkyl, ω-phosphoalkyl, or ω-thiophosphoalkyl.

[0304] In some embodiments, the ionizable lipid has the following structure:

[0305] [ka] It has one of the following.

[0306] In a preferred embodiment, the ionizable lipid is [(4-hydroxybutyl)azanediyl]di(hexane-6,1-diyl)bis(2-hexyldecanoate), also known as ALC-0315, and has the following formula:

[0307] [ka] As shown in the figure.

[0308] In some embodiments, the molar ratio of ionizable lipid to neutral lipid is in the range of about 4.1:1.0 to about 4.9:1.0, 4.5:1.0 to about 4.8:1.0, or 4.7:1.0 to about 4.8:1.0. In some embodiments, the molar ratio of cationic lipid to neutral lipid is in the range of about 2:1 to about 8:1, preferably 5:1 to 1:1.

[0309] In some embodiments, the molar ratio of ionizable lipid to polymer-conjugated lipid ranges from about 35:1 to about 25:1 or from 100:1 to about 20:1.

[0310] In some embodiments, the ionizable lipid has the following structure:

[0311] [ka] It has.

[0312] Further aspects of the present invention include: i) a first cationic lipid as an ionizable lipid (a) having a first effective pKa; ii) a second cationic lipid as the ionizable lipid (a) having a second effective pKa, the second effective pKa exceeding the first effective pKa; iii) neutral lipids; iv) steroids, v) polymer-conjugated lipids; vi) a therapeutic agent encapsulated within or associated with the lipid nanoparticles, or a pharmaceutically acceptable salt or prodrug thereof; and vii) Surfactants and having an effective pKa between a first effective pKa and a second effective pKa.

[0313] In some embodiments, the first effective pKa is less than 5.75. In some embodiments, the second effective pKa is greater than 6.25. In some embodiments, the lipid nanoparticles have an effective pKa in the range of 5.90 to 6.35. In some embodiments, the molar ratio of the first cationic lipid to the second cationic lipid is in the range of 1:20 to 1:2.

[0314] In some embodiments, the LNPs or LiNPs of the invention comprise a first cationic lipid as the ionizable lipid (a) or a second cationic lipid as the ionizable lipid (a), either or both of which have the structure of formula aI:

[0315] [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof (In the formula, L 1 or L 2 One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NRa C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond, R a is H or C1~C 12 is alkyl, R 1a and R 1b is, in each occurrence, independently (a) H or C1-C 12 alkyl, or (b) R 1a is H or C1~C 12 alkyl, and R 1b together with the carbon atom attached to it, the adjacent R 1b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 2a and R 2b is, in each occurrence, independently (a) H or C1-C 12 alkyl, or (b) R 2a is H or C1~C 12 alkyl, and R 2b together with the carbon atom attached to it, the adjacent R 2b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 3a and R 3b is, in each occurrence, independently (a) H or C1-C 12 alkyl, or (b) R 3a is H or C1~C 12 alkyl, and R 3b together with the carbon atom attached to it, the adjacent R 3b and together with the carbon atom attached thereto form a carbon-carbon double bond, R 4a and R 4b is, in each occurrence, independently (a) H or C1-C12 alkyl, or (b) R 4a is H or C1~C 12 alkyl, and R 4b together with the carbon atom attached to it, the adjacent R 4b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 5 and R 6 are each independently methyl or cycloalkyl; R 7 is, in each occurrence, independently H or C1-C 12 is alkyl, R 8 and R 9 are each independently unsubstituted C1 to C 12 alkyl, or R 8 and R 9 together with the nitrogen atom to which they are attached form a 5-, 6- or 7-membered heterocyclic ring containing one nitrogen atom, a and d are each independently an integer of 0 to 24, b and c are each independently an integer of 1 to 24; e is 1 or 2; x is 0, 1 or 2).

[0316] In some embodiments, the first and second cationic lipids as the ionizable lipid (a) are each independently selected from lipids of formula aI. In some embodiments, the first cationic lipid, or the second cationic lipid, or both, have the structure of formula a-II:

[0317] [ka] or a pharmaceutically acceptable salt, tautomer, prodrug or stereoisomer thereof (In the formula, L 1 or L 2One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O- or a direct bond, G 1 is C1-C2 alkylene, -(C=O)-, -O(C=O)-, -SC(=O)-, -NR a C(=O)- or a direct bond, G 2 -C(=O)-, -(C=O)O-, -C(=O)S-, -C(=O)NR a - or a direct bond, G 3 is a C1-C6 alkylene, R a is H or C1~C 12 is alkyl, R 1a and R 1b is, in each occurrence, independently: (a) H or C1-C 12 alkyl, or (b) R 1a is H or C1~C 12 alkyl, and R 1b together with the carbon atom attached to it, the adjacent R 1b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 2a and R 2b is, in each occurrence, independently: (a) H or C1-C 12 alkyl, or (b) R 2a is H or C1~C 12 alkyl, and R 2b together with the carbon atom attached to it, the adjacent R 2b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 3a and R 3b is, in each occurrence, independently (a): H or C1-C 12 alkyl, or (b) R 3a is H or C1~C 12 alkyl, and R 3b together with the carbon atom attached to it, the adjacent R 3b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 4a and R 4b is, in each occurrence, independently: (a) H or C1-C 12 alkyl, or (b) R 4a is H or C1~C 12 alkyl, and R 4b together with the carbon atom attached to it, the adjacent R 4b and together with the carbon atom attached thereto form a carbon-carbon double bond; R 5 and R 6 are each independently H or methyl; R 7 is C4~C 20 is alkyl, R 8 and R 9 are independently C1 to C 12 alkyl, or R 8 and R 9together with the nitrogen atom to which they are attached form a 5-, 6- or 7-membered heterocyclic ring; a, b, c, and d are each independently an integer of 1 to 24; x is 0, 1 or 2).

[0318] In some embodiments, the first and second cationic lipids as the ionizable lipid (a) are each independently selected from lipids of formula a-II:

[0319] In some embodiments, the first cationic lipid as the ionizable lipid (a), or the second cationic lipid as the ionizable lipid (a), or both, has the formula a-III:

[0320] [ka] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof. (In the formula, L 1 or L 2 One of the groups is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR a C(=O)O-, and L 1 or L 2 The other is -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) x -, -SS-, -C(=O)S-, SC(=O)-, -NR a C(=O)-, -C(=O)NR a -, NR a C(=O)NR a -, -OC(=O)NR a -or-NR aC(=O)O- or a direct bond, G 1 and G 2 are each independently unsubstituted C1 to C 12 Alkylene or C1-C 12 is alkenylene, G 3 is C1~C 24 Alkylene, C1-C 24 alkenylene, C3-C8 cycloalkylene, C3-C8 cycloalkenylene; R a is H or C1~C 12 is alkyl, R 1 and R 2 are independently C6 to C 24 Alkyl or C6-C 24 is alkenyl, R 3 H, OR 5 , CN, -C(=O)OR 4 , -OC(=O)R 4 or -NR 5 C(=O)R 4 and R 4 is C1~C 12 is alkyl, R 5 is H or C1-C6 alkyl, x is 0, 1 or 2).

[0321] In some embodiments, the first and second cationic lipids as the ionizable lipid (a) are each independently selected from lipids of formula a-III:

[0322] In some embodiments, the first cationic lipid as the ionizable lipid (a), or the second cationic lipid as the ionizable lipid (a), or both, is represented by formula a-IV:

[0323] [ka] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof. (In the formula, G 1 or G 2 In each occurrence, one of the following is selected from -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, and -S(O) y -, -SS-, -C(=O)S-, SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(=O)O-, and G 1 or G 2 The other is, in each occurrence, -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) y -, -SS-, -C(=O)S-, -SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(═O)O— or a direct bond, and L, in each occurrence, is ~ O(C=O)-, ~ represents a covalent bond to X, X is CR a and Z is an alkyl, cycloalkyl, or, when n is 1, a monovalent moiety containing at least one polar functional group; or Z is an alkylene, cycloalkylene, or, when n is greater than 1, a polyvalent moiety containing at least one polar functional group; R a are independently H, C1 through C in each occurrence. 12 Alkyl, C1-C 12 Hydroxyl alkyl, C1-C 12 Aminoalkyl, C1-C 12 Alkylaminylalkyl, C1-C12 Alkoxyalkyl, C1-C 12 Alkoxycarbonyl, C1-C 12 Alkylcarbonyloxy, C1-C 12 Alkylcarbonyloxyalkyl or C1-C 12 alkylcarbonyl, R, in each occurrence, is independently: (a) H or C1-C 12 alkyl, or (b) R, together with the carbon atom to which it is bonded, forms a carbon-carbon double bond with an adjacent R and its bonded carbon atom; R 1 and R 2 In each occurrence, the following structure:

[0324] [ka] and a 1 and a 2 is, in each occurrence, independently an integer from 3 to 12; b 1 and b 2 is independently 0 or 1 in each occurrence, c 1 and c 2 is, in each occurrence, independently an integer from 5 to 10; and d 1 and d 2 is, in each occurrence, independently an integer from 5 to 10; y is, in each occurrence, independently an integer from 0 to 2; and n is an integer from 1 to 6; Each of alkyl, alkylene, hydroxylalkyl, aminoalkyl, alkylaminylalkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, and alkylcarbonyl is optionally substituted with one or more substituents.

[0325] In some embodiments, the first and second cationic lipids as the ionizable lipid (a) are each independently selected from lipids of formula a-IV.

[0326] In some embodiments, the first cationic lipid as the ionizable lipid (a), or the second cationic lipid as the ionizable lipid (a), or both, has the formula aV:

[0327] [ka] or a pharmaceutically acceptable salt, prodrug or stereoisomer thereof, G 1 or G 2 In each occurrence, one of the following is selected from -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, and -S(O) y -, -SS-, -C(=O)S-, SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(=O)O-, and G 1 or G 2 The other is, in each occurrence, -O(C=O)-, -(C=O)O-, -C(=O)-, -O-, -S(O) y -, -SS-, -C(=O)S-, -SC(=O)-, -N(R a )C(=O)-, -C(=O)N(R a )-, -N(R a )C(=O)N(R a )-, -OC(=O)N(R a )- or -N(R a )C(=O)O- or a direct bond; L, in each occurrence, ~ O(C=O)-, ~ represents a covalent bond to X, X is CR a and Z is an alkyl, cycloalkyl, or, when n is 1, a monovalent moiety containing at least one polar functional group; or Z is an alkylene, cycloalkylene, or, when n is greater than 1, a polyvalent moiety containing at least one polar functional group; R a are independently H, C1 through C in each occurrence. 12 Alkyl, C1-C 12 Hydroxyl alkyl, C1-C 12 Aminoalkyl, C1-C 12 Alkylaminylalkyl, C1-C 12 Alkoxyalkyl, C1-C 12 Alkoxycarbonyl, C1-C 12 Alkylcarbonyloxy, C1-C 12 Alkylcarbonyloxyalkyl or C1-C 12 alkylcarbonyl, R, in each occurrence, is independently: (a) H or C1-C 12 alkyl, or (b) R, together with the carbon atom to which it is bonded, forms a carbon-carbon double bond with an adjacent R and its bonded carbon atom; R 1 and R 2 In each occurrence, the following structure:

[0328] [ka] and R' in each occurrence is independently H or C1-C 12 alkyl, and a 1 and a 2 is, in each occurrence, independently an integer from 3 to 12; b 1 and b 2 is independently 0 or 1 in each occurrence, c 1 and c 2 is, in each occurrence, independently an integer from 2 to 12; and d1 and d 2 is, in each occurrence, independently an integer from 2 to 12; y is, in each occurrence, independently an integer from 0 to 2; and n is an integer from 1 to 6; a 1 , a 2 , c 1 , c 2 , d 1 and d 2 is a 1 +c 1 +d 1 The sum of the numbers must be an integer between 18 and 30. 2 +c 2 +d 2 is selected to be an integer from 18 to 30, and each of the alkyl, alkylene, hydroxylalkyl, aminoalkyl, alkylaminylalkyl, alkoxyalkyl, alkoxycarbonyl, alkylcarbonyloxy, alkylcarbonyloxyalkyl, and alkylcarbonyl is optionally substituted with one or more substituents.

[0329] In some embodiments, the first and second cationic lipids as the ionizable lipid (a) are each independently selected from lipids of formula aV:

[0330] In some embodiments, the first and second cationic lipids as the ionizable lipid (a) have the following structure:

[0331] [ka] Each of them has:

[0332] In some embodiments, the first cationic lipid as the ionizable lipid (a), the second cationic lipid as the ionizable lipid (a), or both, has the following structure:

[0333] [ka] It has one of the following.

[0334] In some embodiments, when a compound of Formula a-II is used, the total molar percentage of cationic lipids as ionizable lipids (a) in the lipid nanoparticles is in the range of 40 to 55 molar percent relative to the total lipids present in the lipid nanoparticles. In some embodiments, the molar ratio of total cationic lipids to neutral lipids is in the range of about 2:1 to about 8:1. In some embodiments, the molar ratio of total cationic lipids to steroids is in the range of 5:1 to 1:1. In some embodiments, the molar ratio of total cationic lipids to polymer-conjugated lipids is in the range of about 100:1 to about 20:1.

[0335] In some embodiments, the neutral lipid is distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoyl-phosphatidylethanolamine (POPE) and dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoylphosphatidylethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidylethanolamine (DSPE), 16-O-monomethylPE, 16-O-dimethylPE, 18-1-trans In some embodiments, the neutral lipid is PE, 1-stearioyl-2-oleoylphosphatidyethanolamine (SOPE), or 1,2-dielideyl-sn-glycero-3-phosphoethanolamine (transDOPE), and preferably, the neutral lipid is DSPC, DPPC, DMPC, DOPC, POPC, DOPE, or SM. In some embodiments, the neutral lipid is DSPC. In some embodiments, the steroid is cholesterol.

[0336] In some embodiments, the polymer-conjugated lipid is present at a concentration in the range of 1.0 to 2.5 mole percent, preferably about 1.7 mole percent, and the polymer-conjugated lipid is present at a concentration of about 1.5 mole percent.

[0337] In some embodiments, the polymer-conjugated lipid is a PEGylated lipid. In some embodiments, the PEGylated lipid is PEG-DAG, PEG-PE, PEG-S-DAG, PEG-cer or PEG dialkyloxypropylcarbamate. In some embodiments, the PEGylated lipid is represented by the following formula (a-VI):

[0338] [ka] or a pharmaceutically acceptable salt, tautomer or stereoisomer thereof (In the formula, R 12 and R 13 are each independently a linear or branched, saturated or unsaturated alkyl chain containing 10 to 30 carbon atoms, the alkyl chain optionally being interrupted by one or more ester linkages; w has an average value in the range of 30 to 60. In some cases, R 12 and R 13 are each independently a linear saturated alkyl chain containing 12 to 16 carbon atoms. Optionally, the average w ranges from 42 to 55, and preferably the average w is about 49. In some embodiments, the PEGylated lipid has the following formula (VIa):

[0339] [ka] with an average w of about 49).

[0340] In some embodiments, the lipid nanoparticles form a plurality of nanoparticles with a polydispersity of less than 0.12. Preferably, the polydispersity is less than 0.08.

[0341] In some embodiments, the average diameter is in the range of 50 nm to 100 nm, and preferably the diameter is in the range of 60 nm to 85 nm.

[0342] Aspects of the present invention relate to methods of administering a therapeutic agent to a patient in need thereof, comprising administering to the patient lipid nanoparticles of the present invention or pharmaceutical compositions of the present invention.

[0343] A further aspect of the present invention relates to a method of treating a disease in a patient in need thereof, comprising administering to the patient lipid nanoparticles comprising a surfactant of the present invention, or a pharmaceutical composition comprising a surfactant, wherein the therapeutic agent is effective to treat the disease.

[0344] In a preferred embodiment, component (b) of the nanoparticles used in the various aspects of the present invention comprises, or more preferably consists of, an ionizable lipidoid of the following formula (b-1) or a protonated form thereof: Ionizable lipidoids of the following formula (b-1) or a protonated form thereof that can be used as preferred component (b) in the context of the present invention are described in detail in PCT application WO 2014 / 207231.

[0345] Therefore, component (b) is a lipidoid of the following formula (b-1):

[0346] [ka] where the variables a, b, p, m, n and R 1A ~R 6A is defined as follows: a is 1 and b is an integer from 2 to 4, or a is an integer from 2 to 4 and b is 1; p is 1 or 2; m is 1 or 2, n is 0 or 1, and m+n is ≧2; R 1A ~R 6A are, independently of each other, hydrogen; -CH2-CH(OH)-R 7A , -CH(R 7A )-CH2-OH, -CH2-CH2-(C=O)-OR 7A, -CH2-CH2-(C=O)-NH-R 7A ;-CH2-R 7A -C(NH)-NH; a poly(ethylene glycol) chain; and a receptor ligand, R 7A is selected from C3-C18 alkyl and C3-C18 alkenyl having one C-C double bond; However, R 1A ~R 6A At least two residues of -CH2-CH(OH)-R 7A , -CH(R 7A )-CH2-OH, -CH2-CH2-(C=O)-OR 7A , -CH2-CH2-(C=O)-NH-R 7A and -CH2-R 7A Selected from R 7A is selected from C3-C18 alkyl or C3-C18 alkenyl having one C-C double bond) or preferably comprises or consists of a protonated form thereof, in which one or more of the nitrogen atoms contained in the compound of formula (I) are protonated to give a compound having a positive charge.

[0347] Preferably, R 1A ~R 6A is hydrogen; the group -CH2-CH(OH)-R 7A , -CH(R 7A )-CH2-OH, -CH2-CH2-(C=O)-OR 7A , -CH2-CH2-(C=O)-NH-R 7A ; and -CH2-R 7A are independently selected from R 7A is selected from C3-C18 alkyl and C3-C18 alkenyl having one C-C double bond, provided that R 1A ~R 6A and more preferably at least two residues of R 1A ~R 6A and even more preferably at least three residues of R 1A ~R 6A At least four residues of -CH2-CH(OH)-R7A , -CH(R 7A )-CH2-OH, -CH2-CH2-(C=O)-OR 7A , -CH2-CH2-(C=O)-NH-R 7A and -CH2-R 7A and R 7A is selected from C3-C18 alkyl and C3-C18 alkenyl having one C-C double bond. More preferably, R 1A ~R 6A is hydrogen and the group -CH2-CH(OH)-R 7A are independently selected from R 7A is selected from C3-C18 alkyl and C3-C18 alkenyl having one C-C double bond, provided that R 1A ~R 6A and more preferably at least two residues of R 1A ~R 6A and even more preferably at least three residues of R 1A ~R 6A At least four residues of the group -CH2-CH(OH)-R 7A and R 7A is selected from C3-C18 alkyl and C3-C18 alkenyl having one CC double bond.

[0348] Preferably, R 7A is selected from C8-C18 alkyl and C8-C18 alkenyl having one C-C double bond, more preferably C8-C12 alkyl and C8-C12 alkenyl having one C-C double bond. Generally, the alkyl group R 7A As such, it is more preferred than an alkenyl group.

[0349] base R 1A ~R 6Ais a protecting group for an amino group, such as those described in, for example, WO 2006 / 138380, preferred embodiments of which are t-butoxycarbonyl (Boc), 9-fluorenylmethoxycarbonyl (Fmoc) or carbobenzyloxy (Cbz).

[0350] base R 1A ~R 6A A useful example is the work of Philipp and Wagner in “Gene and Cell Therapy - Therapeutic Mechanisms and Strategy”, 3 rd Edition, Chapter 15. CRC Press, Taylor & Francis Group LLC, Boca Raton 2009. Preferred receptor ligands for lung tissue are described in Pfeifer et al. 2010, Ther Deliv. 1(1):133-48. Preferred receptor ligands include synthetic cyclic or linear peptides, such as those derived from screening peptide libraries for binding to specific cell surface structures or specific cell types, cyclic or linear RGD peptides, synthetic or natural carbohydrates (such as sialic acid, galactose, or mannose), or synthetic ligands derived from carbohydrates, for example, peptides, antibodies specifically recognizing cell surface structures, folate, epidermal growth factor and peptides derived therefrom, transferrin, anti-transferrin receptor antibodies, nanobodies and antibody fragments, or approved drugs that bind to known cell surface molecules.

[0351] base R 1A ~R 6A As long as any one of the above is a poly(ethylene glycol) chain, the molecular weight of the poly(ethylene glycol) chain is preferably 100 to 20,000 g / mol, more preferably 1,000 to 10,000 g / mol, and most preferably 1,000 to 5,000 g / mol.

[0352] The variable p in formula (b-1) is preferably 1.

[0353] In formula (b-1), m is 1 or 2, n is 0 or 1, and m+n is ≧2. In other words, when m is 1, n must also be 1, and when m is 2, n can be 0 or 1. When n is 0, m must be 2. When n is 1, m can be 1 or 2.

[0354] The variable n in formula (b-1) is preferably 1. It is more preferable that m is 1 and n is 1.

[0355] Therefore, the combination of p=1, m=1 and n=1 is also preferred.

[0356] With respect to the variables a and b in formula (b-1), it is preferred that one of a and b is 1 and the other is 2 or 3. It is more preferred that a is 1 and b is 2, or a is 2 and b is 1. Most preferably, a is 1 and b is 2.

[0357] In view of the above, it is believed that the compound of formula (b-1) is a compound of formula (b-1a), and that component (b) is a lipidoid of formula (b-1a) below: R 1A -NR 2A -CH2-(CH2) a -NR 3A -CH2-(CH2) b -NR 4A -CH2-(CH2) a -NR 5A -R 6A (b-1a), (Wherein a, b and R 1A ~R 6A is as defined in formula (b-1), including its preferred embodiments. or a protonated form thereof, wherein one or more of the nitrogen atoms shown in formula (b-1a) are protonated to provide a compound having a positive charge. More preferably, it comprises or consists of:

[0358] According to a further preferred embodiment, the compound of formula (b-1) is a compound of formula (b-1b), and component (b) is a lipidoid compound of formula (b-1b)

[0359] [ka] (In the formula, R 1A ~R 6A is defined as in formula (Ia), including its preferred embodiments. or a protonated form thereof, wherein one or more nitrogen atoms shown in formula (b-1b) are protonated to provide a compound having a positive charge. It comprises or consists of:

[0360] Thus, according to a particularly preferred embodiment, component (b) comprises or consists of a lipidoid compound of formula (b-1b) above or a protonated form thereof, R 1A ~R 6A is hydrogen and -CH2-CH(OH)-R 7A are independently selected from R 7A is selected from C8-C18 alkyl and C8-C18 alkenyl having one C-C double bond, provided that R 1A ~R 6A At least two residues of -CH2-CH(OH)-R 7A and more preferably R 1A ~R 6A and even more preferably at least three residues of R 1A ~R 6A At least four residues of -CH2-CH(OH)-R 7A and R 7A is selected from C8-C18 alkyl and C8-C18 alkenyl having one CC double bond.

[0361] Examples of suitable lipidoid compounds that may be used as ionizable lipidoids in the context of the present invention include those with the following structures:

[0362] [ka] An example of such a lipidoid is cationic lipidoid dL_05(R) having the formula:

[0363] According to a further exemplary embodiment, component (b) is an ionizable lipid of formula (b-2):

[0364] [ka] (In the formula, R 1B is an organic group containing one or more primary, secondary, or tertiary amino groups) or R 1B wherein one or more nitrogen atoms contained in a primary, secondary or tertiary amino group are protonated to provide a compound having a positive charge, in its protonated form It comprises or consists of:

[0365] Preferably, the compound of formula (b-2) has the following structure:

[0366] [ka] It has.

[0367] According to another exemplary embodiment, component (b) is an ionizable lipid of formula (b-3):

[0368] [ka] (In the formula, R 1C and R 2C are independently selected from C8 to C18 alkyl groups and C8 to C18 alkenyl groups, preferably C12 to C18 alkyl groups and C12 to C18 alkenyl groups; R 3C is a C1 to C6 alkanediyl group, preferably a C2 or C3 alkanediyl group, R 4C and R 5C are independently hydrogen or C1-C3 alkyl, preferably methyl. or a protonated form thereof, in which one or more of the nitrogen atoms contained in the compound of formula (b-3) are protonated to give a compound having a positive charge. An example of the ionizable lipid of formula (b-3) is DLin-MC3-DMA (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate).

[0369] According to yet another exemplary embodiment, component (b) is an ionizable lipid of formula (b-4):

[0370] [ka] (In the formula, R 1D and R 2D are independently selected from C8 to C18 alkyl groups and C8 to C18 alkenyl groups, preferably C12 to C18 alkyl groups and C12 to C18 alkenyl groups; R 3D is a C1-C6 alkanediyl group, preferably a C2 alkanediyl group, R 4D and R 5D are independently hydrogen or C1-C3 alkyl, preferably methyl. or a protonated form thereof, in which one or more of the nitrogen atoms contained in the compound of formula (b-4) are protonated to give a compound having a positive charge. It comprises or consists of:

[0371] According to yet another exemplary embodiment, component (b) is an ionizable lipidoid of formula (b-5):

[0372] [ka] (In the formula, R 1E ~R 5E are, independently of each other, hydrogen, -CH-CH(OH)-R 7E , -CH(R 7E )-CH2-OH, -CH2-CH2-(C=O)-OR 7E , -CH2-CH2-(C=O)-NH-R 7E and -CH2-R 7E Selected from R 7E is selected from C3-C18 alkyl or C3-C18 alkenyl having one C-C double bond, provided that R 1E ~R 5E At least two residues of -CH2-CH(OH)-R 7E , -CH(R 7E )-CH2-OH, -CH2-CH2-(C=O)-OR 7E , -CH2-CH2-(C=O)-NH-R 7E and -CH2-R 7E Selected from R 7E is selected from C3-C18 alkyl or C3-C18 alkenyl having one C-C double bond) or a protonated form thereof, in which one or more of the nitrogen atoms contained in the compound of formula (b-5) are protonated to give a compound having a positive charge. It comprises or consists of:

[0373] In formula (b-5), R 1E ~R 5E are preferably independently —CH—CH(OH)—R 7E and R 7E is selected from C8-C18 alkyl or C8-C18 alkenyl having one CC double bond.

[0374] Yet another exemplary ionizable lipid suitable for use in the present invention, which may be included in or comprised by component (b), is the ionizable lipid disclosed in PCT Application WO 2012 / 000104, beginning on page 104 of this document, as "cationic lipids of Formula I," including all of the specific embodiments thereof also discussed therein.

[0375] Further exemplary ionizable lipidoids suitable for use in the present invention that may be included in or comprised by component (b) are those disclosed and claimed in PCT Application WO 2010 / 053572 on page 4 as "amino alcohol lipidoids," including all compounds of the general formula set out in the Summary of the Invention, and further defined in the remainder of the application.

[0376] Further exemplary ionizable lipidoids suitable for use in the present invention that may be included in or comprised by component (b) are those disclosed in PCT Application WO 2014 / 028487, including specific embodiments thereof, as amine containing lipidoids of Formulae I-V.

[0377] A further preferred example of an ionizable lipid suitable for use in the present invention, which may be included in or comprised by component (b), is the ionizable lipid ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) (ALC-0315), or a protonated form thereof, in which the nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0378] A further preferred example of an ionizable lipid suitable for use in the present invention, which may be included in or comprised by component (b), is the ionizable lipid (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, or a protonated form thereof, in which the nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0379] Yet another preferred example of an ionizable lipid suitable for use in the present invention, which may be included in or comprised by component (b), is the ionizable lipid heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102), or a protonated form thereof, in which the nitrogen atom of the compound is protonated to result in a compound having a positive charge.

[0380] In addition to preferred optional components (a) a therapeutic agent, preferably a nucleic acid, and (b) at least one selected from permanent cationic lipids, ionizable lipids and ionizable lipidoids, preferably an ionizable lipid or an ionizable lipidoid, the nanoparticles may contain the following components (c1) to (c6): (c1) lipids with non-ionizable sterol structures; (c2) phosphoglyceride lipids, (c3) PEG-conjugated lipids, (c4) polysarcosine-conjugated lipids, (c5) PAS-modified lipid, and (c6) may include one or more of the following cationic polymers:

[0381] As will be understood by the skilled reader, the possibility that the nanoparticles comprise one or more of components (c1)-(c6) encompasses not only combinations of (c1)-(c6), but also combinations of different components of one type, e.g., two components (c2), or combinations of different components of one type with other components (c1)-(c6).

[0382] Component (c1) is a lipid having a sterol structure. Therefore, suitable lipids are compounds having a steroid core structure with a hydroxyl group at the 3-position of the A ring.

[0383] An exemplary non-ionizable lipid having a sterol structure that may be comprised by or comprised of component (c1) is represented by the structure of formula (c1-1):

[0384] [ka] (In the formula, R 1L is a C3 to C12 alkyl group).

[0385] Further exemplary non-ionizable lipids having a sterol structure that may be comprised by or comprised by component (c1) include those disclosed by S. Patel et al., Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA, Nature Communications, 2020, 11:983, particularly those illustrated in Figure 2 of this publication.

[0386] Preferably, component (c1) comprises or consists of cholesterol.

[0387] Component (c2) is a phosphoglyceride.

[0388] Preferably, component (c2) is a phospholipid selected from the compounds of formula (c2-1):

[0389] [ka] (In the formula, R 1F and R 2F are independently selected from C8 to C18 alkyl groups and C8 to C18 alkenyl groups, preferably C12 to C18 alkyl groups and C12 to C18 alkenyl groups. or a pharmaceutically acceptable salt thereof and a phospholipid of formula (c2-2)

[0390] [ka] (In the formula, R 1G and R 2G are independently selected from C8 to C18 alkyl groups and C8 to C18 alkenyl groups, preferably C12 to C18 alkyl groups and C12 to C18 alkenyl groups. or a pharmaceutically acceptable salt thereof It comprises or consists of:

[0391] More preferably, component (c2) comprises or consists of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC) or a pharmaceutically acceptable salt thereof, or 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) or a pharmaceutically acceptable salt thereof.

[0392] Exemplary salt forms of the compound of formula (c2-1) include salts formed between an acidic -OH group and a base, or salts formed between an amino group and an acid. Examples of salts formed with bases include alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts, and ammonium salts. Examples of salts formed with acids include salts formed with acidic groups of nucleic acids, but other salts are not excluded. Examples of salts formed with inorganic acids include chlorides, bromides, or iodides, sulfates, nitrates, phosphates, hydrogen phosphates or dihydrogen phosphates, carbonates, and hydrogen carbonates.

[0393] Exemplary salt forms of the compound of formula (c2-2) include salts formed between the acidic -OH group bonded to the P atom and a base, or salts formed between a quaternary amino group and an anion. Examples of salts formed with bases include alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts, and ammonium salts. Examples of salts formed with anions include salts formed with acidic groups of nucleic acids, but other salts are not excluded. Examples of salts formed with inorganic acids include chlorides, bromides, or iodides, sulfates, nitrates, phosphates, hydrogen phosphates or dihydrogen phosphates, carbonates, and hydrogen carbonates.

[0394] Component (c3) is a PEG-conjugated lipid, ie a lipid covalently linked to a polyethylene glycol chain.

[0395] Preferably, component (c3) is a compound of formula (c3-1)

[0396] [ka] (In the formula, R 1H and R 2Hare independently selected from C8 to C18 alkyl groups and C8 to C18 alkenyl groups, preferably C12 to C18 alkyl groups and C12 to C18 alkenyl groups, and p is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60. Compound of formula (c3-2)

[0397] [ka] (In the formula, R 1J and R 2J are independently selected from C8 to C18 alkyl groups and C8 to C18 alkenyl groups, preferably C12 to C18 alkyl groups and C12 to C18 alkenyl groups, and q is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60. or a pharmaceutically acceptable salt thereof, or a compound of formula (c3-3)

[0398] [ka] (In the formula, R 1K and R 2K are independently a C8-C18 alkyl group or a C8-C18 alkenyl group, preferably a C12-C18 alkyl group or a C12-C18 alkenyl group, and q is an integer of 5 to 200, preferably 10 to 100, and more preferably 20 to 60.

[0399] Exemplary salt forms of the compound of formula (c3-2) include salts formed by the acidic -OH group bonded to the P atom and a base. Examples of salts formed with bases include alkali metal salts such as sodium or potassium salts; alkaline earth metal salts such as calcium or magnesium salts; and ammonium salts.

[0400] More preferably, component (c3) comprises or consists of 1,2-dimyristoyl-sn-glycerol methoxy(polyethylene glycol) (DMG-PEG), and even more preferably component d) comprises or consists of 1,2-dimyristoyl-sn-glycerol methoxy(polyethylene glycol)-2000 (DMG-PEG2k) or 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159).

[0401] Component (c4) is a polysarcosine-conjugated lipid, i.e., a lipid of formula (c4-1): -[C(O)-CH2-N(CH3)] r - (c4-1) (wherein r represents the number of repeating units, preferably 10 to 100) is a lipid covalently linked to a polymer moiety.

[0402] Component (c5) is a PAS-modified lipid, for example, a lipid covalently linked to a polymer moiety formed by repeating proline (pro) / alanine (ala) / serine (ser) residues.

[0403] With regard to the PAS-modified lipids used herein, the contents of WO 2017 / 109087 and EP 3394266 are incorporated herein by reference. In particular, the definitions and embodiments listed below, particularly those listing nucleic acids encoding PAS polypeptides, are incorporated herein by reference. The PAS-modified lipid may, for example, comprise a polypeptide consisting of at least 100 amino acid residues of proline, alanine, and optionally serine, wherein the polypeptide forms a random coil.

[0404] Component (c6) is cationic polymer.Suitable polymer for forming nanoparticles containing nucleic acid is known in the art.Exemplary suitable cationic polymers are discussed in AC Silva et al., Current Drug Metabolism, 16, 2015, 3-16 and the references therein, JC Kasper et al., J. Contr. Rel. 151 (2011), 246-255, WO 2014 / 207231 and the references therein, and WO 2016 / 097377 and the references therein.

[0405] Suitable cationic oligomers or polymers include, in particular, cationic polymers that include a plurality of units that include amino groups, which can be protonated to provide a positive charge on the polymer.

[0406] (1), (2), (3) and (4) below:

[0407] [ka] Preferred are polymers comprising multiple units independently selected from the formula: wherein one or more of the nitrogen atoms of repeat units (1), (2), (3) and / or (4) can be protonated to provide a positive charge on the polymer.

[0408] The following four classes of polymers, which contain multiple units containing amino groups, are particularly preferred as cationic polymers:

[0409] A first preferred class includes poly(ethyleneimine) (“PEI”), including branched poly(ethyleneimine) (“brPEI”).

[0410] A second preferred class of cationic polymers are polymers comprising, as side chains and / or as end groups, a plurality of groups of formula (c6-1) as disclosed as groups of formula (II) in WO 2014 / 207231 (applicant ethris GmbH):

[0411] [ka] where the variables a, b, p, m, n and R 2 ~R 6 is defined independently for each group of formula (c6-1) in such groups as follows: a is 1 and b is an integer from 2 to 4, or a is an integer from 2 to 4 and b is 1; p is 1 or 2; m is 1 or 2, n is 0 or 1, and m+n is ≧2; R 2 ~R 5 are, independently of one another, hydrogen; a group -CH-CH(OH)-R 7 , -CH(R 7 )-CH2-OH, -CH2-CH2-(C=O)-OR 7 , -CH2-CH2-(C=O)-NH-R 7 or -CH2-R 7 Selected from R 7 is selected from a C3-C18 alkyl or a C3-C18 alkenyl having one C-C double bond; a protecting group for an amino group; and a poly(ethylene glycol) chain; R 6 is hydrogen; the group -CH2-CH(OH)-R 7 , -CH(R 7 )-CH-OH, -CH2-CH2-(C=O)-OR 7 , -CH2-CH2-(C=O)-NH-R 7 or -CH2-R 7 Selected from R 7is selected from a C3-C18 alkyl or a C3-C18 alkenyl having one C-C double bond; a protecting group for an amino group; -C(NH)-NH2; a poly(ethylene glycol) chain; and a receptor ligand; One or more of the nitrogen atoms shown in formula (c6-1) can be protonated to provide a cationic group of formula (c6-1).

[0412] With regard to these polymers and further preferred definitions of the variables contained in formula (c6-1) above, the respective disclosures in WO 2014 / 207231 regarding the groups in formula (II) also apply to the invention described herein.

[0413] A third preferred class of cationic polymers are polymers comprising, as repeat units, a plurality of groups of formula (c6-2) as disclosed as groups of formula (III) in WO 2014 / 207231 (applicant ethris GmbH):

[0414] [ka] where the variables a, b, p, m, n and R 2 ~R 5 is independently defined for each group of formula (6c-2) in such groups as follows: a is 1 and b is an integer from 2 to 4, or a is an integer from 2 to 4 and b is 1; p is 1 or 2; m is 1 or 2, n is 0 or 1, and m+n is ≧2; R 2 ~R 5 are, independently of one another, hydrogen; a group -CH-CH(OH)-R 7 , -CH(R 7 )-CH2-OH, -CH2-CH2-(C=O)-OR 7 , -CH2-CH2-(C=O)-NH-R 7 or -CH2-R 7 Selected from R7 is selected from C3-C18 alkyl or C3-C18 alkenyl having one C-C double bond; a protecting group for an amino group; -C(NH)-NH2; and a poly(ethylene glycol) chain; One or more of the nitrogen atoms shown in formula (c6-2) may be protonated to provide a cationic group of formula (c6-2).

[0415] With regard to these polymers and further preferred definitions of the variables contained in formula (c6-2) above, the respective disclosures in WO 2014 / 207231 regarding their repeat units of formula (III) also apply to the invention described herein.

[0416] A fourth preferred class of cationic polymers is represented by the statistical copolymers disclosed in WO 2016 / 097377 (applicant ethris GmbH), which have the following formulae (a1) and (a2):

[0417] [ka] (a) a plurality of repeating units independently selected from the repeating units and the following equations (b1) to (b4):

[0418] [ka] (b) a plurality of repeating units independently selected from the repeating units Including, The molar ratio of the total repeat units (a) to the total repeat units (b) is in the range of 0.7 / 1.0 to 1.0 / 0.7, and one or more nitrogen atoms of the repeat units (a) and / or (b) contained in the copolymer can be protonated to provide a cationic copolymer.

[0419] With regard to further preferred definitions of this copolymer, the respective disclosures in WO 2016 / 097377 also apply to the invention described herein. As specified therein, particularly preferred copolymers are linear copolymers comprising or consisting of repeating units (a1) and (b1).

[0420] When nanoparticles contain nucleic acid as a preferred therapeutic agent, as optional components of nanoparticles, in addition to nucleic acid, polyanionic components other than nucleic acid can also be included.Examples of such polyanions are polyglutamic acid and chondroitin sulfate.When such polyanionic components other than nucleic acid are used in nanoparticles, their amount is preferably limited so that the amount of negative charge provided by polyanionic components is not greater than the amount of negative charge provided by nucleic acid.

[0421] As described above, the lipid or lipidoid nanoparticles suspended in the aqueous vehicle solution comprise (a) a therapeutic agent, preferably a nucleic acid, and (b) at least one selected from a permanent cationic lipid, an ionizable lipid, and an ionizable lipidoid, preferably an ionizable lipid or an ionizable lipidoid. When a lipidoid is included, the nanoparticles are referred to herein as lipidoid nanoparticles.

[0422] Preferably, the nanoparticles are Nucleic acids as therapeutic agents (a), (b) at least one selected from permanent cationic lipids, ionizable lipids and ionizable lipidoids, preferably an ionizable lipid or an ionizable lipidoid; and possibly lipids having a non-ionizable sterol structure (c1); phosphoglyceride lipids (c2), PEG-conjugated lipids (c3), Polysarcosine-conjugated lipid (c4), PAS lipid (c5), Cationic polymer (c6) It comprises, and more preferably consists of, one or more of:

[0423] Exemplary suspensions comprising nanoparticles formed from the components listed above and also suitable for use in the context of the present invention include those disclosed by S. Patel et al., Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA, Nature Communications, 2020, 11:983.

[0424] It will be appreciated that the components of the nanoparticles, and in particular one or more of components (a) and (b), and optionally (c1)-(c6), will typically be included as a mixture in the nanoparticles.

[0425] With respect to the amounts of these components, the nanoparticles a therapeutic agent, preferably a nucleic acid; and 30 to 65 mol % of at least one selected from permanent cationic lipids, ionizable lipids and ionizable lipidoids, preferably an ionizable lipid or an ionizable lipidoid (b); and the following components: a lipid (c1) having 10 to 50 mol% of a sterol structure; 4 to 50 mol% phosphoglyceride lipids (c2), 0.5 to 10 mol% of one of a PEG-conjugated lipid (c3), a polysarcosine-conjugated lipid (c4), and a PAS-modified lipid (c5), or any combination thereof; 0.5 to 10 mol% of a cationic polymer (c6), It is further preferred that the composition contains one or more of the above in an amount such that the total of (b) and (c1) to (c6) is 100 mol %, and more preferably consists of these.

[0426] With respect to component (b), 30-65 mol% of at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids, it is understood that the indicated molar percentage refers to the total amount of these components in the nanoparticles when two or more of the cationic lipids, ionizable lipids, and ionizable lipidoids are present as component (b). Similarly, it is understood that the molar percentages for components (c1)-(c6) are indicated with the proviso that not all of these components need be present in the nanoparticles. Thus, for example, a cationic polymer may or may not be present in the context of this preferred embodiment, but if present, it is used in an amount of 0.5-10 mol%. As further indicated above, in the context of this preferred embodiment, the amounts of components (c1), (c2), (c3), (c4), (c5), and / or (c6) are such that the total amount of (b) and (c1)-(c6) equals 100 mol%.

[0427] Nanoparticles are Nucleic acid (a), (b) at least one selected from permanent cationic lipids, ionizable lipids and ionizable lipidoids, preferably an ionizable lipid or an ionizable lipidoid; lipids having a non-ionizable sterol structure (c1); phosphoglyceride lipids (c2), and It is further preferred that it comprises or consists of a PEG-conjugated lipid (c3).

[0428] In terms of the amounts of these components, the nanoparticles Nucleic acid (a), 30 to 65 mol % of at least one selected from permanent cationic lipids, ionizable lipids and ionizable lipidoids, preferably an ionizable lipid or an ionizable lipidoid (b); a lipid (c1) having 10 to 50 mol% of a sterol structure; 4 to 50 mol% of phosphoglyceride lipids (c2), and 0.5 to 10 mol% of PEG-conjugated lipid (c3), It is more preferable that the total of (b) and (c1) to (c3) is 100 mol %, and more preferably that the total consists of the above.

[0429] In accordance with the above information regarding preferred therapeutic agents, in particular nucleic acids, and regarding preferred components of the lipid composition other than the therapeutic agent, lipidoid nanoparticles in the context of the present invention preferably comprise: (a) mRNA as a nucleic acid; (b) an ionizable lipidoid of formula (b-1b)

[0430] [ka] (In the formula, R 1A ~R 6A is hydrogen and -CH2-CH(OH)-R 7A are independently selected from R 7A is selected from C8-C18 alkyl and C8-C18 alkenyl having one C-C double bond, provided that R 1A ~R 6A At least two residues of -CH2-CH(OH)-R 7A and more preferably R 1A ~R 6A At least four residues of -CH2-CH(OH)-R 7A and R 7A is selected from C8-C18 alkyl and C8-C18 alkenyl having one C-C double bond or one or more of the nitrogen atoms shown in formula (b-1b) are protonated to provide a cationic lipidoid, in its protonated form (c1) A lipid having a non-ionizable sterol structure of formula (c1-1)

[0431] [ka] (In the formula, R 1L is a C3 to C12 alkyl group), (c2) Phosphoglyceride of formula (c2-2)

[0432] [ka] (In the formula, R 1G and R 2G are independently selected from C8 to C18 alkyl groups and C8 to C18 alkenyl groups, preferably C12 to C18 alkyl groups and C12 to C18 alkenyl groups), or a pharmaceutically acceptable salt thereof, and (c3) PEG-conjugated lipid of formula (c3-1)

[0433] [ka] (In the formula, R 1H and R 2H are independently selected from C8 to C18 alkyl groups and C8 to C18 alkenyl groups, preferably C12 to C18 alkyl groups and C12 to C18 alkenyl groups, and p is an integer from 5 to 200, preferably 10 to 100, more preferably 20 to 60. In such lipidoid particle compositions, the lipidoid dL_05(R) having the formula shown above may be a particularly preferred variant of the ionizable lipid.

[0434] Another preferred exemplary composition of lipid nanoparticles suitable for use in the context of the present invention comprises a nucleic acid, more preferably mRNA, as the therapeutic agent, ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate) as the ionizable lipidoid (b), or a protonated form thereof, wherein a nitrogen atom of the compound is protonated to result in a compound having a positive charge, and optionally the following components (d1) to (d8): (d1) 2-[(polyethylene glycol)-2000]-N,N-ditetradecylacetamide (ALC-0159) (d2) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) (d3) cholesterol (d4) Potassium chloride (d5) Potassium dihydrogen phosphate (d6) Sodium chloride (d7) disodium phosphate dihydrate (d8) Sucrose Further comprising one or more of:

[0435] More preferably, they further include at least (d1), (d2) and (d3), and even more preferably, they include all of (d1) to (d8).

[0436] Yet another preferred exemplary composition of lipid nanoparticles suitable for use in the context of the present invention comprises a nucleic acid, more preferably mRNA, as the therapeutic agent, heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate (SM-102) as the ionizable lipid (b), or a protonated form thereof, wherein a nitrogen atom of the compound is protonated to result in a compound having a positive charge, and optionally the following components (e1) to (e7): (e1) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), (e2) cholesterol, (e3) 1,2-dimyristoyl-rac-glycero-3-methoxypolyethylene glycol-2000 (PEG2000 DMG), (e4) Trometamol hydrochloride (e5) Sodium acetate trihydrate (e6) acetic acid (e7) Sucrose Contains one or more of:

[0437] More preferably, they further include at least (e1), (e2) and (e3), and even more preferably, they include all of (e1) to (e7).

[0438] Yet another preferred exemplary composition of lipid nanoparticles suitable for use in the context of the present invention comprises a nucleic acid as a therapeutic agent, more preferably mRNA, DLin-MC3-DMA ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl-4-(dimethylamino)butanoate) or a protonated form thereof, wherein the nitrogen atom of the compound is protonated, and optionally the following components (e1) to (e7): (e1) 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), (e2) cholesterol, (e3) PEG2000-C-DMG (α-(3'-{[1,2-di(myristyloxy)propanoxy]carbonylamino}propyl)-ω-methoxy, polyoxyethylene), (e4) 2-amino-2-(hydroxymethyl)propane-1,3-diol (trometamol) hydrochloride (e5) Disodium hydrogen phosphate, heptahydrate (e6) Potassium dihydrogen phosphate, anhydrous (e7) Sodium chloride Contains one or more of:

[0439] More preferably, components (e1), (e2) and (e3) are present, and even more preferably, they include all of (e1)-(e6).

[0440] The composition of the nanoparticles is preferably such that the weight ratio of the weight of nucleic acid to the total weight of components other than nucleic acid in the nanoparticles is in the range of 50:1 to 1:1, more preferably 40:1 to 2:1, and most preferably 30:1 to 3:1.

[0441] The N / P ratio, i.e., the ratio of the number of amine nitrogen atoms contributed by the ionizable lipid or ionizable lipidoid to the number of phosphate groups contributed by the nucleic acid of the nanoparticle, is preferably in the range of 0.5 to 20, more preferably in the range of 0.5 to 10, when nucleic acid is included as a therapeutic agent.

[0442] The suspended lipid or lipidoid nanoparticles preferably have a Z-average diameter in the range of 10-500 nm, more preferably 10-250 nm, and even more preferably 20-200 nm. The particle diameters shown are the hydrodynamic diameters of the particles, as determined by dynamic light scattering (DLS). Measurements are typically performed at 25°C. Due to the stabilizing effect of non-ionic surfactants, this average diameter can be maintained even after the suspension is exposed to physical stress conditions.

[0443] The polydispersity index of the suspended nanoparticles is preferably in the range of 0.02 to 0.4, more preferably in the range of 0.03 to 0.2. The polydispersity index can be determined by dynamic light scattering (DLS). Measurements are typically performed at 25°C. Due to the stabilizing effect of the non-ionic surfactant, this polydispersity index can be maintained even after the suspension is exposed to physical stress conditions.

[0444] It is possible to provide a suspension containing various lipid or lipidoid nanoparticles as defined above, i.e. particles that differ with respect to their constituents, but preferably the nanoparticles contained in the suspension are of the same constituents.

[0445] Nanoparticles can be conveniently prepared by mixing a solution containing nucleic acid in an aqueous solvent, for example, a citrate buffer solution having a pH of 4.5, and optionally containing a salt such as sodium chloride, with a solution containing ionizable lipids or ionizable lipidoids in an organic solvent, for example, ethanol.Furthermore, optional components can be incorporated, for example, by adding them to one of the two solutions.The nanoparticles produced in this way can be further processed by chromatography and / or dialysis and / or tangential flow filtration (TFF) to obtain nanoparticles of the desired liquid composition.Preferably, they are further processed using TFF.

[0446] To provide a nanoparticle suspension, it is also possible to rely on lyophilized nanoparticles prepared according to the procedure mentioned above, followed by freeze-drying, which are then resuspended in an aqueous vehicle solution.

[0447] In the stable suspensions provided by various aspects of the present invention, nanoparticles are suspended in an aqueous vehicle solution.

[0448] The vehicle solution is an aqueous solution, i.e., a solution in which water is the major solvent relative to the total volume of solvents, preferably a solution containing more than 70% water, more preferably more than 90% water as solvent, expressed as a volume percentage of water in the total volume of solvents contained in the vehicle solution (at a temperature of 25°C). Most preferably, water is the only solvent in the vehicle solution. Thus, the vehicle solution is liquid at room temperature (e.g., 25°C).

[0449] The weight per volume ratio of nanoparticles in the vehicle solution is preferably in the range of 0.1 g / L to 300 g / L, more preferably 0.2 g / L to 300 g / L, even more preferably 0.5 g / L to 250 g / L, and most preferably 0.5 g / L to 125 g / L (measured at 25°C).

[0450] When the nanoparticles comprise a nucleic acid as a therapeutic agent, the concentration of the nucleic acid provided by the lipid or lipidoid nanoparticles in the suspension is preferably in the range of 0.01 to 10 mg / ml, more preferably 0.02 to 10 mg / ml, even more preferably 0.05 to 5 mg / ml, and most preferably 0.05 to 2.5 mg / ml relative to the total volume of the suspension (measured at 25°C).

[0451] As explained above, the lipid or lipidoid nanoparticles contained in the suspension preferably have a Z-average diameter in the range of 10-500 nm, more preferably 10-250 nm, and even more preferably 20-200 nm. The particle diameters indicated are the hydrodynamic diameters of the particles, as determined by dynamic light scattering (DLS). Measurements are typically performed at 25°C.

[0452] The polydispersity index of the nanoparticles contained in the suspension is preferably in the range of 0.02 to 0.4, more preferably in the range of 0.03 to 0.2. The polydispersity index can be determined by dynamic light scattering (DLS). Measurements are generally carried out at 25°C.

[0453] By using a surfactant, preferably a non-ionic surfactant, the nanoparticle suspension is stabilized against particle aggregation under conditions of physical stress in the context of the present invention. To achieve this effect, the surfactant is incorporated into the suspension, preferably into the aqueous vehicle solution as an excipient.

[0454] In some embodiments, the LNPs and / or LiNPs are not lyophilized. In some embodiments, the surfactant is added before the lyophilization process. In some embodiments, the surfactant is not present in the vehicle solution during the lyophilization process.

[0455] Typically, the presence of surfactant does not cause changes in the biological activity of nanoparticles. Biological activity refers to the expression level of therapeutic nucleic acid in target cells. Biological activity can be quantified, for example, by in vitro transfection of cell lines (e.g., HEK-293) with nanoparticles, followed by Southern / Northern blot analysis of the resulting nucleic acid or ELISA-based protein quantification. Calculated as the average of three measurements per concentration, the detected protein level should not differ by more than 10%, preferably by 5% or less, and more preferably not statistically different, when the same assay is performed with the same LNP or LiNP without surfactant.

[0456] Typically, the presence of surfactant does not cause a change in the physical properties of the nanoparticles, measured as the hydrodynamic diameter of the nanoparticles and as the percentage of encapsulated nucleic acid.

[0457] The hydrodynamic diameter of nanoparticles can be measured, for example, via dynamic light scattering (also photon correlation spectroscopy). Optionally, the average of three measurements of the hydrodynamic diameter of nanoparticles in the presence of a surfactant should not differ by more than 5%, preferably by 1% or less, and more preferably not statistically different, from the same nanoparticles in the absence of surfactant. The viscosity change of surfactants must be taken into account during the measurement. The percentage of encapsulated nucleic acid can be determined, for example, by measuring fluorescence intensity with a RiboGreen assay. Nanoparticles are analyzed under two different conditions: untreated samples for exogenous nucleic acids and samples treated with Triton X-100 for total mRNA. The percentage content of encapsulated nucleic acid is calculated. Optionally, the value calculated from the average of three measurements of nanoparticles in the absence of surfactant should not differ by more than 5%, optionally by 3% or less, and better not statistically different, from the same nanoparticles in the presence of surfactant.

[0458] As will be appreciated by the skilled reader, the measures employed to stabilize a nanoparticle suspension against particle aggregation may prevent nanoparticle aggregation or reduce the extent of nanoparticle aggregation compared to a situation in which the measures are not applied. Preferably, the stabilization of a nanoparticle suspension is evidenced by an increase in the Z-average particle size of the suspended particles of less than 50%, more preferably less than 20%, even more preferably less than 10%, under conditions of physical stress, and most preferably by the absence of such an increase.

[0459] Similarly, stabilization of a nanoparticle suspension against particle aggregation under conditions of physical stress will be understood to mean preventing or reducing aggregation of nanoparticles that may be observed in the absence of stabilization when the nanoparticle suspension is exposed to conditions of physical stress.

[0460] The physical stress conditions to which nanoparticle suspensions may be exposed are frequently those encountered during handling or transport of the suspension. These include, for example, rapid movement of a volume of suspension, which may cause collisions of the nanoparticles contained in the unstabilized suspension. Examples of physical stress conditions include shaking, stirring, vibrating, mixing, inverting, tapping, or dropping of the nanoparticle suspension, or physical stress conditions caused, for example, by pumping the nanoparticle suspension or withdrawing it into a syringe. As will be understood by the skilled reader, physical stress conditions include not only the conditions to which nanoparticle suspensions are exposed during their regular handling, but also conditions to which the suspension may be exposed exceptionally (such as transporting under difficult conditions) or inadvertently (such as dropping a sample of the suspension).

[0461] Various types of surfactants can be used in the context of the present invention, and non-ionic surfactants are preferably used to stabilize suspension.Therefore, surfactants preferably include, and are more preferably, non-ionic surfactants.Examples of suitable non-ionic surfactants include fatty alcohol ethoxylates, fatty acid ethoxylates, block copolymers of ethylene oxide and propylene oxide, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil and ethoxylated vitamin E.

[0462] Thus, the surfactant used in the context of the present invention in the nanoparticle suspension preferably comprises, and even more preferably is, at least one selected from the group of fatty alcohol ethoxylates, fatty acid ethoxylates, block copolymers of ethylene oxide and propylene oxide, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil and ethoxylated vitamin E.

[0463] According to another embodiment, the surfactant used in the context of the present invention in the nanoparticle suspension preferably comprises, and even more preferably is, at least one selected from the group of fatty alcohol ethoxylates, fatty acid ethoxylates, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil and ethoxylated vitamin E.

[0464] Preferably, the block copolymer of ethylene oxide and propylene oxide is a poloxamer. The poloxamer is preferably One poly(propylene oxide) block B of formula (p-1):

[0465] [ka] (wherein s is an integer from 15 to 60), and Two poly(ethylene oxide) blocks A of formula (p-2):

[0466] [ka] (wherein, r is independently an integer of 8 to 150, preferably 10 to 150, for each block.) It contains:

[0467] Thus, it is preferred that the surfactant comprises, and more preferably is, a poloxamer, such as the preferred poloxamers discussed above. However, the present invention, in its various aspects, also provides and relates to poloxamer-free suspensions.

[0468] It is particularly preferred that the non-ionic surfactant used for stabilization according to the invention comprises or is at least one selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 80, polyoxyethylene lauryl ether, polyoxyethylene-35 castor oil, D-α-tocopherol polyethylene glycol 1000 succinate, and tyloxapol. According to another embodiment, the non-ionic surfactant used for stabilization according to the invention comprises or is at least one selected from the group consisting of polysorbate 20, polysorbate 80, polyoxyethylene lauryl ether, polyoxyethylene-35 castor oil, D-α-tocopherol polyethylene glycol 1000 succinate, and tyloxapol.

[0469] The vehicle solution in which the nanoparticles are suspended generally contains a surfactant dissolved therein, and as the skilled reader will recognize, this does not exclude the possibility that a certain amount of surfactant molecules may be adsorbed onto the lipid or lipidoid nanoparticles contained in the suspension.

[0470] In the context of the present invention, it has been found that the beneficial effects of surfactants can be achieved at relatively low concentrations in the suspension, for example, at 0.01% (w / v).Therefore, surfactants are typically contained in the suspension in an amount of 0.01% (w / v) or more, relative to the total volume of the suspension of nanoparticles in the aqueous vehicle solution (typically measured at 25°C).

[0471] For example, the use according to the invention involves the incorporation of surfactant into a nanoparticle suspension, preferably into the aqueous vehicle, in an amount of 0.01-10% (w / v), preferably 0.1-10% (w / v), more preferably 0.25-5% (w / v), even more preferably 0.33-2.5% (w / v), even more preferably 0.45-1.5% (w / v), and most preferably 0.5-1.5% (w / v), based on the total volume of the suspension of nanoparticles in the aqueous vehicle. As will be appreciated, indications of substance concentration in % (w / v) or (weight / volume) correspond to the amount of substance in a volume of 100 mL, typically measured at 25°C, such that 1% (w / v) corresponds to 1 g of surfactant per 100 mL of total suspension volume.

[0472] Similarly, the method according to the invention may involve the incorporation of surfactant into the nanoparticle suspension in an amount of, for example, 0.01-10% (w / v), preferably 0.1-10% (w / v), more preferably 0.25-5% (w / v), even more preferably 0.33-2.5% (w / v), even more preferably 0.45-1.5% (w / v) and most preferably 0.5-1.5% (w / v) relative to the total volume of the suspension of nanoparticles in aqueous vehicle (typically measured at 25°C).

[0473] While the concentrations of 0.5 to 1.5% (w / v) outlined above are particularly preferred, the present invention in various embodiments also provides and relates to suspensions with lower concentrations of surfactant, for example in the range of 0.01 to 0.45% (w / v), or 0.1 to 0.40% (w / v).

[0474] In the context of various embodiments of the present invention, in the suspension of lipid nanoparticles or lipidoid nanoparticles in aqueous vehicle solution, it is generally preferred that surfactant is not essentially bound to nanoparticles, for example, is not essentially contained in nanoparticles, and is not essentially attached to nanoparticles.For example, in the context of various embodiments of the present invention, more than 90 wt%, preferably more than 95 wt%, of the total amount of surfactant that is contained or incorporated in the suspension of lipid nanoparticles or lipidoid nanoparticles in aqueous vehicle solution is present in the aqueous vehicle solution without being bound to nanoparticles.

[0475] In addition to the surfactant, other excipients may be present in the vehicle solution. Preferably, the vehicle solution further comprises at least one of a sugar and a salt, more preferably sucrose and NaCl.

[0476] Surfactant can be conveniently incorporated into nanoparticle suspension by, for example, adding surfactant to the suspension that comprises aqueous vehicle solution and lipid or lipidoid nanoparticles, or adding lipid or lipidoid nanoparticles to the aqueous vehicle solution that comprises surfactant.For example, as stated above, when nanoparticles are presented in lyophilized form, they can be resuspended in aqueous vehicle solution that contains surfactant.

[0477] To that extent, the present invention provides a method for preparing a suspension of lipid or lipidoid nanoparticles as defined herein, comprising the steps of: mixing at least one selected from a permanent cationic lipid, an ionizable lipid, and an ionizable lipidoid dissolved in an organic phase with a therapeutic agent dissolved in an aqueous solution to produce a preparation of lipid or lipidoid nanoparticles; combining the nanoparticles with a surfactant to obtain a suspension of nanoparticles in the aqueous vehicle solution; Also provided is a method comprising:

[0478] Preferably, the method comprises the following steps: i) producing a preparation of lipid or lipidoid nanoparticles by mixing at least one selected from a permanent cationic lipid, an ionizable lipid, and an ionizable lipidoid dissolved in an organic phase with a therapeutic agent dissolved in an aqueous solution; ii) diluting the lipid or lipidoid nanoparticle preparation by diluting with a first solution; iii) concentrating the diluted preparation of lipid or lipidoid nanoparticles by buffer exchange using ultra / diafiltration in a TFF, wherein a second solution is used for ultra / diafiltration; iv) Obtaining a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle containing a surfactant. and / or wherein the first solution comprises between 0.01% w / v and 10% w / v surfactant, preferably between 0.1% w / v and 10% surfactant, more preferably between 0.25% w / v and 5% w / v surfactant, even more preferably between 0.33% w / v and 2.5% w / v surfactant, even more preferably between 0.45% w / v and 1.5% w / v surfactant, and most preferably between 0.5% w / v and 1.5% w / v surfactant; and / or the second solution comprises 0.01% w / v to 10% w / v surfactant, preferably 0.1% w / v to 10% surfactant, more preferably 0.25% w / v to 5% w / v surfactant, even more preferably 0.33% w / v to 2.5% w / v surfactant, even more preferably 0.45% w / v to 1.5% w / v surfactant, and most preferably 0.5% w / v to 1.5% w / v surfactant; The final concentration of surfactant from the combined first and second solutions is 0.01% w / v to 10% w / v surfactant, preferably 0.1% w / v to 10% surfactant, more preferably 0.25% w / v to 5% w / v surfactant, even more preferably 0.33% w / v to 2.5% w / v surfactant, even more preferably 0.45% w / v to 1.5% w / v surfactant, and most preferably 0.5% w / v to 1.5% w / v surfactant, based on the total volume of the suspension of nanoparticles in the aqueous vehicle solution.

[0479] In the above method, it is preferred that incorporation of surfactant into the suspension does not occur before or during step i).

[0480] Furthermore, it is preferred that surfactant be added with both the first and second solutions. For example, 30-70 wt% of surfactant, preferably 40-60 wt% and more preferably 45-55 wt% of surfactant, based on the total weight of surfactant in the suspension obtained in step iv) can be added with the first solution, and 70-30 wt% of surfactant, preferably 60-40 wt% and more preferably 55-45 wt% of surfactant, based on the total weight of surfactant in the suspension obtained in step iv) can be added with the second solution, so that the total amount of surfactant added with the first and second solutions is 100 wt%. Generally, it is preferred that approximately half of the surfactant is added with the first solution, and approximately half of the surfactant is added with the second solution.

[0481] The therapeutic agent present in lipid or lipidoid nanoparticles used in the context of the present invention, preferably nucleic acid such as RNA, preferably mRNA, is particularly useful in medical situations and for the treatment or prevention of diseases and disorders, preferably for the treatment or prevention of diseases or disorders that rely on nucleic acid as an active agent.Therefore, the suspension is generally provided or used as a medicine or pharmaceutical composition.The present invention also provides lipid or lipidoid nanoparticle formulations, including the suspension of lipid or lipidoid nanoparticles according to the present invention as described herein.

[0482] In particular, the nanoparticle suspension or formulation is suitable for administration to a subject. In this way, a therapeutic agent, preferably a nucleic acid such as RNA, preferably mRNA, contained in the nanoparticles of the suspension can also be administered to the subject.

[0483] Upon administration to a subject, the therapeutic agent, preferably a nucleic acid contained in a particle of lipid or lipidoid nanoparticles, can be delivered to a target cell. The term "delivered to a target cell" preferably refers to the transfer of the nucleic acid to the cell. Administration can be achieved in a variety of ways known to skilled practitioners, including administration to or via the respiratory tract, for example, by aerosolization of a suspension, or intramuscular or intravenous administration.

[0484] By administering the suspension to a subject, disease or disorder can be treated or prevented. The term "disease" refers to any possible pathological condition that can be treated, prevented, or vaccinated by using the suspension. The disease can be, for example, inherited, acquired, infectious or non-infectious, age-related, cardiovascular, metabolic, intestinal, neoplastic (especially cancer) or genetic. For example, disease can be based on irregularities in physiological processes, molecular processes, biochemical reactions within an organism, which in turn can be based on, for example, the genetic equipment of an organism, behavioral factors, social factors, or environmental factors (such as exposure to chemicals or radiation).

[0485] To that extent, the present invention also provides a suspension of lipid or lipidoid nanoparticles or a formulation of lipid or lipidoid nanoparticles according to the invention as described herein for use in the treatment or prevention of disease. Similarly, a suspension of lipid or lipidoid nanoparticles or a formulation of lipid or lipidoid nanoparticles according to the invention as described therein may be used in a method of treating or preventing disease, the method comprising administering the suspension or formulation to a subject in need thereof.

[0486] In a related aspect, the present invention also provides a suspension of lipid or lipidoid nanoparticles according to the invention, or a formulation of lipid or lipidoid nanoparticles as described herein, for use as a medicament.

[0487] For example, the present invention provides a suspension of lipid or lipidoid nanoparticles or a formulation of lipid or lipidoid nanoparticles according to the invention as described herein for use in vaccination or immunization. Similarly, a suspension of lipid or lipidoid nanoparticles or a formulation of lipid or lipidoid nanoparticles according to the invention as described therein may be used in a method of vaccination or immunization comprising administering the suspension or formulation to a subject in need thereof.

[0488] In accordance with a further aspect, the present invention provides a method of inducing an immune response against a target pathogen in a subject in need thereof, the method comprising administering to the subject a suspension of lipid or lipidoid nanoparticles or a formulation of lipid or lipidoid nanoparticles according to the present invention as described herein.

[0489] In another example, the present invention provides a suspension of lipid or lipidoid nanoparticles or a formulation of lipid or lipidoid nanoparticles according to the invention as described therein for use in the treatment of cancer. Similarly, a suspension of lipid or lipidoid nanoparticles or a formulation of lipid or lipidoid nanoparticles according to the invention as described therein may be used in a method of treating cancer, the method comprising administering the suspension or formulation to a subject in need thereof.

[0490] In a further aspect, the present invention provides a method for avoiding or reducing side effects of treatment with lipid or lipidoid nanoparticles comprising at least one therapeutic agent as described herein, comprising the steps of: i) determining whether a pharmaceutical composition comprising lipid or lipidoid nanoparticles aggregates when subjected to mechanical or thermal stress by determining the aggregation level of said pharmaceutical composition before and after subjecting said pharmaceutical composition to said mechanical or thermal stress; ii) if the lipid or lipidoid nanoparticles show aggregation after the test of step (i), then adding a surfactant, as defined herein, to the lipid or lipidoid nanoparticle formulation to obtain an LNP or LiNP suspension with a final surfactant concentration of between 0.01% w / v and 10% w / v surfactant, preferably between 0.1% w / v and 10% surfactant, more preferably between 0.25% w / v and 5% w / v surfactant, even more preferably between 0.33% w / v and 2.5% w / v surfactant, even more preferably between 0.45% w / v and 1.5% w / v surfactant, and most preferably between 0.5% w / v and 1.5% w / v surfactant; iii) Reconstitution by mixing to produce a stable suspension of lipid or lipidoid nanoparticles. The present invention provides a method comprising:

[0491] In a related aspect, the present invention further provides a method for reducing one or more side effects associated with a vaccine or anticancer formulation comprising a lipid or lipidoid nanoparticle having a nucleic acid as described herein, the method comprising modifying the vaccine or anticancer formulation by adding a surfactant as described herein to the vaccine or anticancer formulation comprising a suspension of lipid or lipidoid nanoparticles. Preferably, the surfactant is 0.01% w / v to 10% w / v surfactant, preferably 0.1% w / v to 10% w / v surfactant, more preferably 0.25% w / v to 5% w / v surfactant, even more preferably 0.33% w / v to 2.5% w / v surfactant, even more preferably 0.45% w / v to 1.5% w / v surfactant, and most preferably 0.5% w / v to 1.5% w / v surfactant.

[0492] As mentioned above, the surfactant is preferably at least one non-ionic surfactant selected from the group consisting of fatty alcohol ethoxylates, fatty acid ethoxylates, block copolymers of ethylene oxide and propylene oxide, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil and ethoxylated vitamin E, more preferably at least one, or even more preferably one, selected from the group consisting of poloxamer 124, poloxamer 188, poloxamer 338, poloxamer 407, polysorbate 20, polysorbate 80, polyoxyethylene lauryl ether, polyoxyethylene-35 castor oil, D-α-tocopherol polyethylene glycol 1000 succinate and tyloxapol. Consistent with the above and preferred embodiments, the surfactant is a block copolymer of ethylene oxide and propylene oxide, preferably a poloxamer selected from the group of poloxamer 124, poloxamer 188, poloxamer 338, and poloxamer 407. Consistent with alternative embodiments, the poloxamer can be a poloxamer other than poloxamer 188 or poloxamer 407.

[0493] In a related aspect, the present invention provides a method for reducing the occurrence or severity of one or more side effects associated with an LNP / LiNP-based vaccine in a subject, the method comprising administering to the subject a vaccine or anticancer formulation comprising a suspension of lipid nanoparticles or lipidoid nanoparticles as described herein.

[0494] A reduction in the occurrence or severity of one or more side effects may be caused, for example, by a reduction in LNP / LiNP aggregation, which may be measured by determining the hydrodynamic diameter of the nanoparticles, e.g., via dynamic light scattering or photon correlation spectroscopy.

[0495] Generally, the therapeutic agent, preferably a nucleic acid, is contained in the nanoparticles in an effective amount. The term "effective amount" refers to an amount sufficient to induce a detectable therapeutic response or prophylactic effect in the subject to which the pharmaceutical composition is administered. Accordingly, the content of nucleic acid is not limited as long as it is useful for the treatment or prevention described above. As specified above, compositions containing nucleic acid-containing particles preferably contain the particles in an amount sufficient to provide the nucleic acid contained in the particles at a concentration of 0.01 to 10 mg / ml, more preferably 0.02 to 10 mg / ml, even more preferably 0.05 to 5 mg / ml, and most preferably 0.05 to 2.5 mg / ml, relative to the total volume of the composition. Similarly, when the lipid or lipidoid nanoparticle suspension or lipid or lipidoid nanoparticle formulation according to the present invention described therein is administered to a subject, it is understood that it is administered in an effective amount.

[0496] Exemplary subjects include mammals such as dogs, cats, pigs, cows, sheep, horses, rodents, e.g., rats, mice, and guinea pigs, or primates, e.g., gorillas, chimpanzees, and humans. In a most preferred embodiment, the subject is a human.

[0497] Several documents, including patent applications and manufacturer's manuals, are cited herein. The disclosures of these documents, although not believed to be relevant with respect to the patentability of this invention, are hereby incorporated by reference in their entirety. More particularly, all referenced documents are incorporated by reference to the same extent as if each individual document was specifically and individually indicated to be incorporated by reference. [Example]

[0498] 1 [Example 1] Shaking resistance of nanoparticles in the presence of different excipients and at various excipient concentrations 1.1 Method: 1.1.1 Nanoparticle preparation Lipidoid nanoparticles were formulated from an ionizable lipidoid (dL_05®, Scheme 1), helper lipids DPPC (1,2-dipalmitoyl l-sn-glycero-3-phosphocholine, Avanti Polar Lipids) and cholesterol (Avanti Polar Lipids), and the PEG lipid DMG-PEG2k (1,2-dimyristoyl l-sn-glycerol methoxy(polyethylene glycol)-2000, Avanti Polar Lipids) in the molar ratios of 8.00 / 5.29 / 4.41 / 0.88, respectively. Appropriate amounts of stock solutions of lipids in HPLC-grade ethanol at concentrations of 50, 20, 20, and 20 mg / mL, respectively, were combined. The formulation process was carried out by rapid solvent exchange. Using a NanoAssemblr benchtop (Precision NanoSystems), the lipid mixture in ethanol was combined with mRNA in citrate buffer (10 mM citric acid, 150 mM NaCl, pH 4.5) at a volume ratio of 1:4. The resulting formulation had an mRNA concentration of 0.2 mg / mL at an N / P ratio of 8. After 30 minutes of incubation at room temperature, the formulation was purified via dialysis against water using a Slide-A-Lyzer MINI dialysis device (20k, 2 mL, Thermo Scientific). If concentration of the suspension was required, a SpeedVac (concentrator plus, Eppendorf) was used in V-AQ mode at 45 °C.

[0499] [ka]

[0500] Scheme 1: Chemical structure of dL_05(R) 1.1.2 Mixing of nanoparticles with excipients The excipients used in this experiment are listed in Table 5. Dilutions of the excipients were prepared according to their solubility in water at the stock solution concentrations shown in Table 5. LNPs were mixed with the excipients to yield excipient concentrations of 0% (w / v), 0.01% (w / v), 0.1% (w / v), 1% (w / v), and 10% (w / v) (indicated separately on the graph, if possible), and an LNP concentration of 0.2 mg mRNA / mL.

[0501] [Table 6]

[0502] 1.1.3 Shaking of nanoparticle suspension For stress testing, 100 μL of the LNP / excipient mix was shaken on a vortex (Vortex Genie 2, Scientific Industries) for 1 min at maximum speed.

[0503] 1.1.4 Measurement of complex size and PdI The hydrodynamic diameter (Z-average, size) and polydisperity index (PdI) of the nanoparticles were measured by dynamic light scattering (DLS) using a Zetasizer Nano-ZS (Malvern Instruments) equipped with an automatic attenuator and reported as intensity particle size distribution. Samples were measured undiluted at 25°C.

[0504] 1.2 Results This experimental setup aimed to test the particle stability of LNP suspensions under conditions of physical stress. The results are shown in Figure 1. In the absence of excipients (0% (w / v)), LNPs aggregated (increased size and PdI before vs. after shaking) and showed a loss of suspension integrity after shaking. In the presence of the excipients used, nanoparticle integrity remained stable at excipient concentrations >0.01% (w / v). The overall size increase at 10% (w / v) can generally be explained by the increased viscosity of the suspension induced by the high excipient concentration. This leads to a decrease in the Brownian motion of the nanoparticles, which are interpreted as larger particles by the DLS software. Since there was no difference in size before and after shaking, the stability of the nanoparticles can again be demonstrated.

[0505] 2 [Example 2] Shaking resistance of nanoparticles at different nanoparticle concentrations 2.1 Method: 2.1.1 Nanoparticle preparation See section 1.1.1.

[0506] 2.1.2 Mixing of nanoparticles with excipients See section 1.1.2. In this experimental setup, only poloxamer 188 (Kolliphor P188) was used at an excipient concentration of 1% (w / v). As a control, one sample was used without excipient. LNPs were used at mRNA concentrations of 0.01 mg / mL, 0.1 mg / mL, 1 mg / mL, and 2.5 mg / mL.

[0507] 2.1.3 Shaking of nanoparticle suspension See section 1.1.3.

[0508] 2.1.4 Measurement of complex size and PdI See section 1.1.4.

[0509] 2.2 Results This experiment aimed to identify the concentration limits of LNP present in the suspension. The results are presented in Figure 2. The results show that shaking leads to a deterioration of nanoparticle quality at all concentrations tested. Aggregate formation (increased size and / or PdI) was detected at all LNP concentrations in the absence of excipients. In contrast, the presence of excipients stabilized the nanoparticle suspension at all LNP concentrations tested, demonstrating that the beneficial effect applies across a wide LNP concentration range.

[0510] 3 [Example 3] Shaking resistance of MC3-LNP in the presence of different excipients and at various excipient concentrations 3.1 Method: 3.1.1 Nanoparticle preparation To formulate the MC3 LNP lipid-stock solution of DLin-MC3-DMA ((6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate), DSPC, cholesterol, and DMPE-PEG2k were prepared in ethanol at 10 mg / mL, 20 mg / mL, 20 mg / mL, and 20 mg / mL, respectively. The ethanol stock solution (557 μL DLin-MC3-DMA, 69 μL DSPC, 129 μL cholesterol, 35 μL DMPE-PEG2k, 461 μL ethanol) was mixed and fused with an aqueous mRNA solution (0.2667 mg / mL in citrate buffer) at a volume ratio of 3:1 (mRNA:lipid) and a total flow rate of 12 mL / min using a NanoAssemblr device. After 30 minutes of incubation at room temperature, the formulation was purified via dialysis against water using a Slide-A-Lyzer MINI dialysis device (20k, 2 mL, Thermo Scientific). If concentration of the suspension was required, a SpeedVac (concentrator plus, Eppendorf) was used in V-AQ mode at 45°C.

[0511] 3.1.2 Mixing of nanoparticles with excipients See section 1.1.2. In addition to the excipients already listed in Table 5, Kolliphor P124, Geismar (BASF) was also tested as an excipient. Stock solutions of the substance were prepared at 20% (w / v) and handled in the same way as the other excipients.

[0512] 3.1.3 Shaking of nanoparticle suspension See section 1.1.3.

[0513] 3.1.4 Measurement of complex size and PdI See section 1.1.4.

[0514] 3.2 Results This experiment aimed to determine whether the observed protective effect of the excipients was a specific property of the tested LNP (containing dL_05(R)) or could be considered a general property. To this end, the LNP used in Example 1 was replaced with MC3-LNP, a known LNP formulation used for the delivery of various nucleic acids. The data are summarized in Figure 3. The results show a high similarity to the data generated in Example 1. Shaking leads to a decrease in particle quality (increase in size and PdI) in the absence of excipients. The presence of different excipients, at concentrations above 0.01% (w / v), leads to stabilization of the suspension and prevents aggregation during physical stress. These data demonstrate that the protective effect is independent of the LNP composition used.

[0515] 4 [Example 4] Shaking resistance of ALC-0315 LNPs in the presence of different excipients and at various excipient concentrations 4.1 Method: 4.1.1 Nanoparticle preparation To formulate an ALC-0315 LNP lipid stock solution of ALC-0315 (((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate)), DSPC, cholesterol, and ALC-0159 (2-[(Polyethylenglykol)-2000]-N,N-ditetradecylacetamide) were prepared in ethanol at 25 mg / mL, 20 mg / mL, 20 mg / mL, and 25 mg / mL, respectively. The ethanol stock solution was heated to 50°C for 30 minutes and mixed. For an exemplary amount of 1 mg mRNA, the following volumes were combined: 574 μL ALC-0315, 156 μL DSPC, 311 μL cholesterol, 71 μL ALC-0519, 138 μL ethanol. Using a NanoAssemblr device, the mix was fused with an aqueous mRNA solution (3750 μL, 0.2667 mg / mL in citrate buffer) at a volume ratio of 3:1 (mRNA:lipid) and a total flow rate of 12 mL / min. After 30 minutes of incubation at room temperature, the formulation was purified via dialysis against water using a Slide-A-Lyzer MINI dialysis device (20k, 2 mL, Thermo Scientific). If concentration of the suspension was required, a SpeedVac (concentrator plus, Eppendorf) was used at 45°C in V-AQ mode.

[0516] 4.1.2 Mixing of nanoparticles with excipients See section 1.1.2. In addition to the excipients already listed in Table 5, Kolliphor P124, Geismar (BASF) was also tested as an excipient. Stock solutions of the substances were prepared at 20% (w / v) and handled in the same way as the other excipients. Concentrations ranging from 0.1% (w / v) to 10% (w / v) of the excipient were tested.

[0517] 4.1.3 Shaking of nanoparticle suspension See section 1.1.3.

[0518] 4.1.4 Measurement of complex size and PdI See section 1.1.4.

[0519] 4.2 Results This experiment aimed to determine whether the observed protective effect of the excipients was a specific property of the tested LNP (containing dL_05(R)) or could be considered a general property. To this end, the LNP used in Example 1 was replaced by ALC-0315, which contains LNP and the lipid composition of the Covid vaccine Comirnaty. The results are summarized in Figure 4 and show a high similarity to the data generated in Examples 1 and 3. Shaking leads to a decrease in particle quality (increase in size and PdI) in the absence of excipients. The presence of different excipients, at concentrations above 0.01% (w / v), leads to suspension stabilization and prevents aggregation during physical stress. These data further demonstrate that the protective effect is independent of the LNP composition used.

[0520] 5 [Example 5] Shaking resistance of Comirnaty® in the presence of different excipients and at various excipient concentrations 5.1 Method: 5.1.1 Mixing of nanoparticles with excipients Comirnaty® was commercially supplied. The excipients used in this example are listed in the table. Dilutions of the excipients were prepared according to their solubility in water at the stock solution concentrations shown in the table. LNPs were mixed with the excipients to result in excipient concentrations of 0% (w / v), 0.01% (w / v), 0.1% (w / v), 0.5% (w / v), 1% (w / v), 2.5% (w / v), and 5% (w / v) (where possible), and an LNP concentration of 0.075 mg mRNA / mL.

[0521] [Table 7]

[0522] 5.1.2 Shaking of nanoparticle suspension See section 1.1.3.

[0523] 5.1.3 Measurement of complex size and PdI See section 1.1.4.

[0524] 5.2 Results This experiment aimed to determine whether the observed protective effect of this excipient was a specific property of the tested LNP (containing dL_05) or could be considered a general property. To this end, the LNP used in Example 1 was replaced by a commercially available mRNA / LNP formulation used for vaccination: Comirnaty® (BioNTech / Pfizer). The data are summarized in Figure 5. The results show a high similarity to the data generated in Example 1. Shaking, without excipients, leads to a deterioration in particle quality (increase in hydrodynamic diameter by >20%). The presence of different excipients, at concentrations above 0.01% (w / v), leads to stabilization of the suspension and prevents aggregation during physical stress.

[0525] Example 6: Shaking resistance of SpikeVax® in the presence of representative excipients 6.1 Method: 6.1.1 Mixing of nanoparticles with excipients SpikeVax® (Moderna) was commercially supplied. LNPs were mixed with Kolliphor P188 (poloxamer 188) to yield an excipient concentration of 1% (w / v) and an LNP concentration of 0.15 mg mRNA / mL according to the table.

[0526] [Table 8]

[0527] 6.1.2 Shaking of nanoparticle suspensions For stress testing, 100 μL of the LNP / excipient mix was shaken on a vortex (Vortex Genie 2, Scientific Industries) at maximum speed for 1, 5, 30, 60, and 90 minutes.

[0528] 6.1.3 Measurement of complex size and PdI See section 1.1.4.

[0529] 6.2 Results This experiment aimed to determine whether the observed protective effect of this excipient was a specific property of the tested LNP (containing dL_05) or could be considered a general property. To this end, the LNP used in Example 1 was replaced by a commercially available mRNA / LNP formulation used for vaccination: Spikevax® (Moderna). The data are summarized in Figure 6. The results show a high similarity to the data generated in Example 1. Shaking, in the absence of excipients, leads to a decrease in particle quality (increase in size and PdI). The presence of Kolliphor P188, at a concentration of 1% (w / v), leads to stabilization of the suspension and prevents aggregation during physical stress.

[0530] Example 7: Analysis of poloxamer binding to LiNPs using preparative size-exclusion chromatography This experiment aims to determine whether a poloxamer such as p188 that is added to LNPs after nanoprecipitation binds (specifically, attaches or integrates) to the LNPs or LiNPs, or whether it remains in solution.

[0531] Formulations containing LiNP and P188 were separated on a size exclusion chromatography (SEC) column to determine whether P188 was bound / associated with the particles under these conditions.

[0532] material and method 7.1.1 Materials

[0533] [Table 9]

[0534] 7.1.2 Method LiNPs and LiNP formulations containing P188 were separated via size exclusion chromatography. Single fractions were analyzed for poloxamer content via HPLC, size distribution by DLS, and integrity by the Ribogreen assay.

[0535] 7.1.2.1 PrepSEC Preparative size-exclusion chromatography was performed on an Äkta Purifier system using a HiPrep 16 / 60 Sephacryl S-500 HR (cv 120 mL) column. The running buffer was 25 mM MOPS, 150 mM NaCl, pH 6.8. The flow rates for sample application and elution were set at 1 mL / min. For preparative runs, 2.5 mL fractions were collected during elution. The UV signal at 260 nm and conductivity were monitored during the run.

[0536] 7.1.2.2 HPLC analysis The parameter settings of the HPLC device are summarized in Table 1. The solvent gradient profile can be found in Table 9.

[0537] [Table 10]

[0538] [Table 11]

[0539] result HPLC calibration curves were prepared using P188 reference solutions ranging from 0.2 to 7 mg / mL (Figures 8, 9, and 10).

[0540] Selected fractions after size-exclusion chromatography were analyzed by HPLC for the presence of poloxamer. The absorbance at 260 nm in the elution profile indicates that LiNPs elute within an elution volume of 50–70 mL (fractions 3–13, Figure 7). The integrity of LiNPs was confirmed by DLS and ribogreen assays.

[0541] Within the fractions of the main LiNP peak, the authors were unable to detect any P188 by HPLC (see illustration in Figure 11, fraction 9).

[0542] Only in the later elution fractions 23, 24, 25 and 26 was P188 detected at concentrations of 0.2-0.5 mg / mL (Figures 12 and 13).

[0543] summary Poloxamer could be detected separately from intact LNPs according to their molecular weight differences using preparative size-exclusion chromatography. Intact LiNPs were detected according to the elution profile measured at 260 nm wavelength for fractions 3–13. The authors were able to verify particle integrity by DLS measurements and ribogreen assay. Poloxamer was detected by HPLC in later elution fractions 23–26. Based on this data, the authors conclude that poloxamer added to LNPs does not bind to the particles.

[0544] [Table 12] [Brief explanation of the drawings]

[0545] [Figure 1-1] FIG. 1 shows the size distribution (A) and polydispersity index (B) of LNPs before (black bars) and after (white bars) shaking in the presence of various concentrations of different excipients. [Figure 1-2] (As mentioned above.) [Figure 2-1]FIG. 1 shows the size distribution (A) and polydispersity index (B) of LNPs at different concentrations before (black bars) and after (white bars) shaking in the presence of 1% (w / v) poloxamer 188. [Figure 2-2] (As mentioned above.) [Figure 3-1] FIG. 1 shows the size distribution (A) and polydispersity index (B) of MC3-LNPs before (black bars) and after (white bars) shaking in the presence of various concentrations of different excipients. [Figure 3-2] (As mentioned above.) [Figure 4-1] Figure 1 shows the size distribution (A) and polydispersity index (B) of ALC-0315 LNPs in the presence of various concentrations of different excipients before (black bars) and after (white bars) shaking. [Figure 4-2] (As mentioned above.) [Figure 5] FIG. 1 shows the size distribution of Comirnaty® LNPs before (black bars) and after (white bars) shaking in the presence of various concentrations of different excipients. [Figure 6] FIG. 1 shows the size distribution and polydispersity index of Spikeevax® LNPs before (black bars) and after (white bars) shaking in the presence of 1% (w / v) Kolliphor P188. [Figure 7] Figure 1 shows a size exclusion chromatogram (based on lipidoid in Scheme 1) of LNP formulated with poloxamer P188. The X-axis corresponds to elution volume in mL and the Y-axis is the signal, UV 260 nm. [Figure 8] FIG. 1 shows HPLC calibration curves for poloxamer P188 at 0.2, 0.5 and 1 mg / mL. [Figure 9] FIG. 1 shows HPLC calibration curves for poloxamer P188 at 3, 5 and 7 mg / mL. [Figure 10] FIG. 1 shows an HPLC calibration plot for poloxamer P188. [Figure 11]FIG. 1 shows a comparison of the signal between a standard sample containing 0.5 mg / mL poloxamer and fraction 9 containing LiNPs. [Figure 12] FIG. 1 shows an HPLC chromatogram showing fractions 23 and 24 compared to a 0.5 mg / mL poloxamer P188 standard. [Figure 13] FIG. 1 shows an HPLC chromatogram showing fractions 25 and 26 compared to a 0.5 mg / mL poloxamer P188 standard.

Claims

1. 1. Use of a surfactant to stabilize a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle against particle aggregation under conditions of physical stress, wherein the lipid or lipidoid nanoparticles comprise the following components (a) and (b): (a) a therapeutic agent, and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; The use.

2. 2. The use of surfactant according to claim 1, wherein the physical stress state is selected from shaking, stirring, vibrating, mixing, inverting, tapping or dropping of the suspension, or a combination thereof, or the physical stress state is caused by pumping or withdrawing the suspension into a syringe.

3. 3. The use of a surfactant according to claim 1 or 2, wherein the surfactant is incorporated as an excipient in the aqueous vehicle solution.

4. 4. The use of a surfactant according to claim 3, wherein said surfactant is essentially not bound to said nanoparticles.

5. The use of a surfactant according to any one of claims 1 to 4, wherein said surfactant is not present in the vehicle solution during the freeze-drying process.

6. The use of a surfactant according to any one of claims 1 to 5, wherein the surfactant is a non-ionic surfactant.

7. 7. The use of a surfactant according to claim 6, wherein the surfactant is at least one nonionic surfactant selected from the group consisting of fatty alcohol ethoxylates, fatty acid ethoxylates, block copolymers of ethylene oxide and propylene oxide, alkylphenol ethoxylates or oligomers of alkylphenol ethoxylates, fatty acid esters of sorbitol, ethoxylated fatty acid esters of sorbitol, fatty acid esters of glycerol, ethoxylated castor oil and ethoxylated vitamin E.

8. 8. Use of a surfactant according to any one of claims 1 to 7, wherein the suspension of lipid or lipidoid nanoparticles in an aqueous vehicle solution contains the surfactant at a concentration of 0.01 to 10% (w / v).

9. The use of a surfactant according to claim 8, wherein said suspension of nanoparticles comprises said surfactant at a concentration of 0.5 to 1.5% (w / v).

10. The use of a surfactant according to any one of claims 1 to 9, wherein the therapeutic agent is mRNA.

11. Use of a surfactant according to any one of claims 1 to 10, wherein said nanoparticles are free of poloxamer 188 and / or free of poloxamer 407.

12. The nanoparticles are an ionizable lipidoid (b) of the following formula (b-1): 【Chemical 1】 (In the formula, a is 1 and b is an integer from 2 to 4, or a is an integer from 2 to 4 and b is 1; p is 1 or 2; m is 1 or 2, n is 0 or 1, and m+n is ≧2; R １Ａ ~R ６Ａ are, independently of each other, hydrogen; ２ —CH(OH)—R ７Ａ , —CH(R ７Ａ )-CH ２ —OH, —CH ２ -CH ２ -(C=O)-OR ７Ａ , -CH ２ -CH ２ -(C=O)-NH-R ７Ａ ;-CH ２ -R ７Ａ ;-C(NH)-NH ２ a poly(ethylene glycol) chain; and a receptor ligand, R ７Ａ is selected from C3 to C18 alkyl and C3 to C18 alkenyl having one C-C double bond; However, R １Ａ ~R ６Ａ At least two residues of ２ —CH(OH)—R ７Ａ , —CH(R ７Ａ )-CH ２ —OH, —CH ２ -CH ２ -(C=O)-OR ７Ａ , -CH ２ -CH ２ -(C=O)-NH-R ７Ａ and -CH ２ -R ７Ａ and R ７Ａ is selected from C3-C18 alkyl or C3-C18 alkenyl having one C-C double bond. or a protonated form thereof, in which one or more of the nitrogen atoms contained in the compound of formula (b-1) are protonated to give a compound having a positive charge. Use of a surfactant according to any one of claims 1 to 11, comprising:

13. The nanoparticles comprise as ionizable lipid (b): (6Z,9Z,28Z,31Z)-heptatriaconta-6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, or a protonated form thereof, wherein the nitrogen atom of the compound is protonated; ((4-hydroxybutyl)azanediyl)bis(hexane-6,1-diyl)bis(2-hexyldecanoate), or a protonated form thereof, wherein the nitrogen atom of the compound is protonated, and / or (heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate), or its protonated form, wherein the nitrogen atom of the compound is protonated. Use of the surfactant according to any one of claims 1 to 13, comprising:

14. A suspension of lipid or lipidoid nanoparticles in an aqueous vehicle solution, the aqueous vehicle solution comprising a surfactant, the lipid or lipidoid nanoparticles comprising the following components (a) and (b): (a) a therapeutic agent, preferably a nucleic acid; and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; wherein the suspension of nanoparticles comprises the surfactant at a concentration of 0.5 to 1.5% (w / v).

15. A suspension of lipid or lipidoid nanoparticles in an aqueous vehicle solution, the aqueous vehicle solution comprising a surfactant, the lipid or lipidoid nanoparticles comprising the following components (a) and (b): (a) a therapeutic agent, preferably a nucleic acid; and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; wherein the surfactant is essentially not bound to the nanoparticles.

16. 1. A method for stabilizing a suspension of lipid or lipidoid nanoparticles in an aqueous vehicle against particle aggregation under conditions of physical stress, the method comprising: (a) a therapeutic agent, preferably a nucleic acid, and (b) at least one selected from permanent cationic lipids, ionizable lipids, and ionizable lipidoids; and incorporating a surfactant into the suspension of lipid or lipidoid nanoparticles.

17. Steps below: i) producing a lipid nanoparticle (LNP) or lipidoid nanoparticle (LiNP) preparation by mixing at least one selected from a permanent cationic lipid, an ionizable lipid, and an ionizable lipidoid dissolved in an organic phase with a therapeutic agent dissolved in an aqueous solution; ii) diluting said preparation of lipid or lipidoid nanoparticles by diluting with a first solution; iii) concentrating the diluted preparation of lipid or lipidoid nanoparticles by buffer exchange by ultra / diafiltration in a TFF, wherein a second solution is used for the ultra / diafiltration; iv) Obtaining a suspension of lipid or lipidoid nanoparticles wherein the first solution comprises between 0.01% w / v and 10% surfactant, preferably between 0.25% w / v and 5% w / v surfactant, more preferably between 0.33% w / v and 2.5% w / v surfactant, more preferably between 0.45% w / v and 1.5% w / v surfactant, and most preferably between 0.5% w / v and 1.5% w / v surfactant; and / or the second solution comprises between 0.01% w / v and 10% surfactant, preferably between 0.25% w / v and 5% w / v surfactant, more preferably between 0.33% w / v and 2.5% w / v surfactant, more preferably between 0.45% w / v and 1.5% w / v surfactant, and most preferably between 0.5% w / v and 1.5% w / v surfactant; 17. The method of claim 16, wherein the final concentration of surfactant from the combined first and second solutions is between 0.01% and 10% surfactant, preferably between 0.25% and 5% w / v surfactant, more preferably between 0.33% and 2.5% w / v surfactant, more preferably between 0.45% and 1.5% w / v surfactant, and most preferably between 0.5% and 1.5% w / v surfactant, based on the total volume of the suspension of the nanoparticles in the aqueous vehicle solution.

18. 18. The method of claim 17, wherein the surfactant is added to both the first and second solutions.

19. 19. The method of claim 17 or 18, wherein approximately half of the surfactant is added to the first solution and approximately half of the surfactant is added to the second solution.

20. 20. An LNP or LiNP suspension obtainable by the method according to any one of claims 17 to 19.

21. 21. The LNP or LiNP suspension of claim 20 for use in vaccination or immunization.

22. 1. A method of avoiding side effects in treatment with LNPs or LiNPs having at least one therapeutic agent, comprising: i) determining whether a pharmaceutical composition comprising LNPs or LiNPs aggregates when subjected to mechanical or thermal stress by determining its aggregation level before and after subjecting said pharmaceutical composition to said mechanical or thermal stress; ii) if the LNP or LiNP exhibit aggregation after the test of step (i), then adding surfactant to the LNP or LiNP formulation to obtain an LNP or LiNP suspension having a final surfactant concentration of 0.01% w / v to 10% w / v, preferably 0.1% w / v to 10% w / v, more preferably 0.25% w / v to 5%, even more preferably 0.33% to 2.5%, even more preferably 0.45% to 1.5%, and most preferably 0.5% to 1.5%; iii) Reconstitution by mixing to produce a stable LNP or LiNP suspension. The method comprising:

23. A method for reducing one or more side effects associated with a vaccine formulation or anti-cancer formulation comprising LNPs or LiNPs having nucleic acids, the method comprising modifying the vaccine formulation or anti-cancer formulation by adding a surfactant to the vaccine formulation comprising an LNP or LiNP suspension.

24. 24. The method of claim 23, wherein the surfactant is present in an amount of 0.01% to 10% w / v, preferably 0.1% to 10% w / v, more preferably 0.25% to 5%, even more preferably 0.33% to 2.5%, even more preferably 0.45% to 1.5%, and most preferably 0.5% to 1.5%.

25. 22. A method of reducing the occurrence or severity of one or more side effects associated with an LNP / LiNP-based vaccine or LNP / LiNP cancer therapy in a subject, the method comprising administering to the subject a vaccine formulation or anti-cancer formulation comprising the LNP or LiNP suspension of any one of claims 1 to 15, or 21.

Images